PMID- 30501481
OWN - NLM
STAT- MEDLINE
DCOM- 20190111
LR  - 20201221
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 379
IP  - 26
DP  - 2018 Dec 27
TI  - Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
PG  - 2517-2528
LID - 10.1056/NEJMoa1812836 [doi]
AB  - BACKGROUND: Ibrutinib has been approved by the Food and Drug Administration for the 
      treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 
      but has not been compared with chemoimmunotherapy. We conducted a phase 3 trial to 
      evaluate the efficacy of ibrutinib, either alone or in combination with rituximab, 
      relative to chemoimmunotherapy. METHODS: Patients 65 years of age or older who had 
      untreated CLL were randomly assigned to receive bendamustine plus rituximab, 
      ibrutinib, or ibrutinib plus rituximab. The primary end point was progression-free 
      survival. The Alliance Data and Safety Monitoring Board made the decision to release 
      the data after the protocol-specified efficacy threshold had been met. RESULTS: A 
      total of 183 patients were assigned to receive bendamustine plus rituximab, 182 to 
      receive ibrutinib, and 182 to receive ibrutinib plus rituximab. Median 
      progression-free survival was reached only with bendamustine plus rituximab. The 
      estimated percentage of patients with progression-free survival at 2 years was 74% 
      with bendamustine plus rituximab and was higher with ibrutinib alone (87%; hazard 
      ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.26 to 
      0.58; P<0.001) and with ibrutinib plus rituximab (88%; hazard ratio, 0.38; 95% CI, 
      0.25 to 0.59; P<0.001). There was no significant difference between the 
      ibrutinib-plus-rituximab group and the ibrutinib group with regard to 
      progression-free survival (hazard ratio, 1.00; 95% CI, 0.62 to 1.62; P=0.49). With a 
      median follow-up of 38 months, there was no significant difference among the three 
      treatment groups with regard to overall survival. The rate of grade 3, 4, or 5 
      hematologic adverse events was higher with bendamustine plus rituximab (61%) than 
      with ibrutinib or ibrutinib plus rituximab (41% and 39%, respectively), whereas the 
      rate of grade 3, 4, or 5 nonhematologic adverse events was lower with bendamustine 
      plus rituximab (63%) than with the ibrutinib-containing regimens (74% with each 
      regimen). CONCLUSIONS: Among older patients with untreated CLL, treatment with 
      ibrutinib was superior to treatment with bendamustine plus rituximab with regard to 
      progression-free survival. There was no significant difference between ibrutinib and 
      ibrutinib plus rituximab with regard to progression-free survival. (Funded by the 
      National Cancer Institute and Pharmacyclics; ClinicalTrials.gov number, NCT01886872 
      .).
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Ruppert, Amy S
AU  - Ruppert AS
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Heerema, Nyla A
AU  - Heerema NA
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Zhao, Weiqiang
AU  - Zhao W
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Booth, Allison M
AU  - Booth AM
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Ding, Wei
AU  - Ding W
AUID- ORCID: 0000-0001-9811-4601
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Bartlett, Nancy L
AU  - Bartlett NL
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Brander, Danielle M
AU  - Brander DM
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Barr, Paul M
AU  - Barr PM
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Rogers, Kerry A
AU  - Rogers KA
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Parikh, Sameer A
AU  - Parikh SA
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Coutre, Steven
AU  - Coutre S
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Hurria, Arti
AU  - Hurria A
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Brown, Jennifer R
AU  - Brown JR
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Blachly, James S
AU  - Blachly JS
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Ozer, Hatice G
AU  - Ozer HG
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Major-Elechi, Brittny
AU  - Major-Elechi B
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Fruth, Briant
AU  - Fruth B
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Nattam, Sreenivasa
AU  - Nattam S
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Larson, Richard A
AU  - Larson RA
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Erba, Harry
AU  - Erba H
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Litzow, Mark
AU  - Litzow M
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Owen, Carolyn
AU  - Owen C
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Kuzma, Charles
AU  - Kuzma C
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Abramson, Jeremy S
AU  - Abramson JS
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Little, Richard F
AU  - Little RF
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Smith, Scott E
AU  - Smith SE
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Stone, Richard M
AU  - Stone RM
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Mandrekar, Sumithra J
AU  - Mandrekar SJ
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
FAU - Byrd, John C
AU  - Byrd JC
AD  - From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., 
      N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and 
      Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., 
      M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); 
      Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and 
      First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North 
      Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); 
      Stanford University School of Medicine, Stanford (S.C.), and the City of Hope 
      Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber 
      Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer 
      Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort 
      Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and 
      Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom 
      Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer 
      Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).
LA  - eng
SI  - ClinicalTrials.gov/NCT01886872
GR  - R01 CA197870/CA/NCI NIH HHS/United States
GR  - K23 CA178183/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - UG1 CA232760/CA/NCI NIH HHS/United States
GR  - R01 CA183444/CA/NCI NIH HHS/United States
GR  - UG1 CA189823/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - U10 CA180867/CA/NCI NIH HHS/United States
GR  - U10 CA180888/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - U10 CA180836/CA/NCI NIH HHS/United States
GR  - UG1 CA189858/CA/NCI NIH HHS/United States
GR  - U10 CA180857/CA/NCI NIH HHS/United States
GR  - U10 CA180850/CA/NCI NIH HHS/United States
GR  - U10 CA180863/CA/NCI NIH HHS/United States
GR  - U10 CA180790/CA/NCI NIH HHS/United States
GR  - U10 CA180820/CA/NCI NIH HHS/United States
GR  - P30 CA033572/CA/NCI NIH HHS/United States
GR  - U10 CA180833/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20181201
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 1X70OSD4VX (ibrutinib)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 981Y8SX18M (Bendamustine Hydrochloride)
SB  - AIM
SB  - IM
CIN - N Engl J Med. 2019 Apr 25;380(17):1679. PMID: 31018078
CIN - N Engl J Med. 2019 Apr 25;380(17):1679. PMID: 31018079
CIN - N Engl J Med. 2019 Apr 25;380(17):1679-1681. PMID: 31018080
MH  - Aged
MH  - Aged, 80 and over
MH  - Bendamustine Hydrochloride/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Hematologic Diseases/chemically induced
MH  - Humans
MH  - *Immunotherapy
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy/mortality/therapy
MH  - Male
MH  - Progression-Free Survival
MH  - Pyrazoles/adverse effects/*therapeutic use
MH  - Pyrimidines/adverse effects/*therapeutic use
MH  - Rituximab/adverse effects/*therapeutic use
MH  - Survival Analysis
PMC - PMC6325637
MID - NIHMS1517583
EDAT- 2018/12/07 06:00
MHDA- 2019/01/12 06:00
CRDT- 2018/12/04 06:00
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/01/12 06:00 [medline]
PHST- 2018/12/04 06:00 [entrez]
AID - 10.1056/NEJMoa1812836 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 
      Dec 1.

PMID- 28418267
OWN - NLM
STAT- MEDLINE
DCOM- 20170814
LR  - 20201221
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 35
IP  - 13
DP  - 2017 May 1
TI  - BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
PG  - 1437-1443
LID - 10.1200/JCO.2016.70.2282 [doi]
AB  - Purpose Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in 
      chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has 
      been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause 
      relapse, but data regarding the prevalence and natural history of these mutations 
      are limited. Patients and Methods Patients accrued to four sequential studies of 
      ibrutinib were included in these analyses. Deep sequencing for BTK and PLCG2 was 
      performed retrospectively on patients who experienced relapse and prospectively on a 
      screening population. Results With a median follow-up time of 3.4 years, the 
      estimated cumulative incidence of progression at 4 years is 19% (95% CI, 14% to 
      24%). Baseline karyotypic complexity, presence of del(17)(p13.1), and age less than 
      65 years were risk factors for progression. Among patients who experienced relapse, 
      acquired mutations of BTK or PLCG2 were found in 85% (95% CI, 71% to 94%), and these 
      mutations were detected an estimated median of 9.3 months (95% CI, 7.6 to 11.7 
      months) before relapse. Of a group of 112 patients examined prospectively, eight 
      patients have experienced relapse, and all of these patients had acquired resistance 
      mutations before relapse. A resistance mutation was detected in an additional eight 
      patients who have not yet met criteria for clinical relapse. Conclusion Relapse of 
      chronic lymphocytic leukemia after ibrutinib is an issue of increasing clinical 
      significance. We show that mutations in BTK and PLCG2 appear early and have the 
      potential to be used as a biomarker for future relapse, suggesting an opportunity 
      for intervention.
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Ruppert, Amy S
AU  - Ruppert AS
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Guinn, Daphne
AU  - Guinn D
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Lehman, Amy
AU  - Lehman A
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Blachly, James S
AU  - Blachly JS
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Lozanski, Arletta
AU  - Lozanski A
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Heerema, Nyla A
AU  - Heerema NA
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Zhao, Weiqiang
AU  - Zhao W
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Coleman, Joshua
AU  - Coleman J
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Jones, Daniel
AU  - Jones D
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Abruzzo, Lynne
AU  - Abruzzo L
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Gordon, Amber
AU  - Gordon A
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Mantel, Rose
AU  - Mantel R
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Smith, Lisa L
AU  - Smith LL
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - McWhorter, Samantha
AU  - McWhorter S
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Davis, Melanie
AU  - Davis M
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Doong, Tzyy-Jye
AU  - Doong TJ
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Ny, Fan
AU  - Ny F
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Lucas, Margaret
AU  - Lucas M
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Chase, Weihong
AU  - Chase W
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Jones, Jeffrey A
AU  - Jones JA
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Flynn, Joseph M
AU  - Flynn JM
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Maddocks, Kami
AU  - Maddocks K
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Rogers, Kerry
AU  - Rogers K
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Jaglowski, Samantha
AU  - Jaglowski S
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Andritsos, Leslie A
AU  - Andritsos LA
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Awan, Farrukh T
AU  - Awan FT
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Blum, Kristie A
AU  - Blum KA
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Grever, Michael R
AU  - Grever MR
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Johnson, Amy J
AU  - Johnson AJ
AD  - All authors: The Ohio State University, Columbus, OH.
FAU - Byrd, John C
AU  - Byrd JC
AD  - All authors: The Ohio State University, Columbus, OH.
LA  - eng
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - R01 CA197870/CA/NCI NIH HHS/United States
GR  - K23 CA178183/CA/NCI NIH HHS/United States
GR  - P30 CA014236/CA/NCI NIH HHS/United States
GR  - R01 CA177292/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R01 CA183444/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20170213
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of Clinical 
      Oncology
JID - 8309333
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 1X70OSD4VX (ibrutinib)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase)
RN  - EC 2.7.10.2 (BTK protein, human)
RN  - EC 3.1.4.3 (Phospholipase C gamma)
RN  - M95KG522R0 (ofatumumab)
SB  - IM
CIN - 1451
MH  - Adult
MH  - Agammaglobulinaemia Tyrosine Kinase
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/administration & dosage
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology/therapeutic use
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy/*enzymology/genetics
MH  - Male
MH  - Middle Aged
MH  - Phospholipase C gamma/genetics
MH  - Protein-Tyrosine Kinases/*genetics/metabolism
MH  - Pyrazoles/administration & dosage/pharmacology/*therapeutic use
MH  - Pyrimidines/administration & dosage/pharmacology/*therapeutic use
PMC - PMC5455463
EDAT- 2017/04/19 06:00
MHDA- 2017/08/15 06:00
CRDT- 2017/04/19 06:00
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2017/08/15 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
AID - 702282 [pii]
AID - 10.1200/JCO.2016.70.2282 [doi]
PST - ppublish
SO  - J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 
      Feb 13.

PMID- 27903528
OWN - NLM
STAT- MEDLINE
DCOM- 20170818
LR  - 20210202
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 129
IP  - 5
DP  - 2017 Feb 2
TI  - Consensus guidelines for the diagnosis and management of patients with classic hairy 
      cell leukemia.
PG  - 553-560
LID - 10.1182/blood-2016-01-689422 [doi]
AB  - Hairy cell leukemia is an uncommon hematologic malignancy characterized by 
      pancytopenia and marked susceptibility to infection. Tremendous progress in the 
      management of patients with this disease has resulted in high response rates and 
      improved survival, yet relapse and an appropriate approach to re-treatment present 
      continuing areas for research. The disease and its effective treatment are 
      associated with immunosuppression. Because more patients are being treated with 
      alternative programs, comparison of results will require general agreement on 
      definitions of response, relapse, and methods of determining minimal residual 
      disease. The development of internationally accepted, reproducible criteria is of 
      paramount importance in evaluating and comparing clinical trials to provide optimal 
      care. Despite the success achieved in managing these patients, continued 
      participation in available clinical trials in the first-line and particularly in the 
      relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened 
      an international conference to provide common definitions and structure to guide 
      current management. There is substantial opportunity for continued research in this 
      disease. In addition to the importance of optimizing the prevention and management 
      of the serious risk of infection, organized evaluations of minimal residual disease 
      and treatment at relapse offer ample opportunities for clinical research. Finally, a 
      scholarly evaluation of quality of life in the increasing number of survivors of 
      this now manageable chronic illness merits further study. The development of 
      consensus guidelines for this disease offers a framework for continued enhancement 
      of the outcome for patients.
FAU - Grever, Michael R
AU  - Grever MR
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      James Cancer Hospital, Columbus, OH.
FAU - Abdel-Wahab, Omar
AU  - Abdel-Wahab O
AD  - Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 
      New York, NY.
FAU - Andritsos, Leslie A
AU  - Andritsos LA
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      James Cancer Hospital, Columbus, OH.
FAU - Banerji, Versha
AU  - Banerji V
AD  - Section of Hematology/Oncology, University of Manitoba, Winnipeg, MB, Canada.
FAU - Barrientos, Jacqueline
AU  - Barrientos J
AD  - Department of Medicine, Hofstra North Shore-Long Island Jewish School of Medicine, 
      Hofstra University, Hempstead, NY.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      James Cancer Hospital, Columbus, OH.
FAU - Call, Timothy G
AU  - Call TG
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Catovsky, Daniel
AU  - Catovsky D
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, United 
      Kingdom.
FAU - Dearden, Claire
AU  - Dearden C
AD  - Department of Haemato-Oncology, Royal Marsden Biomedical Research Centre, London, 
      United Kingdom.
FAU - Demeter, Judit
AU  - Demeter J
AD  - First Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
FAU - Else, Monica
AU  - Else M
AD  - Division of Molecular Pathology, The Institute of Cancer Research, London, United 
      Kingdom.
FAU - Forconi, Francesco
AU  - Forconi F
AD  - Haematology Department, University Hospital Trust and Cancer Sciences Unit, Cancer 
      Research UK and National Institute for Health Research Experimental Cancer Medicine 
      Centres, Faculty of Medicine, University of Southampton, Southampton, United 
      Kingdom.
FAU - Gozzetti, Alessandro
AU  - Gozzetti A
AD  - Hematology, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
FAU - Ho, Anthony D
AU  - Ho AD
AD  - Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
FAU - Johnston, James B
AU  - Johnston JB
AD  - Section of Hematology/Oncology, University of Manitoba, Winnipeg, MB, Canada.
FAU - Jones, Jeffrey
AU  - Jones J
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      James Cancer Hospital, Columbus, OH.
FAU - Juliusson, Gunnar
AU  - Juliusson G
AD  - Department of Hematology, Skne University Hospital and Stem Cell Center, Lund 
      University, Lund, Sweden.
FAU - Kraut, Eric
AU  - Kraut E
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      James Cancer Hospital, Columbus, OH.
FAU - Kreitman, Robert J
AU  - Kreitman RJ
AD  - Laboratory of Molecular Biology, National Cancer Institute, National Institutes of 
      Health, Bethesda, MD.
FAU - Larratt, Loree
AU  - Larratt L
AD  - Department of Medicine, University of Alberta, Edmonton, AB, Canada.
FAU - Lauria, Francesco
AU  - Lauria F
AD  - Hematology, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - Department of Pathology, The Ohio State University, Columbus, OH.
FAU - Montserrat, Emili
AU  - Montserrat E
AD  - Department of Hematology, Hospital Clinic, University of Barcelona, Barcelona, 
      Spain.
FAU - Parikh, Sameer A
AU  - Parikh SA
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Park, Jae H
AU  - Park JH
AD  - Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 
      New York, NY.
FAU - Polliack, Aaron
AU  - Polliack A
AD  - Department of Hematology, Hadassah University Hospital and Hebrew University Medical 
      School, Jerusalem, Israel.
FAU - Quest, Graeme R
AU  - Quest GR
AD  - Department of Laboratory Medicine and Pathology, University Health Network, Toronto, 
      ON, Canada.
FAU - Rai, Kanti R
AU  - Rai KR
AD  - Department of Medicine, Hofstra North Shore-Long Island Jewish School of Medicine, 
      Hofstra University, Hempstead, NY.
FAU - Ravandi, Farhad
AU  - Ravandi F
AD  - Section of Developmental Therapeutics, Department of Leukemia, University of Texas 
      MD Anderson Cancer Center, Houston, TX.
FAU - Robak, Tadeusz
AU  - Robak T
AD  - Department of Hematology, Medical University of Lodz, Lodz, Poland.
FAU - Saven, Alan
AU  - Saven A
AD  - Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA.
FAU - Seymour, John F
AU  - Seymour JF
AD  - Haematology Department, Peter MacCallum Cancer Centre, University of Melbourne, 
      Melbourne, VIC, Australia.
FAU - Tadmor, Tamar
AU  - Tadmor T
AD  - Hematology Unit, Bnai-Zion Medical Center, and the Rappaport Faculty of Medicine, 
      Technion Institute of Technology, Haifa, Israel.
FAU - Tallman, Martin S
AU  - Tallman MS
AD  - Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 
      New York, NY.
FAU - Tam, Constantine
AU  - Tam C
AD  - Haematology Department, Peter MacCallum Cancer Centre, University of Melbourne, 
      Melbourne, VIC, Australia.
FAU - Tiacci, Enrico
AU  - Tiacci E
AD  - Institute of Hematology, Department of Medicine, University and Hospital of Perugia, 
      Perugia, Italy.
FAU - Troussard, Xavier
AU  - Troussard X
AD  - Department of Hematology, Centre Hospitalier Universitaire Cte de Nacre, Caen, 
      France.
FAU - Zent, Clive S
AU  - Zent CS
AD  - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, 
      NY.
FAU - Zenz, Thorsten
AU  - Zenz T
AD  - Department of Molecular Therapy in Hematology and Oncology, National Center for 
      Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany; and.
FAU - Zinzani, Pier Luigi
AU  - Zinzani PL
AD  - Institute of Hematology "Sergnoli," University of Bologna, Bologna, Italy.
FAU - Falini, Brunangelo
AU  - Falini B
AD  - Institute of Hematology, Department of Medicine, University and Hospital of Perugia, 
      Perugia, Italy.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161130
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antineoplastic Agents)
RN  - 395575MZO7 (Pentostatin)
RN  - 47M74X9YT5 (Cladribine)
SB  - AIM
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Cladribine/*therapeutic use
MH  - Disease Management
MH  - Humans
MH  - Leukemia, Hairy Cell/*diagnosis/*drug therapy
MH  - Neoplasm Recurrence, Local/diagnosis/drug therapy
MH  - Neoplasm, Residual/diagnosis/drug therapy
MH  - Pentostatin/*therapeutic use
MH  - Treatment Outcome
PMC - PMC5290982
EDAT- 2016/12/03 06:00
MHDA- 2017/08/19 06:00
CRDT- 2016/12/02 06:00
PHST- 2016/01/21 00:00 [received]
PHST- 2016/11/06 00:00 [accepted]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2017/08/19 06:00 [medline]
PHST- 2016/12/02 06:00 [entrez]
AID - S0006-4971(20)33728-9 [pii]
AID - 2016/689422 [pii]
AID - 10.1182/blood-2016-01-689422 [doi]
PST - ppublish
SO  - Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 
      30.

PMID- 31771968
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210929
IS  - 2159-8290 (Electronic)
IS  - 2159-8274 (Print)
IS  - 2159-8274 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Feb
TI  - Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
PG  - 214-231
LID - 10.1158/2159-8290.CD-19-0209 [doi]
AB  - Spleen tyrosine kinase (SYK) is a nonmutated therapeutic target in acute myeloid 
      leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising 
      results in combination with chemotherapy, likely reflecting induced mechanisms of 
      resistance to single-agent treatment in vivo. We conducted a genome-scale open 
      reading frame (ORF) resistance screen and identified activation of the RAS-MAPK-ERK 
      pathway as one major mechanism of resistance to SYK inhibitors. This finding was 
      validated in AML cell lines with innate and acquired resistance to SYK inhibitors. 
      Furthermore, patients with AML with select mutations activating these pathways 
      displayed early resistance to SYK inhibition. To circumvent SYK inhibitor therapy 
      resistance in AML, we demonstrate that a MEK and SYK inhibitor combination is 
      synergistic in vitro and in vivo. Our data provide justification for use of ORF 
      screening to identify resistance mechanisms to kinase inhibitor therapy in AML 
      lacking distinct mutations and to direct novel combination-based strategies to 
      abrogate these. SIGNIFICANCE: The integration of functional genomic screening with 
      the study of mechanisms of intrinsic and acquired resistance in model systems and 
      human patients identified resistance to SYK inhibitors through MAPK signaling in 
      AML. The dual targeting of SYK and the MAPK pathway offers a combinatorial strategy 
      to overcome this resistance.This article is highlighted in the In This Issue 
      feature, p. 161.
CI  - 2019 American Association for Cancer Research.
FAU - Cremer, Anjali
AU  - Cremer A
AUID- ORCID: 0000-0003-4701-842X
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's 
      Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Ellegast, Jana M
AU  - Ellegast JM
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's 
      Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Alexe, Gabriela
AU  - Alexe G
AUID- ORCID: 0000-0002-5668-6297
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's 
      Hospital, Harvard Medical School, Boston, Massachusetts.
AD  - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
AD  - Bioinformatics Graduate Program, Boston University, Boston, Massachusetts.
FAU - Frank, Elizabeth S
AU  - Frank ES
AUID- ORCID: 0000-0001-9268-5104
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's 
      Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Ross, Linda
AU  - Ross L
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's 
      Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Chu, S Haihua
AU  - Chu SH
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's 
      Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Pikman, Yana
AU  - Pikman Y
AUID- ORCID: 0000-0002-5336-0216
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's 
      Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Robichaud, Amanda
AU  - Robichaud A
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's 
      Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Goodale, Amy
AU  - Goodale A
AD  - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
FAU - Hupl, Bjrn
AU  - Hupl B
AD  - University Hospital Frankfurt, Department of Hematology/Oncology, Frankfurt/Main, 
      Germany.
AD  - German Cancer Consortium/German Cancer Research Center, Heidelberg, Germany.
FAU - Mohr, Sebastian
AU  - Mohr S
AD  - University Hospital Frankfurt, Department of Hematology/Oncology, Frankfurt/Main, 
      Germany.
FAU - Rao, Arati V
AU  - Rao AV
AD  - Gilead Sciences Inc., Foster City, California.
FAU - Walker, Alison R
AU  - Walker AR
AD  - Department of Internal Medicine, Division of Hematology, Department of Medicine, The 
      Ohio State University, Columbus, Ohio.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Department of Internal Medicine, Division of Hematology, Department of Medicine, The 
      Ohio State University, Columbus, Ohio.
FAU - Piccioni, Federica
AU  - Piccioni F
AD  - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
FAU - Armstrong, Scott A
AU  - Armstrong SA
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's 
      Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Department of Internal Medicine, Division of Hematology, Department of Medicine, The 
      Ohio State University, Columbus, Ohio.
FAU - Oellerich, Thomas
AU  - Oellerich T
AD  - University Hospital Frankfurt, Department of Hematology/Oncology, Frankfurt/Main, 
      Germany. kimberly_stegmaier@dfci.harvard.edu thomas.oellerich@kgu.de.
AD  - German Cancer Consortium/German Cancer Research Center, Heidelberg, Germany.
FAU - Stegmaier, Kimberly
AU  - Stegmaier K
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's 
      Hospital, Harvard Medical School, Boston, Massachusetts. 
      kimberly_stegmaier@dfci.harvard.edu thomas.oellerich@kgu.de.
AD  - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
LA  - eng
GR  - K08 CA222684/CA/NCI NIH HHS/United States
GR  - P50 CA206963/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - R35 CA210030/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20191126
TA  - Cancer Discov
JT  - Cancer discovery
JID - 101561693
RN  - 0 (6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine)
RN  - 0 (Benzamides)
RN  - 0 (Indazoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazines)
RN  - 86K0J5AK6M (mirdametinib)
RN  - 9N3CBB0BIQ (Diphenylamine)
RN  - EC 2.7.10.2 (SYK protein, human)
RN  - EC 2.7.10.2 (Syk Kinase)
RN  - EC 2.7.11.24 (MAPK1 protein, human)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
RN  - EC 3.1.3.48 (PTPN11 protein, human)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 11)
SB  - IM
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology/therapeutic use
MH  - Benzamides/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Clinical Trials, Phase I as Topic
MH  - Clinical Trials, Phase II as Topic
MH  - Diphenylamine/analogs & derivatives/pharmacology/therapeutic use
MH  - Drug Resistance, Neoplasm/drug effects/*genetics
MH  - Drug Synergism
MH  - Female
MH  - Gene Expression Regulation, Leukemic/drug effects
MH  - Humans
MH  - Indazoles/pharmacology/therapeutic use
MH  - Leukemia, Myeloid, Acute/*drug therapy/genetics
MH  - MAP Kinase Signaling System/drug effects/genetics
MH  - Mice
MH  - Mitogen-Activated Protein Kinase 1/genetics/metabolism
MH  - Mitogen-Activated Protein Kinase Kinases/*antagonists & inhibitors/metabolism
MH  - Mutagenesis, Site-Directed
MH  - Mutation
MH  - Open Reading Frames/genetics
MH  - Primary Cell Culture
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics/metabolism
MH  - Pyrazines/pharmacology/therapeutic use
MH  - Syk Kinase/*antagonists & inhibitors/metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC7058374
MID - NIHMS1544862
EDAT- 2019/11/28 06:00
MHDA- 2021/01/30 06:00
CRDT- 2019/11/28 06:00
PHST- 2019/02/18 00:00 [received]
PHST- 2019/10/08 00:00 [revised]
PHST- 2019/11/21 00:00 [accepted]
PHST- 2019/11/28 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
PHST- 2019/11/28 06:00 [entrez]
AID - 2159-8290.CD-19-0209 [pii]
AID - 10.1158/2159-8290.CD-19-0209 [doi]
PST - ppublish
SO  - Cancer Discov. 2020 Feb;10(2):214-231. doi: 10.1158/2159-8290.CD-19-0209. Epub 2019 
      Nov 26.

PMID- 33076970
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210929
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Oct 19
TI  - Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
PG  - 139
LID - 10.1186/s13045-020-00973-4 [doi]
LID - 139
AB  - Acute myeloid leukemia (AML) is a heterogeneous and complex disease, and treatments 
      for this disease have not been curative for the majority of patients. In younger 
      patients, internal tandem duplication of FLT3 (FLT3-ITD) is a common mutation for 
      which two inhibitors (midostaurin and gilteritinib) with varied potency and 
      specificity for FLT3 are clinically approved. However, the high rate of relapse or 
      failed initial response of AML patients suggests that the addition of a second 
      targeted therapy may be necessary to improve efficacy. Using an unbiased large-scale 
      CRISPR screen, we genetically identified BCL2 knockout as having synergistic effects 
      with an approved FLT3 inhibitor. Here, we provide supportive studies that validate 
      the therapeutic potential of the combination of FLT3 inhibitors with venetoclax in 
      vitro and in vivo against multiple models of FLT3-ITD-driven AML. Our unbiased 
      approach provides genetic validation for co-targeting FLT3 and BCL2 and repurposes 
      CRISPR screening data, utilizing the genome-wide scope toward mechanistic 
      understanding.
FAU - Brinton, Lindsey T
AU  - Brinton LT
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Zhang, Pu
AU  - Zhang P
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Williams, Katie
AU  - Williams K
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Canfield, Daniel
AU  - Canfield D
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Sher, Steven
AU  - Sher S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Wasmuth, Ronni
AU  - Wasmuth R
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Beaver, Larry
AU  - Beaver L
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Cempre, Casey
AU  - Cempre C
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Skinner, Jordan
AU  - Skinner J
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Cannon, Matthew
AU  - Cannon M
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Govande, Mukul
AU  - Govande M
AD  - Department of Biomedical Engineering, The Ohio State University, Room 455C, OSUCCC 
      Building, 410 West 12th Avenue, Columbus, OH, 43210, USA.
FAU - Harrington, Bonnie
AU  - Harrington B
AD  - College of Veterinary Medicine, Michigan State University, Lansing, MI, USA.
FAU - Lehman, Amy
AU  - Lehman A
AD  - Center Biostatistics, The Ohio State University, Columbus, OH, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
AD  - College of Pharmacy, The Ohio State University, Columbus, OH, USA.
AD  - College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
AD  - Leukemia Research Program, The Ohio State University James Comprehensive Cancer 
      Center, Columbus, OH, USA.
FAU - Lapalombella, Rosa
AU  - Lapalombella R
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA. rosa.lapalombella@osumc.edu.
AD  - Leukemia Research Program, The Ohio State University James Comprehensive Cancer 
      Center, Columbus, OH, USA. rosa.lapalombella@osumc.edu.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
AD  - Leukemia Research Program, The Ohio State University James Comprehensive Cancer 
      Center, Columbus, OH, USA.
AD  - Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - R01 CA223165/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201019
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
RN  - 0 (Aniline Compounds)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Pyrazines)
RN  - 0 (Sulfonamides)
RN  - 0 (gilteritinib)
RN  - EC 2.7.10.1 (FLT3 protein, human)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
RN  - H88EPA0A3N (Staurosporine)
RN  - ID912S5VON (midostaurin)
RN  - N54AIC43PW (venetoclax)
SB  - IM
MH  - Aniline Compounds/therapeutic use
MH  - Animals
MH  - Antineoplastic Agents/therapeutic use
MH  - Bridged Bicyclo Compounds, Heterocyclic/therapeutic use
MH  - CRISPR-Cas Systems
MH  - Cell Line, Tumor
MH  - Female
MH  - Gene Knockout Techniques
MH  - Genetic Therapy
MH  - Humans
MH  - Leukemia, Myeloid, Acute/genetics/*therapy
MH  - Mice, SCID
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Proto-Oncogene Proteins c-bcl-2/*genetics
MH  - Pyrazines/therapeutic use
MH  - Staurosporine/analogs & derivatives/therapeutic use
MH  - Sulfonamides/therapeutic use
MH  - fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
PMC - PMC7574303
OTO - NOTNLM
OT  - *Acute myeloid leukemia
OT  - *BCL2
OT  - *Combination therapy
OT  - *FLT3
OT  - *Gilteritinib
OT  - *Midostaurin
OT  - *Synergy
OT  - *Venetoclax
COIS- JSB consults for AbbVie, AstraZeneca, and KITE Pharma. All other authors declare no 
      competing interests.
EDAT- 2020/10/21 06:00
MHDA- 2021/06/08 06:00
CRDT- 2020/10/20 05:40
PHST- 2020/07/08 00:00 [received]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2020/10/20 05:40 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
AID - 10.1186/s13045-020-00973-4 [pii]
AID - 973 [pii]
AID - 10.1186/s13045-020-00973-4 [doi]
PST - epublish
SO  - J Hematol Oncol. 2020 Oct 19;13(1):139. doi: 10.1186/s13045-020-00973-4.

PMID- 31915195
OWN - NLM
STAT- MEDLINE
DCOM- 20210609
LR  - 20210811
IS  - 2159-8290 (Electronic)
IS  - 2159-8274 (Print)
IS  - 2159-8274 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar
TI  - Acalabrutinib plus Obinutuzumab in Treatment-Nave and Relapsed/Refractory Chronic 
      Lymphocytic Leukemia.
PG  - 394-405
LID - 10.1158/2159-8290.CD-19-1130 [doi]
AB  - Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor 
      that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular 
      cytotoxicity, making it an attractive candidate for combination therapy with 
      anti-CD20 antibodies. We investigated acalabrutinib plus obinutuzumab in a phase 
      Ib/II study (NCT02296918) of patients with treatment-nave or relapsed/refractory 
      chronic lymphocytic leukemia (CLL). Nineteen treatment-nave and 26 
      relapsed/refractory patients were treated with acalabrutinib (100 mg twice daily) 
      until progression and obinutuzumab (cycle 1: 100 mg day 1, 900 mg day 2, 1000 mg 
      days 8 and 15; cycles 2-6: 1,000 mg day 1). Grade 3/4 adverse events occurred in 71% 
      of patients. Overall response rates were 95% (treatment-nave) and 92% 
      (relapsed/refractory). Thirty-two percent of treatment-nave and 8% of 
      relapsed/refractory patients achieved complete remission. At 36 months, 94% 
      (treatment-nave) and 88% (relapsed/refractory) were progression free. Acalabrutinib 
      plus obinutuzumab was well tolerated, producing high and durable responses in 
      treatment-nave and relapsed/refractory CLL. SIGNIFICANCE: Rituximab plus the less 
      selective BTK inhibitor ibrutinib has not shown benefit in CLL; however, the 
      selective BTK inhibitor acalabrutinib plus the antibody-dependent cellular 
      cytotoxicity-enhanced antibody obinutuzumab yielded durable responses that deepened 
      over time in treatment-nave and relapsed/refractory CLL, supporting the evaluation 
      of this approach in larger, comparative studies in CLL.This article is highlighted 
      in the In This Issue feature, p. 327.
CI  - 2020 American Association for Cancer Research.
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 
      jennifer.woyach@osumc.edu.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Rogers, Kerry A
AU  - Rogers KA
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Bhat, Seema A
AU  - Bhat SA
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Jianfar, Mojgan
AU  - Jianfar M
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Weiss, David M
AU  - Weiss DM
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Andersen, Barbara L
AU  - Andersen BL
AUID- ORCID: 0000-0002-7335-1325
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Gulrajani, Michael
AU  - Gulrajani M
AD  - Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.
FAU - Frigault, Melanie M
AU  - Frigault MM
AD  - Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.
FAU - Hamdy, Ahmed
AU  - Hamdy A
AD  - Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.
FAU - Izumi, Raquel
AU  - Izumi R
AD  - Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.
FAU - Munugalavadla, Veerendra
AU  - Munugalavadla V
AD  - Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.
FAU - Quah, Cheng
AU  - Quah C
AD  - Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.
FAU - Wang, Min-Hui
AU  - Wang MH
AD  - Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, California.
FAU - Byrd, John C
AU  - Byrd JC
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
LA  - eng
SI  - ClinicalTrials.gov/NCT02296918
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R01 CA197870/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200108
TA  - Cancer Discov
JT  - Cancer discovery
JID - 101561693
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Benzamides)
RN  - 0 (IL2 protein, human)
RN  - 0 (Interleukin-2)
RN  - 0 (Pyrazines)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase)
RN  - EC 2.7.10.2 (BTK protein, human)
RN  - I42748ELQW (acalabrutinib)
RN  - O43472U9X8 (obinutuzumab)
SB  - IM
MH  - Adult
MH  - Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors/*genetics
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse 
      effects
MH  - Benzamides/*administration & dosage/adverse effects
MH  - Cell Proliferation/drug effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Interleukin-2/genetics
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy/genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Pyrazines/*administration & dosage/adverse effects
MH  - Rituximab/administration & dosage
MH  - Treatment Outcome
PMC - PMC8176161
MID - NIHMS1704392
EDAT- 2020/01/10 06:00
MHDA- 2021/06/10 06:00
CRDT- 2020/01/10 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2019/12/05 00:00 [revised]
PHST- 2020/01/02 00:00 [accepted]
PHST- 2020/01/10 06:00 [pubmed]
PHST- 2021/06/10 06:00 [medline]
PHST- 2020/01/10 06:00 [entrez]
AID - 2159-8290.CD-19-1130 [pii]
AID - 10.1158/2159-8290.CD-19-1130 [doi]
PST - ppublish
SO  - Cancer Discov. 2020 Mar;10(3):394-405. doi: 10.1158/2159-8290.CD-19-1130. Epub 2020 
      Jan 8.

PMID- 32232486
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210612
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 135
IP  - 24
DP  - 2020 Jun 11
TI  - Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with 
      BTK/PLCG2 mutations.
PG  - 2192-2195
LID - 10.1182/blood.2019003722 [doi]
FAU - Lucas, Fabienne
AU  - Lucas F
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
FAU - Larkin, Karylin
AU  - Larkin K
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
FAU - Gregory, C Thomas
AU  - Gregory CT
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
FAU - Doong, Tzyy-Jye
AU  - Doong TJ
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
FAU - Lozanski, Arletta
AU  - Lozanski A
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - Department of Pathology.
FAU - Misra, Shrilekha
AU  - Misra S
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
FAU - Ngankeu, Apollinaire
AU  - Ngankeu A
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
FAU - Ozer, Hatice Gulcin
AU  - Ozer HG
AD  - Department of Biomedical Informatics.
FAU - Sampath, Deepa
AU  - Sampath D
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
FAU - Thangavadivel, Shanmugapriya
AU  - Thangavadivel S
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
FAU - Yilmaz, Selen A
AU  - Yilmaz SA
AD  - Department of Biomedical Informatics.
FAU - Rogers, Kerry A
AU  - Rogers KA
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
AD  - Division of Pharmaceutics, College of Pharmacy, and.
AD  - Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State 
      University, Columbus, OH.
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
AD  - Division of Pharmaceutics, College of Pharmacy, and.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine.
AD  - The Ohio State University Comprehensive Cancer Center.
AD  - Department of Biomedical Informatics.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R01 CA197870/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Letter
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antineoplastic Agents)
RN  - 0 (BCL2 protein, human)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Piperidines)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Sulfonamides)
RN  - 1X70OSD4VX (ibrutinib)
RN  - EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase)
RN  - EC 2.7.10.2 (BTK protein, human)
RN  - EC 3.1.4.3 (PLCG2 protein, human)
RN  - EC 3.1.4.3 (Phospholipase C gamma)
RN  - JAC85A2161 (Adenine)
RN  - N54AIC43PW (venetoclax)
SB  - AIM
SB  - IM
MH  - Adenine/analogs & derivatives/therapeutic use
MH  - Agammaglobulinaemia Tyrosine Kinase/*genetics
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Bridged Bicyclo Compounds, Heterocyclic/therapeutic use
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy/*genetics
MH  - Male
MH  - Middle Aged
MH  - Molecular Targeted Therapy
MH  - *Mutation
MH  - Phospholipase C gamma/*genetics
MH  - Piperidines/therapeutic use
MH  - Proto-Oncogene Proteins c-bcl-2/*genetics
MH  - Sulfonamides/therapeutic use
PMC - PMC7290091
COIS- Conflict-of-interest disclosure: J.A.W. receives research funding from AbbVie, 
      Janssen, Loxo, Karyopharm, and Morphosys, and has performed consulting for Janssen 
      and Pharmacyclics. J.S.B. has received consulting fees from AbbVie, AstraZeneca, and 
      KITE Pharma. K.A.R. receives research funding from Genentech, AbbVie, and Janssen 
      and has consulted for Acerta Pharma. The remaining authors declare no competing 
      financial interests.
EDAT- 2020/04/02 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - S0006-4971(20)61962-0 [pii]
AID - 2020/BLD2019003722 [pii]
AID - 10.1182/blood.2019003722 [doi]
PST - ppublish
SO  - Blood. 2020 Jun 11;135(24):2192-2195. doi: 10.1182/blood.2019003722.

PMID- 33020282
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210515
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 117
IP  - 42
DP  - 2020 Oct 20
TI  - Mutational landscape and clinical outcome of patients with de novo acute myeloid 
      leukemia and rearrangements involving 11q23/KMT2A.
PG  - 26340-26346
LID - 10.1073/pnas.2014732117 [doi]
AB  - Balanced rearrangements involving the KMT2A gene, located at 11q23, are among the 
      most frequent chromosome aberrations in acute myeloid leukemia (AML). Because of 
      numerous fusion partners, the mutational landscape and prognostic impact of specific 
      11q23/KMT2A rearrangements are not fully understood. We analyzed clinical features 
      of 172 adults with AML and recurrent 11q23/KMT2A rearrangements, 141 of whom had 
      outcome data available. We compared outcomes of these patients with outcomes of 
      1,097 patients without an 11q23/KMT2A rearrangement categorized according to the 
      2017 European LeukemiaNet (ELN) classification. Using targeted next-generation 
      sequencing, we investigated the mutational status of 81 leukemia/cancer-associated 
      genes in 96 patients with 11q23/KMT2A rearrangements with material for molecular 
      studies available. Patients with 11q23/KMT2A rearrangements had a low number of 
      additional gene mutations (median, 1; range 0 to 6), which involved the RAS pathway 
      (KRAS, NRAS, and PTPN11) in 32% of patients. KRAS mutations occurred more often in 
      patients with t(6;11)(q27;q23)/KMT2A-AFDN compared with patients with the other 
      11q23/KMT2A subsets. Specific gene mutations were too infrequent in patients with 
      specific 11q23/KMT2A rearrangements to assess their associations with outcomes. We 
      demonstrate that younger (age <60 y) patients with t(9;11)(p22;q23)/KMT2A-MLLT3 had 
      better outcomes than patients with other 11q23/KMT2A rearrangements and those 
      without 11q23/KMT2A rearrangements classified in the 2017 ELN intermediate-risk 
      group. Conversely, outcomes of older patients (age 60 y) with t(9;11)(p22;q23) were 
      poor and comparable to those of the ELN adverse-risk group patients. Our study shows 
      that patients with an 11q23/KMT2A rearrangement have distinct mutational patterns 
      and outcomes depending on the fusion partner.
FAU - Bill, Marius
AU  - Bill M
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; 
      marius.bill@osumc.edu krzysztof.mrozek@osumc.edu Albert.delaChapelle@osumc.edu.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; 
      marius.bill@osumc.edu krzysztof.mrozek@osumc.edu Albert.delaChapelle@osumc.edu.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
AD  - Alliance for Clinical Trials in Oncology Statistics and Data Center, The Ohio State 
      University Comprehensive Cancer Center, Columbus, OH 43210.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH 43210.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
AD  - Alliance for Clinical Trials in Oncology Statistics and Data Center, The Ohio State 
      University Comprehensive Cancer Center, Columbus, OH 43210.
FAU - Papaioannou, Dimitrios
AU  - Papaioannou D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
FAU - Blachly, James S
AU  - Blachly JS
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH 43210.
FAU - Orwick, Shelley
AU  - Orwick S
AUID- ORCID: 0000-0002-4537-1409
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH 43210.
FAU - Carroll, Andrew J
AU  - Carroll AJ
AD  - Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294.
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell, 
      Lake Success, NY 11042.
FAU - Powell, Bayard L
AU  - Powell BL
AD  - Department of Internal Medicine, Section on Hematology & Oncology, Wake Forest 
      Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, MA 02215.
FAU - de la Chapelle, Albert
AU  - de la Chapelle A
AUID- ORCID: 0000-0001-9345-9248
AD  - Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State 
      University, Columbus, OH 43210; marius.bill@osumc.edu krzysztof.mrozek@osumc.edu 
      Albert.delaChapelle@osumc.edu.
AD  - Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio 
      State University, Columbus, OH 43210.
FAU - Byrd, John C
AU  - Byrd JC
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH 43210.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH 43210.
LA  - eng
GR  - U10 CA077658/CA/NCI NIH HHS/United States
GR  - P50 CA206963/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - UG1 CA233180/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - UG1 CA233331/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - UG1 CA233338/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (KMT2A protein, human)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Chromosome Aberrations
MH  - Female
MH  - Gene Rearrangement/genetics
MH  - Histone-Lysine N-Methyltransferase/*genetics/metabolism
MH  - Humans
MH  - Jacobsen Distal 11q Deletion Syndrome/*genetics/metabolism
MH  - Karyotyping
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Male
MH  - Middle Aged
MH  - Mutation/genetics
MH  - Myeloid-Lymphoid Leukemia Protein/*genetics/metabolism
MH  - Translocation, Genetic/genetics
MH  - Treatment Outcome
PMC - PMC7584992
OTO - NOTNLM
OT  - *KMT2A
OT  - *acute myeloid leukemia
OT  - *clinical outcome
OT  - *gene mutations
OT  - *next-generation sequencing
COIS- Competing interest statement: J.S.B. serves as a consultant/advisory board member 
      for AbbVie, AstraZeneca, and KITE Pharma. The other authors declare no potential 
      conflicts of interest.
EDAT- 2020/10/07 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/10/06 05:26
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/10/06 05:26 [entrez]
AID - 2014732117 [pii]
AID - 202014732 [pii]
AID - 10.1073/pnas.2014732117 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26340-26346. doi: 
      10.1073/pnas.2014732117. Epub 2020 Oct 5.

PMID- 32461631
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210602
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 34
IP  - 12
DP  - 2020 Dec
TI  - Additional gene mutations may refine the 2017 European LeukemiaNet classification in 
      adult patients with de novo acute myeloid leukemia aged<60 years.
PG  - 3215-3227
LID - 10.1038/s41375-020-0872-3 [doi]
AB  - The European LeukemiaNet (ELN) recommendations for diagnosis and management of acute 
      myeloid leukemia (AML) have become an important tool to assess patients' prognosis 
      and guide treatment. We tested the prognostic impact of the 2017 ELN classification 
      in a large cohort of 863 AML patients aged<60 years similarly treated on Cancer and 
      Leukemia Group B/Alliance for Clinical Trials in Oncology studies. Based on 
      multivariable models within each ELN genetic-risk group, we identified additional 
      gene mutations that may refine the 2017 ELN risk classification. BCOR- or 
      SETBP1-mutated favorable-risk patients with non-core-binding factor AML and 
      IDH-mutated adverse-risk patients had intermediate-risk outcomes. Outcomes of 
      NPM1/WT1 co-mutated patients and those of ZRSR2-mutated patients resembled outcome 
      of adverse-risk patients. Moreover, FLT3-ITD(high) allelic ratio conferred adverse 
      rather than intermediate-risk irrespective of the NPM1 mutation status, and DNMT3A 
      mutations associated with very poor survival. Application of these refinements 
      reclassified 9% of current favorable-risk patients and 53% of current 
      intermediate-risk patients to the adverse-risk group, with similar poor survival as 
      current adverse-risk patients. Furthermore, 4% of current favorable-risk patients 
      and 9% of adverse-risk patients were reclassified to the intermediate-risk group.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA. ann-kathrin.eisfeld@osumc.edu.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University, Columbus, OH, USA.
FAU - Mims, Alice
AU  - Mims A
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University, Columbus, OH, USA.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Carroll, Andrew J
AU  - Carroll AJ
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Papaioannou, Dimitrios
AU  - Papaioannou D
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - Monter Cancer Center, Zucker School of Medicine at Hofstra/Northwell, Lake Success, 
      NY, USA.
FAU - Powell, Bayard E
AU  - Powell BE
AD  - Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Dana-Farber/Partners CancerCare, Boston, MA, USA.
FAU - de la Chapelle, Albert
AU  - de la Chapelle A
AUID- ORCID: 0000-0001-9345-9248
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      krzysztof.mrozek@osumc.edu.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AUID- ORCID: 0000-0001-5465-7591
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
LA  - eng
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - UG1 CA189850/CA/NCI NIH HHS/United States
GR  - UG1 CA233180/CA/NCI NIH HHS/United States
GR  - UG1 CA189824/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - UG1 CA233338/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200527
TA  - Leukemia
JT  - Leukemia
JID - 8704895
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Mutation/*genetics
MH  - Prognosis
MH  - Risk Factors
MH  - Young Adult
PMC - PMC7882079
MID - NIHMS1659415
COIS- Conflict of interest The authors declare no conflicts of interest.
EDAT- 2020/05/29 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/05/29 06:00
PHST- 2019/12/14 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/05/12 00:00 [revised]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - 10.1038/s41375-020-0872-3 [pii]
AID - 10.1038/s41375-020-0872-3 [doi]
PST - ppublish
SO  - Leukemia. 2020 Dec;34(12):3215-3227. doi: 10.1038/s41375-020-0872-3. Epub 2020 May 
      27.

PMID- 32820015
OWN - NLM
STAT- In-Process
LR  - 20210517
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Linking)
VI  - 26
IP  - 22
DP  - 2020 Nov 15
TI  - Entospletinib in Combination with Induction Chemotherapy in Previously Untreated 
      Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 
      Expression.
PG  - 5852-5859
LID - 10.1158/1078-0432.CCR-20-1064 [doi]
AB  - PURPOSE: Spleen tyrosine kinase (SYK) signaling is a proposed target in acute 
      myeloid leukemia (AML). Sensitivity to SYK inhibition has been linked to HOXA9 and 
      MEIS1 overexpression in preclinical studies. This trial evaluated the safety and 
      efficacy of entospletinib, a selective inhibitor of SYK, in combination with 
      chemotherapy in untreated AML. PATIENTS AND METHODS: This was an international 
      multicenter phase Ib/II study, entospletinib dose escalation (standard 3+3 design 
      between 200 and 400 mg twice daily) + 7+3 (cytarabine + daunorubicin) in phase Ib 
      and entospletinib dose expansion (400 mg twice daily) + 7+3 in phase II. RESULTS: 
      Fifty-three patients (n = 12, phase Ib and n = 41, phase II) with previously 
      untreated de novo (n = 39) or secondary (n = 14) AML were enrolled (58% male; median 
      age, 60 years) in this study. The composite complete response with entospletinib + 
      7+3 was 70%. Patients with baseline HOXA9 and MEIS1 expression higher than the 
      median had improved overall survival compared with patients with below median HOXA9 
      and MEIS1 expression. Common adverse events were cytopenias, febrile neutropenia, 
      and infection. There were no dose-limiting toxicities. Entospletinib-related skin 
      rash and hyperbilirubinemia were also observed. CONCLUSIONS: Entospletinib with 
      intensive chemotherapy was well-tolerated in patients with AML. Improved survival 
      was observed in patients with HOXA9/MEIS1 overexpression, contrasting published data 
      demonstrating poor survival in such patients. A randomized study will be necessary 
      to determine whether entospletinib was a mediator this observation.
CI  - 2020 American Association for Cancer Research.
FAU - Walker, Alison R
AU  - Walker AR
AD  - The Ohio State University, Columbus, Ohio. Alison.Walker@osumc.edu.
FAU - Byrd, John C
AU  - Byrd JC
AD  - The Ohio State University, Columbus, Ohio.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - The Ohio State University, Columbus, Ohio.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AD  - The Ohio State University, Columbus, Ohio.
FAU - Mims, Alice S
AU  - Mims AS
AD  - The Ohio State University, Columbus, Ohio.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - The Ohio State University, Columbus, Ohio.
FAU - Lin, Tara L
AU  - Lin TL
AUID- ORCID: 0000-0002-0242-6449
AD  - University of Kansas Medical Center, Kansas City, Kansas.
FAU - Crosswell, Howland E
AU  - Crosswell HE
AD  - Bon Secours Mercy Health System, Greenville, South Carolina.
FAU - Zhang, Danjie
AU  - Zhang D
AD  - Gilead Sciences, Inc., Foster City, California.
FAU - Minden, Mark D
AU  - Minden MD
AD  - Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
FAU - Munugalavadla, Veerendra
AU  - Munugalavadla V
AD  - Gilead Sciences, Inc., Foster City, California.
FAU - Long, Lauren
AU  - Long L
AD  - The Ohio State University, Columbus, Ohio.
FAU - Liu, Jinfeng
AU  - Liu J
AUID- ORCID: 0000-0002-0343-8222
AD  - Gilead Sciences, Inc., Foster City, California.
FAU - Pan, Yang
AU  - Pan Y
AD  - Gilead Sciences, Inc., Foster City, California.
FAU - Oellerich, Thomas
AU  - Oellerich T
AD  - Goethe University, Frankfurt am Main, Germany.
AD  - German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany.
FAU - Serve, Hubert
AU  - Serve H
AUID- ORCID: 0000-0001-8472-5516
AD  - Goethe University, Frankfurt am Main, Germany.
AD  - German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany.
FAU - Rao, Arati V
AU  - Rao AV
AD  - Gilead Sciences, Inc., Foster City, California.
FAU - Blum, William G
AU  - Blum WG
AD  - Winship Cancer Institute of Emory University, Atlanta, Georgia.
LA  - eng
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
SB  - IM
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/04/15 00:00 [received]
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:00 [medline]
PHST- 2020/08/22 06:00 [entrez]
AID - 1078-0432.CCR-20-1064 [pii]
AID - 10.1158/1078-0432.CCR-20-1064 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2020 Nov 15;26(22):5852-5859. doi: 10.1158/1078-0432.CCR-20-1064. 
      Epub 2020 Aug 20.

PMID- 26803155
OWN - NLM
STAT- MEDLINE
DCOM- 20170809
LR  - 20181202
IS  - 1367-4811 (Electronic)
IS  - 1367-4803 (Print)
IS  - 1367-4803 (Linking)
VI  - 32
IP  - 10
DP  - 2016 May 15
TI  - MuCor: mutation aggregation and correlation.
PG  - 1557-8
LID - 10.1093/bioinformatics/btw028 [doi]
AB  - MOTIVATION: There are many tools for variant calling and effect prediction, but 
      little to tie together large sample groups. Aggregating, sorting and summarizing 
      variants and effects across a cohort is often done with ad hoc scripts that must be 
      re-written for every new project. In response, we have written MuCor, a tool to 
      gather variants from a variety of input formats (including multiple files per 
      sample), perform database lookups and frequency calculations, and write many types 
      of reports. In addition to use in large studies with numerous samples, MuCor can 
      also be employed to directly compare variant calls from the same sample across two 
      or more platforms, parameters or pipelines. A companion utility, DepthGauge, 
      measures coverage at regions of interest to increase confidence in calls. 
      AVAILABILITY AND IMPLEMENTATION: Source code is freely available at 
      https://github.com/blachlylab/mucor and a Docker image is available at 
      https://hub.docker.com/r/blachlylab/mucor/ CONTACT: 
      james.blachly@osumc.eduSupplementary data: Supplementary data are available at 
      Bioinformatics online.
CI  -  The Author 2016. Published by Oxford University Press.
FAU - Kroll, Karl W
AU  - Kroll KW
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Eisfeld, Ann-Katherin
AU  - Eisfeld AK
AD  - Department of Human Cancer Genetics and Molecular Virology.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - Department of Pathology, The Ohio State University, Columbus, OH 43210 and.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      James Comprehensive Cancer Center, Columbus, OH 43210, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      James Comprehensive Cancer Center, Columbus, OH 43210, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      James Comprehensive Cancer Center, Columbus, OH 43210, USA.
LA  - eng
GR  - U10 CA180861/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20160123
TA  - Bioinformatics
JT  - Bioinformatics (Oxford, England)
JID - 9808944
SB  - IM
MH  - Algorithms
MH  - Animals
MH  - Computational Biology
MH  - Humans
MH  - *Mutation
MH  - Programming Languages
MH  - Sample Size
MH  - *Software
PMC - PMC4866525
EDAT- 2016/01/24 06:00
MHDA- 2017/08/10 06:00
CRDT- 2016/01/24 06:00
PHST- 2015/07/17 00:00 [received]
PHST- 2016/01/18 00:00 [accepted]
PHST- 2016/01/24 06:00 [entrez]
PHST- 2016/01/24 06:00 [pubmed]
PHST- 2017/08/10 06:00 [medline]
AID - btw028 [pii]
AID - 10.1093/bioinformatics/btw028 [doi]
PST - ppublish
SO  - Bioinformatics. 2016 May 15;32(10):1557-8. doi: 10.1093/bioinformatics/btw028. Epub 
      2016 Jan 23.

PMID- 33043294
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210914
IS  - 2631-9268 (Electronic)
IS  - 2631-9268 (Linking)
VI  - 2
IP  - 4
DP  - 2020 Dec
TI  - Characterization and mitigation of fragmentation enzyme-induced dual stranded 
      artifacts.
PG  - lqaa070
LID - 10.1093/nargab/lqaa070 [doi]
LID - lqaa070
AB  - High-throughput short-read sequencing relies on fragmented DNA for optimal sampling 
      of input nucleic acid. Several vendors now offer proprietary enzyme cocktails as a 
      cheaper and more streamlined method of fragmentation when compared to acoustic 
      shearing. We have discovered that these enzymes induce the formation of library 
      molecules containing regions of nearby DNA from opposite strands. Sequencing reads 
      derived from these molecules can lead to artifact-derived variant calls appearing at 
      variant allele frequencies <5%. We present Fragmentation Artifact Detection and 
      Elimination (FADE), software to remove these artifacts from mapped reads and 
      mitigate artifact-related effects on downstream analysis. We find that the artifacts 
      principally affect downstream analyses that are sensitive to a 1-3% artifact bias in 
      the sequencing reads, such as targeted resequencing and rare variant discovery.
CI  -  The Author(s) 2019. Published by Oxford University Press on behalf of NAR Genomics 
      and Bioinformatics.
FAU - Gregory, Thomas
AU  - Gregory T
AUID- ORCID: 0000-0001-9357-369X
AD  - Division of Hematology, Ohio State University,Columbus, OH 43210, USA.
FAU - Ngankeu, Apollinaire
AU  - Ngankeu A
AD  - Division of Hematology, Ohio State University,Columbus, OH 43210, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology, Ohio State University,Columbus, OH 43210, USA.
FAU - Kautto, Esko A
AU  - Kautto EA
AD  - Division of Hematology, Ohio State University,Columbus, OH 43210, USA.
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - Division of Hematology, Ohio State University,Columbus, OH 43210, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Ohio State University,Columbus, OH 43210, USA.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, Ohio State University,Columbus, OH 43210, USA.
LA  - eng
GR  - R01 CA183444/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - T32 GM068412/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20201002
TA  - NAR Genom Bioinform
JT  - NAR genomics and bioinformatics
JID - 101756213
PMC - PMC7531576
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:01
CRDT- 2020/10/12 05:34
PHST- 2020/01/30 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/10/12 05:34 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:01 [medline]
AID - lqaa070 [pii]
AID - 10.1093/nargab/lqaa070 [doi]
PST - ppublish
SO  - NAR Genom Bioinform. 2020 Dec;2(4):lqaa070. doi: 10.1093/nargab/lqaa070. Epub 2020 
      Oct 2.

PMID- 32554930
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 2379-3708 (Electronic)
IS  - 2379-3708 (Linking)
VI  - 5
IP  - 12
DP  - 2020 Jun 18
TI  - LC-FACSeq is a method for detecting rare clones in leukemia.
LID - 134973 [pii]
LID - 10.1172/jci.insight.134973 [doi]
LID - e134973
AB  - Detecting, characterizing, and monitoring rare populations of cells can increase 
      testing sensitivity, give insight into disease mechanism, and inform clinical 
      decision making. One area that can benefit from increased resolution is management 
      of cancers in clinical remission but with measurable residual disease (MRD) by 
      multicolor FACS. Detecting and monitoring genomic clonal resistance to treatment in 
      the setting of MRD is technically difficult and resource intensive due to the 
      limited amounts of disease cells. Here, we describe limited-cell FACS sequencing 
      (LC-FACSeq), a reproducible, highly sensitive method of characterizing clonal 
      evolution in rare cells relevant to different types of acute and chronic leukemias. 
      We demonstrate the utility of LC-FACSeq for broad multigene gene panels and its 
      application for monitoring sequential acquisition of mutations conferring therapy 
      resistance and clonal evolution in long-term ibrutinib treatment of patients with 
      chronic lymphocytic leukemia. This technique is generalizable for monitoring of 
      other blood and marrow infiltrating cancers.
FAU - Hu, Eileen Y
AU  - Hu EY
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
AD  - Medical Scientist Training Program.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
AD  - Department of Biomedical Informatics, and.
FAU - Saygin, Caner
AU  - Saygin C
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
FAU - Ozer, Hatice G
AU  - Ozer HG
AD  - Department of Biomedical Informatics, and.
FAU - Workman, Stephanie E
AU  - Workman SE
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
FAU - Lozanski, Arletta
AU  - Lozanski A
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
FAU - Doong, Tzyy-Jye
AU  - Doong TJ
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
FAU - Chiang, Chi-Ling
AU  - Chiang CL
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
FAU - Bhat, Seema
AU  - Bhat S
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
FAU - Rogers, Kerry A
AU  - Rogers KA
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
FAU - Coombes, Kevin R
AU  - Coombes KR
AD  - Department of Biomedical Informatics, and.
FAU - Jones, Daniel
AU  - Jones D
AD  - Department of Pathology, Ohio State University, Columbus, Ohio, USA.
FAU - Muthusamy, Natarajan
AU  - Muthusamy N
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - Department of Pathology, Ohio State University, Columbus, Ohio, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine and Comprehensive Cancer 
      Center.
LA  - eng
GR  - F30 CA225070/CA/NCI NIH HHS/United States
GR  - R01 CA177292/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - UG1 CA233338/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200618
TA  - JCI Insight
JT  - JCI insight
JID - 101676073
RN  - 0 (Piperidines)
RN  - 1X70OSD4VX (ibrutinib)
RN  - JAC85A2161 (Adenine)
SB  - IM
MH  - Adenine/*analogs & derivatives/therapeutic use
MH  - Clonal Evolution/*immunology
MH  - Clone Cells
MH  - Humans
MH  - Leukemia/*drug therapy/immunology
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
MH  - Mutation/genetics
MH  - Neoplasm, Residual/diagnosis/*drug therapy
MH  - Piperidines/*therapeutic use
PMC - PMC7406301
OTO - NOTNLM
OT  - *Clonal selection
OT  - *Diagnostics
OT  - *Genetics
OT  - *Leukemias
COIS- Conflict of interest: The authors have declared that no conflict of interest exists.
EDAT- 2020/06/20 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/11/15 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
AID - 134973 [pii]
AID - 10.1172/jci.insight.134973 [doi]
PST - epublish
SO  - JCI Insight. 2020 Jun 18;5(12):e134973. doi: 10.1172/jci.insight.134973.

PMID- 26917735
OWN - NLM
STAT- MEDLINE
DCOM- 20160809
LR  - 20210202
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 127
IP  - 8
DP  - 2016 Feb 25
TI  - Ribosomal revelation.
PG  - 958-9
LID - 10.1182/blood-2015-12-688994 [doi]
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - THE OHIO STATE UNIVERSITY.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Ribosomal Proteins)
SB  - AIM
SB  - IM
CON - Blood. 2016 Feb 25;127(8):1007-16. PMID: 26675346
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics
MH  - *Mutation, Missense
MH  - Neoplasm Recurrence, Local/*genetics
MH  - Ribosomal Proteins/*genetics
EDAT- 2016/02/27 06:00
MHDA- 2016/08/10 06:00
CRDT- 2016/02/27 06:00
PHST- 2016/02/27 06:00 [entrez]
PHST- 2016/02/27 06:00 [pubmed]
PHST- 2016/08/10 06:00 [medline]
AID - S0006-4971(20)30412-2 [pii]
AID - 10.1182/blood-2015-12-688994 [doi]
PST - ppublish
SO  - Blood. 2016 Feb 25;127(8):958-9. doi: 10.1182/blood-2015-12-688994.

PMID- 26893063
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20191210
IS  - 1558-822X (Electronic)
IS  - 1558-8211 (Print)
IS  - 1558-8211 (Linking)
VI  - 11
IP  - 1
DP  - 2016 Feb
TI  - Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.
PG  - 52-60
LID - 10.1007/s11899-016-0299-0 [doi]
AB  - The field of oncology has been transformed over the course of the last 20 years in 
      large part due to the enhanced understanding of cellular biology and cellular 
      signaling. The indolent natural history of chronic lymphocytic leukemia (CLL) has 
      permitted extensive study of cancer biology and can in some ways be thought of a 
      model for understanding and translating concepts to other diseases. By 
      systematically probing the biology of CLL cells and working out in stepwise fashion 
      the transduction of signals from the surface immunoglobulin to nuclear transcription 
      factors, investigators have paved the way for rational targeting of therapies at 
      natural vulnerabilities that mimic oncogene addiction. These key targets include 
      Bruton's tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), Src, Bcl2, and 
      cyclin-dependent kinases (CDKs). In this review, we will consider these proteins and 
      describe the current and future molecules designed to target them in CLL.
FAU - Maly, Joseph
AU  - Maly J
AD  - Division of Medical Oncology, Department of Internal Medicine, The Ohio State 
      University, Columbus, OH, USA.
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA. james.blachly@osumc.edu.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      james.blachly@osumc.edu.
LA  - eng
GR  - T32 CA165998/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
TA  - Curr Hematol Malig Rep
JT  - Current hematologic malignancy reports
JID - 101262565
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Receptor, Notch1)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase)
RN  - EC 2.7.10.2 (BTK protein, human)
RN  - EC 2.7.10.2 (Syk Kinase)
SB  - IM
MH  - Agammaglobulinaemia Tyrosine Kinase
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Cell Cycle Proteins/antagonists & inhibitors/metabolism
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors/metabolism
MH  - Receptor, Notch1/antagonists & inhibitors/metabolism
MH  - Syk Kinase/antagonists & inhibitors/metabolism
PMC - PMC4969081
MID - NIHMS805055
OTO - NOTNLM
OT  - ACP-196
OT  - Chronic lymphocytic leukemia
OT  - Ibrutinib
OT  - Idelalisib
OT  - Novel therapy
OT  - Targeted therapy
COIS- Conflict of Interest Joseph Maly declares no potential conflicts of interest. James 
      S. Blachly received a grant from Tolero Pharmaceuticals.
EDAT- 2016/02/20 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/02/20 06:00
PHST- 2016/02/20 06:00 [entrez]
PHST- 2016/02/20 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1007/s11899-016-0299-0 [pii]
AID - 10.1007/s11899-016-0299-0 [doi]
PST - ppublish
SO  - Curr Hematol Malig Rep. 2016 Feb;11(1):52-60. doi: 10.1007/s11899-016-0299-0.

PMID- 33268594
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210916
IS  - 2379-3708 (Electronic)
IS  - 2379-3708 (Linking)
VI  - 5
IP  - 23
DP  - 2020 Dec 3
TI  - TP-0903 is active in models of drug-resistant acute myeloid leukemia.
LID - 140169 [pii]
LID - 10.1172/jci.insight.140169 [doi]
LID - e140169
AB  - Effective treatment for AML is challenging due to the presence of clonal 
      heterogeneity and the evolution of polyclonal drug resistance. Here, we report that 
      TP-0903 has potent activity against protein kinases related to STAT, AKT, and ERK 
      signaling, as well as cell cycle regulators in biochemical and cellular assays. In 
      vitro and in vivo, TP-0903 was active in multiple models of drug-resistant FLT3 
      mutant AML, including those involving the F691L gatekeeper mutation and bone marrow 
      microenvironment-mediated factors. Furthermore, TP-0903 demonstrated preclinical 
      activity in AML models with FLT3-ITD and common co-occurring mutations in IDH2 and 
      NRAS genes. We also showed that TP-0903 had ex vivo activity in primary AML cells 
      with recurrent mutations including MLL-PTD, ASXL1, SRSF2, and WT1, which are 
      associated with poor prognosis or promote clinical resistance to AML-directed 
      therapies. Our preclinical studies demonstrate that TP-0903 is a multikinase 
      inhibitor with potent activity against multiple drug-resistant models of AML that 
      will have an immediate clinical impact in a heterogeneous disease like AML.
FAU - Jeon, Jae Yoon
AU  - Jeon JY
AD  - Division of Pharmaceutics and Pharmacology, College of Pharmacy.
FAU - Buelow, Daelynn R
AU  - Buelow DR
AD  - Division of Pharmaceutics and Pharmacology, College of Pharmacy.
FAU - Garrison, Dominique A
AU  - Garrison DA
AD  - Division of Pharmaceutics and Pharmacology, College of Pharmacy.
FAU - Niu, Mingshan
AU  - Niu M
AD  - Division of Pharmaceutics and Pharmacology, College of Pharmacy.
FAU - Eisenmann, Eric D
AU  - Eisenmann ED
AD  - Division of Pharmaceutics and Pharmacology, College of Pharmacy.
FAU - Huang, Kevin M
AU  - Huang KM
AD  - Division of Pharmaceutics and Pharmacology, College of Pharmacy.
FAU - Zavorka Thomas, Megan E
AU  - Zavorka Thomas ME
AD  - Division of Pharmaceutics and Pharmacology, College of Pharmacy.
FAU - Weber, Robert H
AU  - Weber RH
AD  - Division of Pharmaceutics and Pharmacology, College of Pharmacy.
FAU - Whatcott, Clifford J
AU  - Whatcott CJ
AD  - Sumitomo Dainippon Pharma Oncology.
FAU - Warner, Steve L
AU  - Warner SL
AD  - Sumitomo Dainippon Pharma Oncology.
FAU - Orwick, Shelley J
AU  - Orwick SJ
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Carmichael, Bridget
AU  - Carmichael B
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Stahl, Emily
AU  - Stahl E
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Brinton, Lindsey T
AU  - Brinton LT
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Lapalombella, Rosa
AU  - Lapalombella R
AD  - Division of Hematology, Department of Internal Medicine, and.
AD  - Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, and.
AD  - Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio, USA.
FAU - Hertlein, Erin
AU  - Hertlein E
AD  - Division of Hematology, Department of Internal Medicine, and.
AD  - Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Pharmaceutics and Pharmacology, College of Pharmacy.
AD  - Division of Hematology, Department of Internal Medicine, and.
AD  - Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio, USA.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AD  - Division of Hematology, Department of Internal Medicine, and.
AD  - Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio, USA.
FAU - Baker, Sharyn D
AU  - Baker SD
AD  - Division of Pharmaceutics and Pharmacology, College of Pharmacy.
AD  - Division of Hematology, Department of Internal Medicine, and.
AD  - Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio, USA.
LA  - eng
GR  - R01 CA138744/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - P30 CA021765/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201203
TA  - JCI Insight
JT  - JCI insight
JID - 101676073
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 14D65TV20J (dubermatinib)
RN  - EC 2.7.- (Protein Kinases)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm/drug effects
MH  - Female
MH  - Gene Duplication/drug effects
MH  - Humans
MH  - Leukemia, Myeloid, Acute/drug therapy/*genetics/*metabolism
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Mutation/drug effects
MH  - Protein Kinase Inhibitors/metabolism/pharmacology
MH  - Protein Kinases/metabolism
MH  - Pyrimidines/metabolism/*pharmacology
MH  - Sulfonamides/metabolism/*pharmacology
MH  - Tumor Microenvironment/drug effects
MH  - Xenograft Model Antitumor Assays
PMC - PMC7714403
OTO - NOTNLM
OT  - *Drug therapy
OT  - *Hematology
OT  - *Leukemias
OT  - *Oncology
COIS- Conflict of interest: The authors have declared that no conflict of interest exists.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/12/03 05:41
PHST- 2020/05/13 00:00 [received]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/12/03 05:41 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
AID - 140169 [pii]
AID - 10.1172/jci.insight.140169 [doi]
PST - epublish
SO  - JCI Insight. 2020 Dec 3;5(23):e140169. doi: 10.1172/jci.insight.140169.

PMID- 31685543
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20200817
IS  - 1538-7445 (Electronic)
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 80
IP  - 3
DP  - 2020 Feb 1
TI  - Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular 
      Carcinoma Progression.
PG  - 561-575
LID - 10.1158/0008-5472.CAN-19-1117 [doi]
AB  - Owing to the marked sexual dimorphism of hepatocellular carcinoma (HCC), sex hormone 
      receptor signaling has been implicated in numerous aspects of liver cancer 
      pathogenesis. We sought to reconcile the clear contribution of androgen receptor 
      (AR) activity that has been established in preclinical models of HCC with the 
      clinical failure of AR antagonists in patients with advanced HCC by evaluating 
      potential resistance mechanisms to AR-targeted therapy. The AR locus was 
      interrogated for resistance-causing genomic modifications using publicly available 
      primary HCC datasets (1,019 samples). Analysis of HCC tumor and cell line RNA-seq 
      data revealed enriched expression of constitutively active, treatment-refractory AR 
      splice variants (AR-SV). HCC cell lines expressed C-terminal-truncated AR-SV; 28 
      primary HCC samples abundantly expressed AR-SV. Low molecular weight AR species were 
      nuclear localized and constitutively active. Furthermore, AR/AR-SV signaling 
      promoted AR-mediated HCC cell progression and conferred resistance to AR 
      antagonists. Ligand-dependent and -independent AR signaling mediated HCC 
      epithelial-to-mesenchymal transition by regulating the transcription factor SLUG. 
      These data suggest that AR-SV expression in HCC drives HCC progression and 
      resistance to traditional AR antagonists. Novel therapeutic approaches that 
      successfully target AR-SVs may be therapeutically beneficial for HCC. SIGNIFICANCE: 
      Treatment-refractory, constitutively active androgen receptor splice variants 
      promote hepatocellular carcinoma progression by regulating the 
      epithelial-to-mesenchymal transition pathway.
CI  - 2019 American Association for Cancer Research.
FAU - Dauki, Anees M
AU  - Dauki AM
AD  - Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The 
      Ohio State University, Columbus, Ohio.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, College of Medicine, The Ohio State University, Columbus, 
      Ohio.
AD  - Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Kautto, Esko A
AU  - Kautto EA
AUID- ORCID: 0000-0001-8675-8506
AD  - Division of Hematology, College of Medicine, The Ohio State University, Columbus, 
      Ohio.
AD  - Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio.
AD  - Biomedical Sciences Graduate Program, The Ohio State University, Columbus, Ohio.
FAU - Ezzat, Sameera
AU  - Ezzat S
AD  - Department of Public Health, National Liver Institute, Menoufia University, Shebin 
      El-Kom, Egypt.
AD  - National Liver Institute Sustainable Sciences Institute Collaborative Research 
      Center, Menoufia University, Shebin El-kom, Egypt.
FAU - Abdel-Rahman, Mohamed H
AU  - Abdel-Rahman MH
AD  - National Liver Institute Sustainable Sciences Institute Collaborative Research 
      Center, Menoufia University, Shebin El-kom, Egypt.
AD  - Department of Ophthalmology, College of Medicine, The Ohio State University, 
      Columbus, Ohio.
AD  - Division of Human Genetics, Department of Internal Medicine, The Ohio State 
      University, Columbus, Ohio.
AD  - Pathology Department, National Liver Institute, Menoufia University, Shebin El-kom, 
      Egypt.
FAU - Coss, Christopher C
AU  - Coss CC
AD  - Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The 
      Ohio State University, Columbus, Ohio. coss.16@osu.edu.
AD  - Drug Development Institute, OSU Comprehensive Cancer Center, The Ohio State 
      University, Columbus, Ohio.
LA  - eng
GR  - K12 CA133250/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - T32 GM068412/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20191104
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (AR protein, human)
RN  - 0 (Androgen Receptor Antagonists)
RN  - 0 (Androgens)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Androgen)
SB  - IM
MH  - *Alternative Splicing
MH  - Androgen Receptor Antagonists/pharmacology
MH  - Androgens/metabolism
MH  - Apoptosis
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma, Hepatocellular/drug therapy/genetics/*pathology
MH  - Cell Proliferation
MH  - Disease Progression
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Liver Neoplasms/drug therapy/genetics/*pathology
MH  - Male
MH  - Prognosis
MH  - Receptors, Androgen/*genetics
MH  - Signal Transduction
MH  - Tumor Cells, Cultured
PMC - PMC7002251
MID - NIHMS1541848
COIS- Conflict of interest: The authors declare no potential conflicts of interest.
EDAT- 2019/11/07 06:00
MHDA- 2020/08/18 06:00
CRDT- 2019/11/06 06:00
PHST- 2019/04/08 00:00 [received]
PHST- 2019/08/20 00:00 [revised]
PHST- 2019/10/28 00:00 [accepted]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
PHST- 2019/11/06 06:00 [entrez]
AID - 0008-5472.CAN-19-1117 [pii]
AID - 10.1158/0008-5472.CAN-19-1117 [doi]
PST - ppublish
SO  - Cancer Res. 2020 Feb 1;80(3):561-575. doi: 10.1158/0008-5472.CAN-19-1117. Epub 2019 
      Nov 4.

PMID- 23488658
OWN - NLM
STAT- MEDLINE
DCOM- 20140508
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 54
IP  - 10
DP  - 2013 Oct
TI  - Emerging drug profile: cyclin-dependent kinase inhibitors.
PG  - 2133-43
LID - 10.3109/10428194.2013.783911 [doi]
AB  - Abstract As the rational application of targeted therapies in cancer supplants 
      traditional cytotoxic chemotherapy, there is an ever-greater need for a thorough 
      understanding of the complex machinery of the cell and an application of this 
      knowledge to the development of novel therapeutics and combinations of agents. Here, 
      we review the current state of knowledge of the class of targeted agents known as 
      cyclin-dependent kinase (CDK) inhibitors, with a focus on chronic lymphocytic 
      leukemia (CLL). Flavopiridol (alvocidib) is the best studied of the CDK inhibitors, 
      producing a dramatic cytotoxic effect in vitro and in vivo, with the principal 
      limiting factor of acute tumor lysis. Unfortunately, flavopiridol has a narrow 
      therapeutic window and is relatively non-selective with several off-target (i.e. 
      non-CDK) effects, which prompted development of the second-generation CDK inhibitor 
      dinaciclib. Dinaciclib appears to be both more potent and selective than 
      flavopiridol, with at least an order of magnitude greater therapeutic index, and is 
      currently in phase III clinical trials. In additional to flavopiridol and 
      dinaciclib, we also review the current status of other members of this class, and 
      provide commentary as to the future direction of combination therapy including CDK 
      inhibitors.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology.
FAU - Byrd, John C
AU  - Byrd JC
LA  - eng
GR  - K12 CA133250/CA/NCI NIH HHS/United States
GR  - P01 CA081534/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - P01 CA81534/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130729
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cyclins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinases)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Cell Cycle/drug effects
MH  - Clinical Trials as Topic
MH  - Cyclin-Dependent Kinases/*antagonists & inhibitors/metabolism
MH  - Cyclins/metabolism
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy/*metabolism
MH  - Lymphoma/drug therapy/metabolism
MH  - Protein Kinase Inhibitors/pharmacology/*therapeutic use
PMC - PMC3778156
MID - NIHMS474268
EDAT- 2013/03/16 06:00
MHDA- 2014/05/09 06:00
CRDT- 2013/03/16 06:00
PHST- 2013/03/16 06:00 [entrez]
PHST- 2013/03/16 06:00 [pubmed]
PHST- 2014/05/09 06:00 [medline]
AID - 10.3109/10428194.2013.783911 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2013 Oct;54(10):2133-43. doi: 10.3109/10428194.2013.783911. Epub 2013 
      Jul 29.

PMID- 32034234
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20210206
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Feb 7
TI  - Quantifying Hematopoietic Stem Cell Clonal Diversity by Selecting Informative 
      Amplicon Barcodes.
PG  - 2153
LID - 10.1038/s41598-020-59119-8 [doi]
LID - 2153
AB  - Hematopoietic stem cells (HSCs) are functionally and genetically diverse and this 
      diversity decreases with age and disease. Numerous systems have been developed to 
      quantify HSC diversity by genetic barcoding, but no framework has been established 
      to empirically validate barcode sequences. Here we have developed an analytical 
      framework, Selection of informative Amplicon Barcodes from Experimental Replicates 
      (SABER), that identifies barcodes that are unique among a large set of experimental 
      replicates. Amplicon barcodes were sequenced from the blood of 56 adult zebrafish 
      divided into training and validation sets. Informative barcodes were identified and 
      samples with a high fraction of informative barcodes were chosen by bootstrapping. 
      There were 4.21.8 barcoded HSC clones per sample in the training set and 
      3.52.1 in the validation set (p=0.3). SABER reproducibly quantifies functional 
      HSCs and can accommodate a wide range of experimental group sizes. Future 
      large-scale studies aiming to understand the mechanisms of HSC clonal evolution will 
      benefit from this new approach to identifying informative amplicon barcodes.
FAU - Teets, Emily M
AU  - Teets EM
AD  - The Ohio State University College of Medicine, Department of Medicine, Division of 
      Hematology, The Ohio State University Comprehensive Cancer Center, Ohio, USA.
FAU - Gregory, Charles
AU  - Gregory C
AUID- ORCID: 0000-0001-9357-369X
AD  - The Ohio State University College of Medicine, Department of Medicine, Division of 
      Hematology, The Ohio State University Comprehensive Cancer Center, Ohio, USA.
FAU - Shaffer, Jami
AU  - Shaffer J
AD  - The Ohio State University College of Medicine, Department of Medicine, Division of 
      Hematology, The Ohio State University Comprehensive Cancer Center, Ohio, USA.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - The Ohio State University College of Medicine, Department of Medicine, Division of 
      Hematology, The Ohio State University Comprehensive Cancer Center, Ohio, USA.
AD  - The Ohio State University College of Medicine, Department of Biomedical Informatics, 
      Ohio, USA.
FAU - Blaser, Bradley W
AU  - Blaser BW
AUID- ORCID: 0000-0002-3168-5423
AD  - The Ohio State University College of Medicine, Department of Medicine, Division of 
      Hematology, The Ohio State University Comprehensive Cancer Center, Ohio, USA. 
      bradley.blaser@osumc.edu.
LA  - eng
GR  - K08 DK111920/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200207
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Algorithms
MH  - Animals
MH  - *Clonal Evolution
MH  - Genotyping Techniques/*methods/standards
MH  - *Hematopoiesis
MH  - Hematopoietic Stem Cells/cytology/*metabolism
MH  - *Mutation
MH  - Sequence Analysis, DNA/methods/standards
MH  - Zebrafish
PMC - PMC7005852
COIS- The authors declare no competing interests.
EDAT- 2020/02/09 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/02/09 06:00
PHST- 2019/09/19 00:00 [received]
PHST- 2020/01/24 00:00 [accepted]
PHST- 2020/02/09 06:00 [entrez]
PHST- 2020/02/09 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1038/s41598-020-59119-8 [pii]
AID - 59119 [pii]
AID - 10.1038/s41598-020-59119-8 [doi]
PST - epublish
SO  - Sci Rep. 2020 Feb 7;10(1):2153. doi: 10.1038/s41598-020-59119-8.

PMID- 33014332
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 2045-1393 (Print)
IS  - 2045-1407 (Electronic)
IS  - 2045-1393 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Sep 4
TI  - Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults 
      with acute lymphoblastic leukemia.
PG  - IJH28
LID - 10.2217/ijh-2020-0009 [doi]
LID - IJH28
AB  - AIM: There are limited data describing incidence of symptomatic venous 
      thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic 
      leukemia (ALL) patients receiving peg-asparaginase. MATERIALS & METHODS: 
      Single-institution retrospective analysis of 44 AYA ALL patients treated with 
      peg-asparaginase. Rates of VTE and proposed risk factors were assessed. RESULTS: 18 
      patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative 
      incidence rate was 25% (95% CI: 13-38%) within 30days of the initial dose. Personal 
      history of thrombosis was statistically significantly associated with an increased 
      risk of VTE with HR of 2.73 (95% CI: 1.40-5.33, p= 0.003) after adjusting for 
      gender. CONCLUSION: These data indicate a high rate of VTE in the AYA ALL population 
      following treatment with peg-asparaginase.
CI  -  2020 Bhavana Bhatnagar.
FAU - Underwood, Brynne
AU  - Underwood B
AD  - Department of Internal Medicine, The Ohio State University, Columbus, OH43210, USA.
FAU - Zhao, Qiuhong
AU  - Zhao Q
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
FAU - Walker, Alison R
AU  - Walker AR
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Mims, Alice S
AU  - Mims AS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Vasu, Sumithira
AU  - Vasu S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Long, Meixiao
AU  - Long M
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Z Haque, Tamanna
AU  - Z Haque T
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Blaser, Bradley W
AU  - Blaser BW
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Grieselhuber, Nicole R
AU  - Grieselhuber NR
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Wall, Sarah A
AU  - Wall SA
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Behbehani, Gregory K
AU  - Behbehani GK
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Larkin, Karilyn
AU  - Larkin K
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Garzon, Ramiro
AU  - Garzon R
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Wang, Tzu-Fei
AU  - Wang TF
AUID- ORCID: 0000-0003-2407-9000
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AUID- ORCID: 0000-0002-4968-0712
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus OH43210, USA.
LA  - eng
PT  - Journal Article
DEP - 20200904
TA  - Int J Hematol Oncol
JT  - International journal of hematologic oncology
JID - 101600758
PMC - PMC7521187
OTO - NOTNLM
OT  - acute lymphoblastic leukemia
OT  - adolescent young adult
OT  - peg-asparaginase
OT  - risk factors
OT  - venous thromboembolism
COIS- Financial & competing interests disclosure The authors have no relevant affiliations 
      or financial involvement with any organization or entity with a financial interest 
      in or financial conflict with the subject matter or materials discussed in the 
      manuscript. This includes employment, consultancies, honoraria, stock ownership or 
      options, expert testimony, grants or patents received or pending, or royalties. No 
      writing assistance was utilized in the production of this manuscript.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:18
PHST- 2020/10/05 06:18 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.2217/ijh-2020-0009 [doi]
PST - epublish
SO  - Int J Hematol Oncol. 2020 Sep 4;9(3):IJH28. doi: 10.2217/ijh-2020-0009.

PMID- 27040705
OWN - NLM
STAT- MEDLINE
DCOM- 20160819
LR  - 20160404
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 43
IP  - 2
DP  - 2016 Apr
TI  - Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic 
      leukemia.
PG  - 265-73
LID - S0093-7754(16)00009-9 [pii]
LID - 10.1053/j.seminoncol.2016.02.003 [doi]
AB  - In the last 10 years, oncology has been transformed by the development and broad 
      availability of small molecule therapies for cancer. Compounds have been and are 
      being developed to target nearly every known relevant component of the cell's 
      machinery. One class of compounds, the cyclin-dependent kinase (CDK) inhibitors, was 
      originally conceived as an anticancer therapeutic based on the premise that as 
      cancer is (in part) defined by loss of cell-cycle control, the interruption of cell 
      cycle could arrest cancer growth. While CDKs do play critical roles in cell cycle, 
      including in cancer, the study of CDK inhibitors in the relatively non-proliferative 
      disease chronic lymphocytic leukemia (CLL) revealed alternate mechanisms both for 
      CDKs, as well as for the role of CDK inhibitors in cancer therapy. In this review, 
      we will consider three CDK inhibitors: alvocidib (flavopiridol), dinaciclib, and 
      TG02. We will discuss their preclinical and clinical development for the treatment 
      of CLL, and suggest that CDK inhibitors remain relevant in CLL, with potential 
      utility in several scenarios.
CI  - Copyright  2016 Elsevier Inc. All rights reserved.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      OH; The Ohio State University James Comprehensive Cancer Center, Columbus, OH. 
      Electronic address: james.blachly@osumc.edu.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      OH; The Ohio State University James Comprehensive Cancer Center, Columbus, OH.
FAU - Grever, Michael
AU  - Grever M
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      OH; The Ohio State University James Comprehensive Cancer Center, Columbus, OH.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160208
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cyclins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Cell Cycle/drug effects
MH  - Clinical Trials as Topic
MH  - Cyclin-Dependent Kinases/*antagonists & inhibitors/metabolism
MH  - Cyclins/metabolism
MH  - Drug Evaluation, Preclinical
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy/metabolism
MH  - Molecular Targeted Therapy
MH  - Protein Kinase Inhibitors/pharmacology/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Alvocidib (Flavopiridol)
OT  - Chronic lymphocytic leukemia
OT  - Cyclin-dependent kinase inhibitors
OT  - Targeted therapy
EDAT- 2016/04/05 06:00
MHDA- 2016/08/20 06:00
CRDT- 2016/04/05 06:00
PHST- 2016/04/05 06:00 [entrez]
PHST- 2016/04/05 06:00 [pubmed]
PHST- 2016/08/20 06:00 [medline]
AID - S0093-7754(16)00009-9 [pii]
AID - 10.1053/j.seminoncol.2016.02.003 [doi]
PST - ppublish
SO  - Semin Oncol. 2016 Apr;43(2):265-73. doi: 10.1053/j.seminoncol.2016.02.003. Epub 2016 
      Feb 8.

PMID- 25100567
OWN - NLM
STAT- MEDLINE
DCOM- 20141118
LR  - 20191210
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 167
IP  - 1
DP  - 2014 Oct
TI  - Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
PG  - 19-32
LID - 10.1111/bjh.13065 [doi]
AB  - Targeted therapy represents a transformation in oncology, a field that has relied 
      primarily on non-selective cytotoxic therapies. Phosphatidylinositol 3-kinase (PI3K) 
      is a family of ubiquitous signalling molecules involved in a wide variety of 
      cellular processes and likewise, in a broad selection of human cancers. The 
      discovery that the p110- form of PI3K is differentially expressed in normal and 
      malignant lymphocytes has led to the development of specific inhibitors that are 
      currently in clinical trials for lymphoma. Downstream effectors of PI3K, including 
      v-akt murine thymoma viral oncogene homolog 1 (AKT; also termed AKT1) and 
      mechanistic target of rapamycin (serine/threonine kinase) (mTOR) are similarly 
      important in lymphoma, and agents targeting these components of the PI3K-AKT-mTOR 
      axis are also underway, although at earlier stages of development. In this review we 
      examine the role of PI3K-AKT-mTOR in normal and malignant lymphocytes, as well as 
      the preclinical and clinical status of a number of inhibitors of this pathway.
CI  -  2014 John Wiley & Sons Ltd.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine and The Ohio State 
      University James Comprehensive Cancer, The Ohio State University, Columbus, OH, USA.
FAU - Baiocchi, Robert A
AU  - Baiocchi RA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140806
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage/*pharmacology/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Humans
MH  - Lymphoma/*drug therapy/*metabolism
MH  - Lymphoma, Non-Hodgkin/drug therapy/*metabolism
MH  - Molecular Targeted Therapy
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Proto-Oncogene Proteins c-akt/antagonists & inhibitors/*metabolism
MH  - Signal Transduction/*drug effects
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*metabolism
MH  - Treatment Outcome
OTO - NOTNLM
OT  - AKT
OT  - PI3K
OT  - lymphoma
OT  - mTOR
OT  - targeted-therapy
EDAT- 2014/08/08 06:00
MHDA- 2014/11/19 06:00
CRDT- 2014/08/08 06:00
PHST- 2014/08/08 06:00 [entrez]
PHST- 2014/08/08 06:00 [pubmed]
PHST- 2014/11/19 06:00 [medline]
AID - 10.1111/bjh.13065 [doi]
PST - ppublish
SO  - Br J Haematol. 2014 Oct;167(1):19-32. doi: 10.1111/bjh.13065. Epub 2014 Aug 6.

PMID- 32545904
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Jun 14
TI  - Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and 
      Gilteritinib in Acute Myeloid Leukemia.
LID - 10.3390/cancers12061574 [doi]
LID - 1574
AB  - Acute myeloid leukemia (AML) is a hematopoietic stem-cell-derived leukemia with 
      often successive derived driver mutations. Late onset acquisition of internal tandem 
      duplication in FLT3 (FLT3-ITD) at a high variant allele frequency often contributes 
      to full transformation to a highly proliferative, rapidly progressive disease with 
      poor outcome. The FLT3-ITD mutation is targetable with approved FLT3 small molecule 
      inhibitors, including midostaurin and gilteritinib. However, outside of patients 
      receiving allogeneic transplant, most patients fail to respond or relapse, 
      suggesting alternative approaches of therapy will be required. We employed 
      genome-wide pooled CRISPR knockout screening as a method for large-scale 
      identification of targets whose knockout produces a phenotypic effect that enhances 
      the antitumor properties of FLT3 inhibitors. Among the candidate targets we 
      identified the effect of XPO1 knockout to be synergistic with midostaurin treatment. 
      Next, we validated the genetic finding with pharmacologic combination of the slowly 
      reversible XPO1 inhibitor selinexor with midostaurin and gilteritinib in FLT3-ITD 
      AML cell lines and primary patient samples. Lastly, we demonstrated improved 
      survival with either combination therapy compared to its monotherapy components in 
      an aggressive AML murine model, supporting further evaluation and rapid clinical 
      translation of this combination strategy.
FAU - Brinton, Lindsey T
AU  - Brinton LT
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210, USA.
FAU - Sher, Steven
AU  - Sher S
AUID- ORCID: 0000-0002-3788-3228
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210, USA.
FAU - Williams, Katie
AU  - Williams K
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210, USA.
FAU - Canfield, Daniel
AU  - Canfield D
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210, USA.
FAU - Wasmuth, Ronni
AU  - Wasmuth R
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210, USA.
FAU - Cempre, Casey
AU  - Cempre C
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210, USA.
FAU - Skinner, Jordan
AU  - Skinner J
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210, USA.
FAU - Lehman, Amy
AU  - Lehman A
AD  - Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210, USA.
AD  - Leukemia Research Program, The Ohio State University James Comprehensive Cancer 
      Center, Columbus, OH 43210, USA.
AD  - Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210, 
      USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210, USA.
AD  - Leukemia Research Program, The Ohio State University James Comprehensive Cancer 
      Center, Columbus, OH 43210, USA.
AD  - College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
AD  - College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.
FAU - Lapalombella, Rosa
AU  - Lapalombella R
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210, USA.
AD  - Leukemia Research Program, The Ohio State University James Comprehensive Cancer 
      Center, Columbus, OH 43210, USA.
LA  - eng
GR  - R35 CA197734/NH/NIH HHS/United States
GR  - NA/Grant of Equipment from StorageReview.com/
GR  - 5P30CA016058/NH/NIH HHS/United States
GR  - 5R01CA223165/NH/NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200614
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7352446
OTO - NOTNLM
OT  - AML
OT  - CRISPR-Cas9 screening
OT  - FLT3
OT  - XPO1
OT  - synergism
COIS- J.S.B consults for AbbVie, AstraZeneca, and KITE Pharma. All other authors declare 
      no conflict of interest. The funders had no role in the design of the study; in the 
      collection, analyses, or interpretation of data; in the writing of the manuscript, 
      or in the decision to publish the results.
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
CRDT- 2020/06/18 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
AID - cancers12061574 [pii]
AID - cancers-12-01574 [pii]
AID - 10.3390/cancers12061574 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Jun 14;12(6):1574. doi: 10.3390/cancers12061574.

PMID- 25110197
OWN - NLM
STAT- MEDLINE
DCOM- 20150522
LR  - 20191210
IS  - 1532-1681 (Electronic)
IS  - 0268-960X (Linking)
VI  - 28
IP  - 5
DP  - 2014 Sep
TI  - Hairy cell leukemia: Update on molecular profiling and therapeutic advances.
PG  - 197-203
LID - S0268-960X(14)00051-4 [pii]
LID - 10.1016/j.blre.2014.06.003 [doi]
AB  - Hairy cell leukemia was initially described as a clinicopathologic entity more than 
      50 years ago. We have subsequently discovered that HCL is really at least two 
      diseases: classical HCL and the hairy cell leukemia variant. The former is among a 
      small group of cancers exceptional for being (nearly) unified by a single genetic 
      lesion, the BRAF V600E mutation. Over the past three decades, tremendous progress in 
      both diagnostic and prognostic clarification has been accompanied by therapeutic 
      advances in classical HCL. Consequently, this once uniformly fatal disease has been 
      converted in most cases into a chronic illness enabling patients to live long and 
      productive lives. In response to standard therapy, patients have high complete 
      remission rates. Unfortunately, the long-term survival curves have not plateaued, 
      revealing that this disease is controlled but not cured. Though rare and 
      representing only about 10% of an already rare disease, those patients with the 
      variant fare exceptionally poorly with standard therapy: complete response rates to 
      purine nucleoside analogs are reported to be less than 50%, whereas the complete 
      response rates in classical HCL are up to 90%. Novel small molecules targeting BRAF 
      and the B-cell receptor signaling complex, and biologic agents like antibodies and 
      immunotoxin conjugates are being explored for those patients who have relapsed. 
      Substantial opportunities for continued research remain. This complex and 
      multi-faceted disease incorporates challenges from altered immunity associated with 
      the underlying disease and its treatments. Considering the rarity of this 
      malignancy, optimization of patient management requires multi-institutional 
      collaboration. The Hairy Cell Leukemia Foundation (www.hairycellleukemia.org) was 
      formed to coordinate these efforts.
CI  - Copyright  2014. Published by Elsevier Ltd.
FAU - Grever, Michael R
AU  - Grever MR
AD  - 395 W. 12th Ave, Room 392, Columbus, OH 43210, USA; Department of Internal Medicine, 
      Division of Hematology at The Ohio State University, Columbus, OH, USA. Electronic 
      address: Michael.grever@osumc.edu.
FAU - Blachly, James S
AU  - Blachly JS
AD  - 320 W. 10th Ave, 406C Starling Loving Hall, Columbus, OH 43210, USA; Department of 
      Internal Medicine, Division of Hematology at The Ohio State University, Columbus, 
      OH, USA. Electronic address: James.blachly@osumc.edu.
FAU - Andritsos, Leslie A
AU  - Andritsos LA
AD  - 320 W. 10th Ave, A352 Starling Loving Hall, Columbus, OH 43210, USA; Department of 
      Internal Medicine, Division of Hematology at The Ohio State University, Columbus, 
      OH, USA. Electronic address: Leslie.andritsos@osumc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140711
PL  - England
TA  - Blood Rev
JT  - Blood reviews
JID - 8708558
SB  - IM
MH  - Biomedical Research
MH  - Disease Management
MH  - Humans
MH  - Immunophenotyping
MH  - Infections/etiology/therapy
MH  - Leukemia, Hairy Cell/complications/*diagnosis/etiology/*therapy
MH  - Molecular Diagnostic Techniques
OTO - NOTNLM
OT  - Hairy cell leukemia
EDAT- 2014/08/12 06:00
MHDA- 2015/05/23 06:00
CRDT- 2014/08/12 06:00
PHST- 2014/03/20 00:00 [received]
PHST- 2014/06/12 00:00 [revised]
PHST- 2014/06/12 00:00 [accepted]
PHST- 2014/08/12 06:00 [entrez]
PHST- 2014/08/12 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - S0268-960X(14)00051-4 [pii]
AID - 10.1016/j.blre.2014.06.003 [doi]
PST - ppublish
SO  - Blood Rev. 2014 Sep;28(5):197-203. doi: 10.1016/j.blre.2014.06.003. Epub 2014 Jul 
      11.

PMID- 31545113
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1029-2403 (Electronic)
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 61
IP  - 2
DP  - 2020 Feb
TI  - Selinexor in combination with decitabine in patients with acute myeloid leukemia: 
      results from a phase 1 study.
PG  - 387-396
LID - 10.1080/10428194.2019.1665664 [doi]
AB  - Current treatment options for older and relapsed or refractory (R/R) acute myeloid 
      leukemia (AML) patients are limited and represent an unmet need. Based on 
      preclinical studies showing strong anti-leukemic effects in vivo, this phase I 
      dose-escalation study assessed the safety and preliminary clinical activity of the 
      oral exportin-1 inhibitor, selinexor, in combination with the hypomethylating agent, 
      decitabine 20mg/m(2), in adults with R/R AML and in older (age60) untreated AML 
      patients. There were no protocol-defined dose limiting toxicities. The recommended 
      phase 2 dose of selinexor was 60mg (35mg/m(2)) given twice-weekly. Notable grade 
      3 toxicities included asymptomatic hyponatremia (68%), febrile neutropenia (44%), 
      sepsis (44%), hypophosphatemia (36%), and pneumonia (28%). In 25 patients, the 
      overall response rate was 40%. Modification of selinexor to a flat dose of 60mg, 
      twice-weekly for two weeks after decitabine, improved tolerability of the regimen 
      and demonstrated preliminary clinical activity in poor-risk patients with AML.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Zhao, Qiuhong
AU  - Zhao Q
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Mims, Alice S
AU  - Mims AS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Vasu, Sumithira
AU  - Vasu S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Behbehani, Gregory K
AU  - Behbehani GK
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Larkin, Karilyn
AU  - Larkin K
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Blum, William
AU  - Blum W
AD  - Department of Hematology and Medical Oncology, Emory University School of Medicine, 
      Winship Cancer Institute, Atlanta, GA, USA.
FAU - Klisovic, Rebecca B
AU  - Klisovic RB
AD  - Department of Hematology and Medical Oncology, Emory University School of Medicine, 
      Winship Cancer Institute, Atlanta, GA, USA.
FAU - Ruppert, Amy S
AU  - Ruppert AS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Oakes, Christopher
AU  - Oakes C
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Ranganathan, Parvathi
AU  - Ranganathan P
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Walker, Alison R
AU  - Walker AR
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Garzon, Ramiro
AU  - Garzon R
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02093403
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R01 CA188269/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190923
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Hydrazines)
RN  - 0 (Triazoles)
RN  - 31TZ62FO8F (selinexor)
RN  - 776B62CQ27 (Decitabine)
RN  - M801H13NRU (Azacitidine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Azacitidine/adverse effects
MH  - Decitabine
MH  - Humans
MH  - Hydrazines
MH  - *Leukemia, Myeloid, Acute/drug therapy
MH  - Triazoles
PMC - PMC7552944
MID - NIHMS1632123
OTO - NOTNLM
OT  - *Acute myeloid leukemia
OT  - *clinical trials
OT  - *decitabine
OT  - *selinexor
EDAT- 2019/09/24 06:00
MHDA- 2021/04/28 06:00
CRDT- 2019/09/24 06:00
PHST- 2019/09/24 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2019/09/24 06:00 [entrez]
AID - 10.1080/10428194.2019.1665664 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2020 Feb;61(2):387-396. doi: 10.1080/10428194.2019.1665664. Epub 2019 
      Sep 23.

PMID- 30692102
OWN - NLM
STAT- MEDLINE
DCOM- 20200319
LR  - 20210622
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Print)
IS  - 2473-9529 (Linking)
VI  - 3
IP  - 3
DP  - 2019 Feb 12
TI  - Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.
PG  - 242-255
LID - 10.1182/bloodadvances.2018024182 [doi]
AB  - Treatment options for acute myeloid leukemia (AML) remain extremely limited and 
      associated with significant toxicity. Nicotinamide phosphoribosyltransferase (NAMPT) 
      is involved in the generation of NAD(+) and a potential therapeutic target in AML. 
      We evaluated the effect of KPT-9274, a p21-activated kinase 4/NAMPT inhibitor that 
      possesses a unique NAMPT-binding profile based on in silico modeling compared with 
      earlier compounds pursued against this target. KPT-9274 elicited loss of 
      mitochondrial respiration and glycolysis and induced apoptosis in AML subtypes 
      independent of mutations and genomic abnormalities. These actions occurred mainly 
      through the depletion of NAD(+), whereas genetic knockdown of p21-activated kinase 4 
      did not induce cytotoxicity in AML cell lines or influence the cytotoxic effect of 
      KPT-9274. KPT-9274 exposure reduced colony formation, increased blast 
      differentiation, and diminished the frequency of leukemia-initiating cells from 
      primary AML samples; KPT-9274 was minimally cytotoxic toward normal hematopoietic or 
      immune cells. In addition, KPT-9274 improved overall survival in vivo in 2 different 
      mouse models of AML and reduced tumor development in a patient-derived xenograft 
      model of AML. Overall, KPT-9274 exhibited broad preclinical activity across a 
      variety of AML subtypes and warrants further investigation as a potential 
      therapeutic agent for AML.
CI  -  2019 by The American Society of Hematology.
FAU - Mitchell, Shaneice R
AU  - Mitchell SR
AUID- ORCID: 0000-0001-9297-781X
AD  - Division of Hematology.
FAU - Larkin, Karilyn
AU  - Larkin K
AUID- ORCID: 0000-0002-1898-9836
AD  - Division of Hematology.
FAU - Grieselhuber, Nicole R
AU  - Grieselhuber NR
AUID- ORCID: 0000-0003-3495-5932
AD  - Division of Hematology.
FAU - Lai, Tzung-Huei
AU  - Lai TH
AD  - Division of Hematology.
FAU - Cannon, Matthew
AU  - Cannon M
AD  - Division of Hematology.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology.
FAU - Sharma, Pratibha
AU  - Sharma P
AD  - Division of Neuro-oncology.
FAU - Asemelash, Yerdanose
AU  - Asemelash Y
AD  - Division of Hematology.
FAU - Zhang, Pu
AU  - Zhang P
AD  - Division of Hematology.
FAU - Goettl, Virginia M
AU  - Goettl VM
AD  - Division of Hematology.
FAU - Beaver, Larry
AU  - Beaver L
AD  - Division of Hematology.
FAU - Mims, Alice
AU  - Mims A
AD  - Division of Hematology.
FAU - Puduvalli, Vinay K
AU  - Puduvalli VK
AUID- ORCID: 0000-0001-8396-9500
AD  - Division of Neuro-oncology.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology.
FAU - Lehman, Amy
AU  - Lehman A
AD  - Center for Biostatistics, and.
FAU - Harrington, Bonnie
AU  - Harrington B
AUID- ORCID: 0000-0003-2658-6188
AD  - College of Veterinary Medicine, The Ohio State University, Columbus, OH.
FAU - Henderson, Sally
AU  - Henderson S
AD  - College of Veterinary Medicine, The Ohio State University, Columbus, OH.
FAU - Breitbach, Justin T
AU  - Breitbach JT
AD  - College of Veterinary Medicine, The Ohio State University, Columbus, OH.
FAU - Williams, Katie E
AU  - Williams KE
AD  - Division of Hematology.
FAU - Dong, Shuai
AU  - Dong S
AUID- ORCID: 0000-0002-2434-2430
AD  - Division of Hematology.
FAU - Baloglu, Erkan
AU  - Baloglu E
AD  - Karyopharm Therapeutics Inc., Newton, MA.
FAU - Senapedis, William
AU  - Senapedis W
AD  - Karyopharm Therapeutics Inc., Newton, MA.
FAU - Kirschner, Karl
AU  - Kirschner K
AUID- ORCID: 0000-0002-4581-920X
AD  - Departments of Computer Science and Electrical Engineering, Mechanical Engineering 
      and Technical Journalism, Bonn-Rhein-Sieg University of Applied Sciences, Sankt 
      Augustin, Germany; and.
FAU - Sampath, Deepa
AU  - Sampath D
AD  - Division of Hematology.
FAU - Lapalombella, Rosa
AU  - Lapalombella R
AUID- ORCID: 0000-0001-6916-9400
AD  - Division of Hematology.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology.
AD  - College of Veterinary Medicine, The Ohio State University, Columbus, OH.
AD  - Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, 
      OH.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - T32 GM068412/GM/NIGMS NIH HHS/United States
GR  - R01 CA223165/CA/NCI NIH HHS/United States
GR  - T32 OD010429/OD/NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
RN  - 0 (Acrylamides)
RN  - 0 (Aminopyridines)
RN  - 0 (Cytokines)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (KPT-9274)
RN  - EC 2.4.2.12 (Nicotinamide Phosphoribosyltransferase)
RN  - EC 2.4.2.12 (nicotinamide phosphoribosyltransferase, human)
SB  - IM
MH  - Acrylamides/*pharmacology
MH  - Aminopyridines/*pharmacology
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Cell Line, Tumor
MH  - Cytokines/*antagonists & inhibitors
MH  - Enzyme Inhibitors/pharmacology
MH  - HL-60 Cells
MH  - Humans
MH  - K562 Cells
MH  - Leukemia, Myeloid, Acute/*drug therapy/enzymology/pathology
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Nicotinamide Phosphoribosyltransferase/*antagonists & inhibitors
MH  - Xenograft Model Antitumor Assays
PMC - PMC6373756
COIS- Conflict-of-interest disclosures: E.B. and W.S. are employees of, and have financial 
      interests in, Karyopharm Therapeutics Inc. J.S.B. has performed consulting for 
      AbbVie, AstraZeneca, and Kite Pharma. V.K.P. performed consulting for Orbus 
      Therapeutics and SK Biosciences. The remaining authors declare no competing 
      financial interests.
EDAT- 2019/01/30 06:00
MHDA- 2020/03/20 06:00
CRDT- 2019/01/30 06:00
PHST- 2018/07/29 00:00 [received]
PHST- 2018/12/06 00:00 [accepted]
PHST- 2019/01/30 06:00 [entrez]
PHST- 2019/01/30 06:00 [pubmed]
PHST- 2020/03/20 06:00 [medline]
AID - bloodadvances.2018024182 [pii]
AID - 2018/024182 [pii]
AID - 10.1182/bloodadvances.2018024182 [doi]
PST - ppublish
SO  - Blood Adv. 2019 Feb 12;3(3):242-255. doi: 10.1182/bloodadvances.2018024182.

PMID- 33947938
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 35
IP  - 7
DP  - 2021 Jul
TI  - Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.
PG  - 1864-1872
LID - 10.1038/s41375-021-01257-7 [doi]
AB  - Standard treatment options in classic HCL (cHCL) result in high response rates and 
      near normal life expectancy. However, the disease itself and the recommended 
      standard treatment are associated with profound and prolonged immunosuppression, 
      increasing susceptibility to infections and the risk for a severe course of 
      COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts 
      and discussed different clinical strategies for the management of these patients. 
      The new recommendations adapt the 2017 consensus for the diagnosis and management 
      with cHCL to the current COVID-19 pandemic. They underline the option of active 
      surveillance in patients with low but stable blood counts, consider the use of 
      targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give 
      recommendations on preventive measures against COVID-19.
FAU - Grever, Michael
AU  - Grever M
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      OH, USA. Michael.grever@osumc.edu.
FAU - Andritsos, Leslie
AU  - Andritsos L
AD  - Division of Hematology Oncology, University of New Mexico Comprehensive Cancer 
      Center, Albuquerque, NM, USA.
FAU - Banerji, Versha
AU  - Banerji V
AD  - Department of Internal Medicine & Biochemistry and Medical Genetics, Rady Faculty of 
      Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
AD  - Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, 
      Canada.
FAU - Barrientos, Jacqueline C
AU  - Barrientos JC
AD  - Department of Medicine, Northwell Health Cancer Institute, Donald and Barbara Zucker 
      School of Medicine at Hofstra/Northwell and Feinstein Institute for Medical 
      Research, New York, NY, USA.
FAU - Bhat, Seema
AU  - Bhat S
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      OH, USA.
FAU - Call, Timothy
AU  - Call T
AD  - Division of Hematology, Mayo Clinic, Rochester, MN, USA.
FAU - Cross, Matthew
AU  - Cross M
AUID- ORCID: 0000-0003-0675-5618
AD  - Royal Marsden Hospital, London, UK.
FAU - Dearden, Claire
AU  - Dearden C
AD  - Royal Marsden Hospital, London, UK.
FAU - Demeter, Judit
AU  - Demeter J
AD  - Department of Internal Medicine and Oncology, Semmelweis University, Budapest, 
      Hungary.
FAU - Dietrich, Sasha
AU  - Dietrich S
AUID- ORCID: 0000-0002-0648-1832
AD  - Department of Hematology, University Hospital, Heidelberg, Germany.
FAU - Falini, Brunangelo
AU  - Falini B
AUID- ORCID: 0000-0002-7198-5965
AD  - Institute of Hematology, Department of Medicine and Surgery, University and Hospital 
      of Perugia, Perugia, Italy.
FAU - Forconi, Francesco
AU  - Forconi F
AD  - Cancer Sciences and Haematology Department, University of Southampton Hospital 
      Trust, Southampton, UK.
FAU - Gladstone, Douglas E
AU  - Gladstone DE
AD  - Johns Hopkins University, Baltimore, MD, USA.
FAU - Gozzetti, Alessandro
AU  - Gozzetti A
AUID- ORCID: 0000-0003-0769-6891
AD  - University of Siena Policlinico S Maria alle Scotte, Siena, Italy.
FAU - Iyengar, Sunil
AU  - Iyengar S
AUID- ORCID: 0000-0003-4863-4160
AD  - Royal Marsden Hospital, London, UK.
FAU - Johnston, James B
AU  - Johnston JB
AUID- ORCID: 0000-0001-6614-083X
AD  - Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
FAU - Juliusson, Gunnar
AU  - Juliusson G
AD  - Stem Cell Centre, Department of Laboratory Medicine, Lund University, and Department 
      of Hematology, Skne University Hospital, Lund, Sweden.
FAU - Kraut, Eric
AU  - Kraut E
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      OH, USA.
FAU - Kreitman, Robert J
AU  - Kreitman RJ
AD  - Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, MD, USA.
FAU - Lauria, Francesco
AU  - Lauria F
AD  - University of Siena Policlinico S Maria alle Scotte, Siena, Italy.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - Department of Pathology, The Ohio State University Medical Center, Columbus, OH, 
      USA.
FAU - Parikh, Sameer A
AU  - Parikh SA
AUID- ORCID: 0000-0002-3221-7314
AD  - Division of Hematology, Mayo Clinic, Rochester, MN, USA.
FAU - Park, Jae
AU  - Park J
AUID- ORCID: 0000-0002-2903-5130
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Polliack, Aaron
AU  - Polliack A
AD  - Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
FAU - Ravandi, Farhad
AU  - Ravandi F
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, 
      USA.
FAU - Robak, Tadeusz
AU  - Robak T
AD  - Department of Hematology, Medical University of Lodz, Lodz, Poland.
FAU - Rogers, Kerry A
AU  - Rogers KA
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      OH, USA.
FAU - Saven, Alan
AU  - Saven A
AD  - Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA, USA.
FAU - Seymour, John F
AU  - Seymour JF
AUID- ORCID: 0000-0003-2188-6835
AD  - Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, 
      University of Melbourne, Melbourne, VIC, Australia.
FAU - Tadmor, Tamar
AU  - Tadmor T
AD  - Hematology Unit, Bnai-Zion Medical Center and Rappaport Faculty of Medicine, 
      Technion Institute Technology, Haifa, Israel.
FAU - Tallman, Martin S
AU  - Tallman MS
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Tam, Constantine S
AU  - Tam CS
AD  - Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, 
      University of Melbourne, Melbourne, VIC, Australia.
FAU - Tiacci, Enrico
AU  - Tiacci E
AD  - Institute of Hematology, Department of Medicine and Surgery, University and Hospital 
      of Perugia, Perugia, Italy.
FAU - Troussard, Xavier
AU  - Troussard X
AD  - Department of Hematology, Centre Hospitalier Universitaire Cte de Nacre, Caen, 
      France.
FAU - Zent, Clive
AU  - Zent C
AUID- ORCID: 0000-0001-6099-3313
AD  - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, 
      NY, USA.
FAU - Zenz, Thorsten
AU  - Zenz T
AUID- ORCID: 0000-0001-7890-9845
AD  - Department of Medical Oncology and Haematology, University Hospital Zrich and 
      University of Zrich, Zrich, Switzerland.
FAU - Zinzani, Pier Luigi
AU  - Zinzani PL
AUID- ORCID: 0000-0002-2112-2651
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna and Instituto di Ematologia 
      "Sergnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale 
      Universit degli Studi, Bologna, Italy.
FAU - Wrmann, Bernhard
AU  - Wrmann B
AUID- ORCID: 0000-0003-2273-5502
AD  - Charit-University Medicine, Berlin, Germany. bernhar.woermann@charite.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210504
TA  - Leukemia
JT  - Leukemia
JID - 8704895
SB  - IM
MH  - COVID-19/*complications/epidemiology/pathology/virology
MH  - Consensus
MH  - Humans
MH  - Leukemia, Hairy Cell/complications/*therapy
MH  - Pandemics
MH  - Practice Guidelines as Topic
MH  - SARS-CoV-2/isolation & purification
MH  - Severity of Illness Index
PMC - PMC8093591
COIS- LA: previously provided consultation services for Innate Pharma and AstraZeneca. VB: 
      VB serves on the Advisory Boards of Gilead, Lundbeck, Janssen, AstraZeneca, and 
      Abbvie and has had research funding from CIHR, LLSC, CCMF, Roche, Janssen, Abbvie, 
      and Lundbeck. VB also received fees from BIOGEN for patented compounds unrelated to 
      this study. JCB: research funding: AstraZeneca, Oncternal, TG therapeutics, 
      Pharmacyclics/AbbVie; Advisory Board: AstraZeneca, Pharmacyclics/Abbvie, Beigene, 
      Genentech, Gilead, Innate. SB: served on Advisory board for Pharmacyclics and 
      Janssen, Beigene and AstraZeneca; received honorarium from OncLive; received travel 
      grant from Arqule. JSB: consulting and Advisory Board: AbbVie, AstraZeneca, INNATE 
      Pharma, KITE Pharma; research funding: MingSight Pharmaceuticals: patents and 
      intellectual property: a leukemia diagnostic device (patent pending). Research work 
      is funded by the Royal Marden Cancer Charity. CD: has been an advisor for 
      Medimmune/Innate Pharma (moxetumomab); consulting/Advisory Board for Abbie and 
      Jansen. JD: has participated in advisory committees in Hungary for Novartis, Bristol 
      Myers Squibb, Amicus, Angelini, Pfizer, Amgen, Roche. AG: Advisory Board: Amgen, 
      Takeda. Research funding: Jansenn and Cilag SPA. Honoraria: Abbvie, Jansenn Cilag, 
      Celgene, Amgen, Takeda. Michael Grever: consultant: AstraZeneca, Pharmacyclics, 
      Ascerta, Axio, Inc. Research funding: Hairy Cell Leukemia Foundation for Patient 
      Data Registry; travel expenses: Hairy Cell Leukemia Foundation; Scientific Board 
      Chair: Hairy Cell Leukemia Foundation Scientific Board (no reimbursement); 
      Scientific Honorarium: University of Pittsburgh. SI: Advisory and speaker fees: 
      Gilead and Takeda; Advisory: Beigene; Speaker fees: Janssen, Takeda, and Gilead. 
      RJK: employment: National Institutes of Health and Regional Cancer Care Associates; 
      Honoraria: PlatformQ, OncLive, Cure; research funding: Innate, AstraZeneca, 
      Novartis, Genetech, Pfizer, Teva, Hairy Cell Leukemia Foundation; patents: 
      coinventor for NIH patent for Moxetumomab Pasudotox. SAP: research funding has been 
      provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG 
      Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which SAP 
      is a principal investigator. SAP has also participated in Advisory Board meetings of 
      Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Innate Pharma, Adaptive 
      Biotechnologies, and AbbVie (he was not personally compensated for his 
      participation). JP: research funding from Genentech, Servier, Takeda, Fate 
      Therapeutics, and Amgen. Consulting fees from Servier, Amgen, AstraZeneca, Innate 
      Pharma, Novartis, Kite Pharma, Takeda, Intellia, and Kura Oncology. FR: Consultancy 
      and HonorariaCelgene, BMS, Amgen, Astellas, Xencor, Agios, AstraZeneca, Orsenix, 
      Innate Pharma, Syros, Taiho, Novartis; research fundingBMS, Amgen, Xencor, 
      Macrogenics, Orsenix, Abbvie, Taiho, Prelude, Astex. TR: research funding: 
      AstraZeneca, Medimmune, Roche, Janssen, Abbvie, Advisory Board; AstraZeneca, Jassen, 
      Abbvie; travel grant: Roche, Janssen; Honoraria: Abbvie, AstraZeneca, Janssen. KAR: 
      received research funding from Genentech, AbbVie, Janssen, and Novartis all paid to 
      her institution, consulted for Acerta Pharma, AstraZeneca, Innate Pharma, Genentech, 
      AbbVie, and Pharmacyclics, received travel funding from AstraZeneca. AS: consultant 
      and Advisory Boards: AstraZeneca and Innate Pharmaceuticals; Speakers Bureau: AbbVie 
      and Pharmacyclics. JFS: AbbVie, Advisory board, speakers bureau, research funding; 
      AstraZeneca, Advisory board; Celgene, Advisory board, speakers bureau, research 
      funding, expert testimony; Genentech, Advisory board; Gilead, Advisory Board; 
      Janssen, Advisory board, research funding; Mei Pharma, Advisory board; Morphosys, 
      Advisory Board; Roche, Advisory board, speakers bureau, research funding, expert 
      testimony; Sunesis, Advisory board; Takeda, Advisory Board. TT: advisor: Roche, 
      AbbVie, Janssen, Takeda, Gilead, AstraZeneca, Novartis. MST: research funding: 
      AbbVie, Amgen, Biosight, Glycomimetics, Orsenix, Rafael; Advisory Boards: Amgen, 
      Daiichi-Sankyo, Delta Fly Pharma, Innate pharmaceuticals, Jazz, Kahr, Kura, 
      Novartis, Orsenix, Roche, Syros; Royalties: UpToDate. CST: Honoraria from Janssen, 
      AbbVie and Beigene, and his hospital receives research funding from Janssen, AbbVie, 
      and Beigene. ET: consultant for Innate Pharma. Research funding: Roche. Travel cost: 
      Shire. Holder of a patent on the use of mutant BRAF as HCL biomarker. Our research 
      work in HCL is funded by the Hairy Cell Leukemia Foundation, the Leukemia and 
      Lymphoma Society, and the Associazione Italiana Ricerca sul Cancro (AIRC). XT: 
      consultant for Innate Pharma, AstraZeneca; advisor: Abbvie. Clive Zent: funding 
      through the University of Rochester for laboratory research, from Acerta/AstraZeneca 
      and TG Therapeutics, and from the Hairy Cell Leukemia Foundation. TZ: advisor: 
      Roche, AbbVie, Janssen, Takeda, Gilead, AstraZeneca. PLZ: Speakers Bureau: Verastem, 
      Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, TG Therap., Takeda, Roche, 
      Eusapharma, Kyowa Kirin; Advisory Board: Verastem, Celltrion, Gilead, Janssen-Cilag, 
      BMS, Servier, Sandoz, MSD, TG Therap., Takeda, Roche, Eusapharma, Kyowa Kirin, ADC 
      Therap.; consultant: Verastem, MSD, Eusapharma, Sanofi. The other authors declare no 
      competing interests.
EDAT- 2021/05/06 06:00
MHDA- 2021/07/20 06:00
CRDT- 2021/05/05 06:14
PHST- 2021/02/26 00:00 [received]
PHST- 2021/04/12 00:00 [accepted]
PHST- 2021/03/11 00:00 [revised]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2021/05/05 06:14 [entrez]
AID - 10.1038/s41375-021-01257-7 [pii]
AID - 1257 [pii]
AID - 10.1038/s41375-021-01257-7 [doi]
PST - ppublish
SO  - Leukemia. 2021 Jul;35(7):1864-1872. doi: 10.1038/s41375-021-01257-7. Epub 2021 May 
      4.

PMID- 30679803
OWN - NLM
STAT- MEDLINE
DCOM- 20190719
LR  - 20210209
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
VI  - 33
IP  - 3
DP  - 2019 Mar
TI  - Implementation of standardized variant-calling nomenclature in the age of 
      next-generation sequencing: where do we stand?
PG  - 809-810
LID - 10.1038/s41375-018-0372-x [doi]
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      ann-kathrin.eisfeld@osumc.edu.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      krzysztof.mrozek@osumc.edu.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance for Clinical Trials in Oncology Statistics and Data Center, The Ohio State 
      University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - de la Chapelle, Albert
AU  - de la Chapelle A
AUID- ORCID: 0000-0001-9345-9248
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      clara.bloomfield@osumc.edu.
LA  - eng
GR  - CA180861/U.S. Department of Health &amp; Human Services | NIH | National Cancer 
      Institute (NCI)/International
PT  - Letter
DEP - 20190124
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
SB  - IM
MH  - Genetic Variation/*genetics
MH  - High-Throughput Nucleotide Sequencing/*standards
MH  - Humans
MH  - Reference Standards
MH  - Sequence Analysis, DNA/standards
EDAT- 2019/01/27 06:00
MHDA- 2019/07/20 06:00
CRDT- 2019/01/26 06:00
PHST- 2018/09/17 00:00 [received]
PHST- 2018/09/24 00:00 [accepted]
PHST- 2019/01/27 06:00 [pubmed]
PHST- 2019/07/20 06:00 [medline]
PHST- 2019/01/26 06:00 [entrez]
AID - 10.1038/s41375-018-0372-x [pii]
AID - 10.1038/s41375-018-0372-x [doi]
PST - ppublish
SO  - Leukemia. 2019 Mar;33(3):809-810. doi: 10.1038/s41375-018-0372-x. Epub 2019 Jan 24.

PMID- 31462731
OWN - NLM
STAT- MEDLINE
DCOM- 20200731
LR  - 20210209
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 34
IP  - 2
DP  - 2020 Feb
TI  - Clinical and molecular characterization of patients with acute myeloid leukemia and 
      sole trisomies of chromosomes 4, 8, 11, 13 or 21.
PG  - 358-368
LID - 10.1038/s41375-019-0560-3 [doi]
AB  - Sole trisomies of chromosomes 4, 8, 11, 13 and 21 account for 89-95% of all sole 
      trisomies in adult AML patients. We analyzed clinical and molecular characteristics 
      of 138 de novo AML patients with sole +4, +8, +11, +13 or +21, and compared them 
      with AML patients with those trisomies occurring in addition to other chromosome 
      abnormalities (non-sole trisomy) and with cytogenetically normal AML (CN-AML) 
      patients. Mutations in methylation-related genes were most commonly observed within 
      each sole trisomy group (+4, 55%; +8, 58%; +11, 71%; +13, 71%; +21, 75% of 
      patients). Patients with sole trisomies, excluding +4, also had frequent mutations 
      in spliceosome genes (+8, 43%; +11, 65%; +13, 65%; +21, 45% of patients). In 
      contrast, +4 patients frequently had mutations in transcription factor genes (44%) 
      and NPM1 (36%). While 48% of patients with sole trisomies harbored mutations in a 
      spliceosome gene, spliceosome mutations were observed in only 24% of non-sole 
      trisomy (n=131, P<0.001) and 19% of CN-AML patients (n=716, P<0.001). Our 
      data suggest that mutations affecting methylation-related genes are a molecular 
      hallmark of sole trisomies. Mutations in spliceosome genes were also commonly 
      observed in many sole trisomy patients and represent a novel finding in this 
      cytogenetic subgroup.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA. Bhavana.Bhatnagar@osumc.edu.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      Bhavana.Bhatnagar@osumc.edu.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University, Columbus, OH, USA.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University, Columbus, OH, USA.
FAU - Papaioannou, Dimitrios
AU  - Papaioannou D
AD  - Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - Monter Cancer Center, Hofstra Northwell School of Medicine, Lake Success, NY, USA.
FAU - Powell, Bayard L
AU  - Powell BL
AD  - Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, USA.
FAU - Carroll, Andrew J
AU  - Carroll AJ
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
LA  - eng
GR  - U10 CA077658/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - UG1 CA233180/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - UG1 CA233331/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - L30 CA220783/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - UG1 CA233338/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190828
TA  - Leukemia
JT  - Leukemia
JID - 8704895
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosomes, Human, Pair 11/genetics
MH  - Chromosomes, Human, Pair 13/genetics
MH  - Chromosomes, Human, Pair 21/genetics
MH  - Chromosomes, Human, Pair 4/genetics
MH  - Chromosomes, Human, Pair 8/genetics
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Male
MH  - Middle Aged
MH  - Trisomy/*genetics
PMC - PMC6995758
MID - NIHMS1065270
COIS- Conflict of interest The authors declare that they have no conflict of interest.
EDAT- 2019/08/30 06:00
MHDA- 2020/08/01 06:00
CRDT- 2019/08/30 06:00
PHST- 2019/03/27 00:00 [received]
PHST- 2019/07/15 00:00 [accepted]
PHST- 2019/07/01 00:00 [revised]
PHST- 2019/08/30 06:00 [pubmed]
PHST- 2020/08/01 06:00 [medline]
PHST- 2019/08/30 06:00 [entrez]
AID - 10.1038/s41375-019-0560-3 [pii]
AID - 10.1038/s41375-019-0560-3 [doi]
PST - ppublish
SO  - Leukemia. 2020 Feb;34(2):358-368. doi: 10.1038/s41375-019-0560-3. Epub 2019 Aug 28.

PMID- 32777116
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20210929
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Print)
IS  - 0361-8609 (Linking)
VI  - 95
IP  - 12
DP  - 2020 Dec
TI  - A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in 
      patients with relapsed or refractory acute myeloid leukemia and high-risk 
      myelodysplastic syndrome.
PG  - 1457-1465
LID - 10.1002/ajh.25958 [doi]
AB  - Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) have poor 
      outcomes and hematopoietic cell transplantation (HCT) is the only curative 
      treatment. New targeted therapies improved survival in select patients with specific 
      mutations, however management of patients without these molecular alterations is an 
      unmet need. We conducted a phase one study of lenalidomide in combination with 
      cytarabine/idarubicin salvage chemotherapy in patients with R/R AML and high-risk 
      myelodysplastic syndromes. A total of 33 patients were enrolled in the study (30 
      AML, 3 MDS), and treated at three dose levels with 3 + 3 design. Dose-limiting 
      toxicity (DLT) was seen in eight patients, including four hematologic DLTs. The most 
      commonly observed non-hematologic serious adverse events were febrile neutropenia, 
      rash, sepsis and renal injury. Dose level -1, consisting of 25mg/d lenalidomide 
      D1-21, 1 g/m(2) cytarabine D5-8, and 8 mg/m(2) idarubicin D5-7 was determined to be 
      the maximum tolerated dose. Note, 15/33 (45%) of patients were able to receive 
      pre-planned 21days of lenalidomide. Overall, 18 patients achieved complete 
      remission (CR) (n = 14) or CR with incomplete count recovery (CRi) (n = 4) with 
      total CR/CRi rate of 56%. The 1-year and 2-year overall survival (OS) were 24% and 
      10%, respectively. Among responders, 10/18 underwent allogeneic HCT and had a 1-year 
      OS of 40%. There was no molecular pattern associated with response. These data 
      demonstrate that the combination had clinical activity in R/R AML. This regimen 
      should be further investigated for patients who relapsed after HCT, and as a bridge 
      therapy to HCT. (ClinicalTrials.gov identifier: NCT01132586).
CI  -  2020 The Authors. American Journal of Hematology published by Wiley Periodicals 
      LLC.
FAU - Saygin, Caner
AU  - Saygin C
AUID- ORCID: 0000-0003-1315-0377
AD  - Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
FAU - Larkin, Karilyn
AU  - Larkin K
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Ngankeu, Apollinaire
AU  - Ngankeu A
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Gregory, Charles T
AU  - Gregory CT
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Phelps, Mitch A
AU  - Phelps MA
AUID- ORCID: 0000-0002-1615-5280
AD  - Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, 
      Ohio.
FAU - Mani, Shylaja
AU  - Mani S
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Walker, Alison
AU  - Walker A
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Garzon, Ramiro
AU  - Garzon R
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Vasu, Sumithira
AU  - Vasu S
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Walsh, Katherine J
AU  - Walsh KJ
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AUID- ORCID: 0000-0002-4869-0712
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Klisovic, Rebecca B
AU  - Klisovic RB
AD  - Department of Hematology and Medical Oncology, Emory University School of Medicine, 
      Winship Cancer Institute, Atlanta, Georgia.
FAU - Grever, Michael R
AU  - Grever MR
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Marcucci, Guido
AU  - Marcucci G
AD  - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope 
      Medical Center, Duarte, California.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
FAU - Blum, William
AU  - Blum W
AD  - Department of Hematology and Medical Oncology, Emory University School of Medicine, 
      Winship Cancer Institute, Atlanta, Georgia.
FAU - Mims, Alice S
AU  - Mims AS
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, Ohio.
LA  - eng
SI  - ClinicalTrials.gov/NCT01132586
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Journal Article
DEP - 20200919
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 04079A1RDZ (Cytarabine)
RN  - F0P408N6V4 (Lenalidomide)
RN  - ZRP63D75JW (Idarubicin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Cytarabine/administration & dosage/adverse effects
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Idarubicin/administration & dosage/adverse effects
MH  - Lenalidomide/administration & dosage/adverse effects
MH  - *Leukemia, Myeloid, Acute/drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - *Myelodysplastic Syndromes/drug therapy/mortality
MH  - Survival Rate
PMC - PMC7821016
COIS- The authors declare no potential conflict of interest.
EDAT- 2020/08/11 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/06/01 00:00 [received]
PHST- 2020/07/26 00:00 [revised]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - AJH25958 [pii]
AID - 10.1002/ajh.25958 [doi]
PST - ppublish
SO  - Am J Hematol. 2020 Dec;95(12):1457-1465. doi: 10.1002/ajh.25958. Epub 2020 Sep 19.

PMID- 32921593
OWN - NLM
STAT- In-Process
LR  - 20210622
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jan
TI  - The Incidence of Invasive Fungal Infections in Patients With AML Treated With a 
      Hypomethylating Agent.
PG  - e76-e83
LID - S2152-2650(20)30429-8 [pii]
LID - 10.1016/j.clml.2020.08.013 [doi]
AB  - BACKGROUND: Newly diagnosed patients with acute myeloid leukemia (AML) who receive 
      induction with a hypomethylating agent (HMA) are often neutropenic with an increased 
      risk for invasive fungal infections (IFIs). This study analyzed the incidence and 
      risk factors for IFIs in these patients, evaluated clinical patterns in antifungal 
      prophylaxis, and assessed the diagnostic utility of tests in this setting. PATIENTS 
      AND METHODS: We studied 117 newly diagnosed patients with AML treated with HMAs at 
      our center, divided into groups based on concern for IFI (cIFI: all possible, 
      probable, and proven IFIs) versus no concern for IFI. The Fisher exact test compared 
      patients with cIFI versus without, and a multivariable logistic regression model 
      estimated odds for cIFI. RESULTS: Sixty-seven (57%) patients had cIFI, with 48 
      possible IFIs, 17 probable, and 2 proven cases. There was no difference in incidence 
      based on home zip code, but the presence of chronic obstructive pulmonary disease 
      was highly associated with cIFI (P= .001), as was male gender (P= .01). 
      Neutropenia at treatment initiation was borderline in significance (P= .08). In 
      diagnostics, 9% of patients had positive serum fungal markers, and 30 patients 
      underwent bronchoscopy, with only 27% of cases yielding positive results. There was 
      a difference in treatment regimens between patients receiving antifungal prophylaxis 
      with mold coverage versus without mold coverage with respect to cIFI (P= .04). 
      CONCLUSIONS: cIFI in patients with AML treated with HMAs remains significant, 
      especially in males and those with chronic obstructive pulmonary disease, who were 
      found to be at higher risk. This may prompt clinicians to consider anti-mold 
      prophylaxis in this setting.
CI  - Copyright  2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Ozga, Michael
AU  - Ozga M
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH.
FAU - Huang, Ying
AU  - Huang Y
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH.
FAU - Grieselhuber, Nicole R
AU  - Grieselhuber NR
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH.
FAU - Wall, Sarah
AU  - Wall S
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH.
FAU - Larkin, Karilyn
AU  - Larkin K
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH.
FAU - Haque, Tamanna
AU  - Haque T
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH.
FAU - Walker, Alison R
AU  - Walker AR
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH.
FAU - Behbehani, Gregory
AU  - Behbehani G
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH.
FAU - Vasu, Sumithira
AU  - Vasu S
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH.
FAU - Maakaron, Joseph E
AU  - Maakaron JE
AD  - Department of Medicine, University of Minnesota, Minneapolis, MN.
FAU - Lustberg, Mark
AU  - Lustberg M
AD  - Division of Infectious Disease, The Ohio State University Wexner Medical Center, 
      Columbus, OH.
FAU - Mims, Alice S
AU  - Mims AS
AD  - Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, 
      OH. Electronic address: alice.mims@osumc.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200821
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
SB  - IM
OTO - NOTNLM
OT  - *Acute myeloid leukemia
OT  - *Anti-mold azoles
OT  - *Antifungal prophylaxis
OT  - *Decitabine
OT  - *Risk stratification
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/14 05:36
PHST- 2020/06/26 00:00 [received]
PHST- 2020/08/10 00:00 [revised]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2020/09/14 05:36 [entrez]
AID - S2152-2650(20)30429-8 [pii]
AID - 10.1016/j.clml.2020.08.013 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):e76-e83. doi: 10.1016/j.clml.2020.08.013. 
      Epub 2020 Aug 21.

PMID- 32759975
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20211002
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 35
IP  - 4
DP  - 2021 Apr
TI  - Comparison of clinical and molecular characteristics of patients with acute myeloid 
      leukemia and either TP73 or TP53 mutations.
PG  - 1188-1192
LID - 10.1038/s41375-020-1007-6 [doi]
FAU - Mims, Alice S
AU  - Mims AS
AUID- ORCID: 0000-0002-8971-2199
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      alice.mims@osumc.edu.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH, USA.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Papaioannou, Dimitrios
AU  - Papaioannou D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH, USA.
FAU - Sampath, Deepa
AU  - Sampath D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Powell, Bayard L
AU  - Powell BL
AD  - Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - Monter Cancer Center, Hofstra Northwell School of Medicine, Lake Success, NY, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AUID- ORCID: 0000-0001-5465-7591
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
LA  - eng
GR  - U10 CA077658/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - UG1 CA233338/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Letter
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200805
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (TP53 protein, human)
RN  - 0 (TP73 protein, human)
RN  - 0 (Tumor Protein p73)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Alleles
MH  - Female
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Myeloid, Acute/*diagnosis/*genetics/mortality
MH  - Male
MH  - *Mutation
MH  - *Phenotype
MH  - Prognosis
MH  - Tumor Protein p73/*genetics
MH  - Tumor Suppressor Protein p53/*genetics
PMC - PMC7862425
MID - NIHMS1660597
COIS- Disclosure of Potential Conflicts of Interest: The authors declare no conflicts of 
      interest.
EDAT- 2020/08/08 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - 10.1038/s41375-020-1007-6 [pii]
AID - 10.1038/s41375-020-1007-6 [doi]
PST - ppublish
SO  - Leukemia. 2021 Apr;35(4):1188-1192. doi: 10.1038/s41375-020-1007-6. Epub 2020 Aug 5.

PMID- 31292113
OWN - NLM
STAT- MEDLINE
DCOM- 20200127
LR  - 20210202
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 134
IP  - 8
DP  - 2019 Aug 22
TI  - Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural 
      history of chronic lymphocytic leukemia.
PG  - 688-698
LID - 10.1182/blood.2019000490 [doi]
AB  - Alterations in global DNA methylation patterns are a major hallmark of cancer and 
      represent attractive biomarkers for personalized risk stratification. Chronic 
      lymphocytic leukemia (CLL) risk stratification studies typically focus on time to 
      first treatment (TTFT), time to progression (TTP) after treatment, and overall 
      survival (OS). Whereas TTFT risk stratification remains similar over time, TTP and 
      OS have changed dramatically with the introduction of targeted therapies, such as 
      the Bruton tyrosine kinase inhibitor ibrutinib. We have shown that genome-wide DNA 
      methylation patterns in CLL are strongly associated with phenotypic differentiation 
      and patient outcomes. Here, we developed a novel assay, termed methylation-iPLEX 
      (Me-iPLEX), for high-throughput quantification of targeted panels of single cytosine 
      guanine dinucleotides from multiple independent loci. Me-iPLEX was used to classify 
      CLL samples into 1 of 3 known epigenetic subtypes (epitypes). We examined the impact 
      of epitype in 1286 CLL patients from 4 independent cohorts representing a 
      comprehensive view of CLL disease course and therapies. We found that epitype 
      significantly predicted TTFT and OS among newly diagnosed CLL patients. 
      Additionally, epitype predicted TTP and OS with 2 common CLL therapies: 
      chemoimmunotherapy and ibrutinib. Epitype retained significance after stratifying by 
      biologically related biomarkers, immunoglobulin heavy chain mutational status, and 
      ZAP70 expression, as well as other common prognostic markers. Furthermore, among 
      several biological traits enriched between epitypes, we found highly biased 
      immunogenetic features, including IGLV3-21 usage in the poorly characterized 
      intermediate-programmed CLL epitype. In summary, Me-iPLEX is an elegant method to 
      assess epigenetic signatures, including robust classification of CLL epitypes that 
      independently stratify patient risk at diagnosis and time of treatment.
CI  -  2019 by The American Society of Hematology.
FAU - Giacopelli, Brian
AU  - Giacopelli B
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Zhao, Qiuhong
AU  - Zhao Q
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Ruppert, Amy S
AU  - Ruppert AS
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Agyeman, Akwasi
AU  - Agyeman A
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Weigel, Christoph
AU  - Weigel C
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Wu, Yue-Zhong
AU  - Wu YZ
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Gerber, Madelyn M
AU  - Gerber MM
AD  - Department of Pathology, The Ohio State University, Columbus, OH.
FAU - Rabe, Kari G
AU  - Rabe KG
AUID- ORCID: 0000-0002-7313-1875
AD  - Division of Biomedical Statistics and Informatics, Department of Health Sciences 
      Research, Mayo Clinic, Rochester, MN.
FAU - Larson, Melissa C
AU  - Larson MC
AD  - Division of Biomedical Statistics and Informatics, Department of Health Sciences 
      Research, Mayo Clinic, Rochester, MN.
FAU - Lu, Junyan
AU  - Lu J
AUID- ORCID: 0000-0002-9211-0746
AD  - European Molecular Biology Laboratory, Heidelberg, Germany.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Rogers, Kerry A
AU  - Rogers KA
AUID- ORCID: 0000-0001-5748-7874
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Wierda, William G
AU  - Wierda WG
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
FAU - Brown, Jennifer R
AU  - Brown JR
AD  - Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA.
FAU - Rai, Kanti R
AU  - Rai KR
AD  - Division of Hematology-Oncology, North Shore-Long Island Jewish Medical System, New 
      Hyde Park, NY.
FAU - Keating, Michael
AU  - Keating M
AD  - Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
FAU - Rassenti, Laura Z
AU  - Rassenti LZ
AD  - Department of Medicine, University of California San Diego, La Jolla, CA.
FAU - Kipps, Thomas J
AU  - Kipps TJ
AD  - Department of Medicine, University of California San Diego, La Jolla, CA.
FAU - Zenz, Thorsten
AU  - Zenz T
AD  - Department of Medical Oncology and Hematology, University Hospital and University of 
      Zrich, Zrich, Switzerland.
FAU - Shanafelt, Tait D
AU  - Shanafelt TD
AD  - Department of Medicine-Hematology, Stanford School of Medicine, Stanford, CA.
FAU - Kay, Neil E
AU  - Kay NE
AUID- ORCID: 0000-0002-5951-5055
AD  - Division of Hematology, Mayo Clinic, Rochester, MN; and.
FAU - Abruzzo, Lynne V
AU  - Abruzzo LV
AD  - Department of Pathology, The Ohio State University, Columbus, OH.
FAU - Coombes, Kevin R
AU  - Coombes KR
AUID- ORCID: 0000-0002-7630-2123
AD  - Department of Biomedical Informatics and.
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - Division of Hematology, Department of Internal Medicine, and.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, and.
AD  - Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, 
      OH.
FAU - Oakes, Christopher C
AU  - Oakes CC
AD  - Division of Hematology, Department of Internal Medicine, and.
AD  - Department of Biomedical Informatics and.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R01 CA182905/CA/NCI NIH HHS/United States
GR  - R01 CA197120/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - P01 CA206978/CA/NCI NIH HHS/United States
GR  - P01 CA081534/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190710
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Biomarkers, Tumor)
SB  - AIM
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - *DNA Methylation
MH  - Disease Progression
MH  - Epigenesis, Genetic
MH  - Genetic Loci
MH  - Genetic Testing
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/*genetics
MH  - Prognosis
PMC - PMC6706807
COIS- Conflict-of-interest disclosure: The authors declare no competing financial 
      interests.
EDAT- 2019/07/12 06:00
MHDA- 2020/01/28 06:00
CRDT- 2019/07/12 06:00
PHST- 2019/03/07 00:00 [received]
PHST- 2019/07/03 00:00 [accepted]
PHST- 2019/07/12 06:00 [pubmed]
PHST- 2020/01/28 06:00 [medline]
PHST- 2019/07/12 06:00 [entrez]
AID - S0006-4971(20)46170-1 [pii]
AID - 2019/BLD2019000490 [pii]
AID - 10.1182/blood.2019000490 [doi]
PST - ppublish
SO  - Blood. 2019 Aug 22;134(8):688-698. doi: 10.1182/blood.2019000490. Epub 2019 Jul 10.

PMID- 31350825
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20200831
IS  - 1752-8062 (Electronic)
IS  - 1752-8054 (Print)
IS  - 1752-8054 (Linking)
VI  - 12
IP  - 6
DP  - 2019 Nov
TI  - Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric 
      Cytogenetically Normal FLT3-ITD AML.
PG  - 641-647
LID - 10.1111/cts.12669 [doi]
AB  - Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations, 
      common in pediatric acute myeloid leukemia (AML), associate with early relapse and 
      poor prognosis. Past studies have suggested additional cooperative mutations are 
      required for leukemogenesis in FLT3-ITD+ AML. Using RNAsequencing and a 
      next-generation targeted gene panel, we broadly characterize the co-occurring 
      genomic alterations in pediatric cytogenetically normal (CN) FLT3-ITD+ AML to gain a 
      deeper understanding of the clonal patterns and heterogeneity at diagnosis and 
      relapse. We show that chimeric transcripts were present in 21 of 34 (62%) of de novo 
      samples, 2 (6%) of these samples included a rare reoccurring fusion partner BCL11B. 
      At diagnosis, the median number of mutations other than FLT3 per patient was 1 
      (range 0-3), which involved 8 gene pathways; WT1 and NPM1 mutations were frequently 
      observed (35% and 24%, respectively). Fusion transcripts and high variant allele 
      frequency (VAF) mutants, which included WT1, NPM1, SMARCA2, RAD21, and TYK2, were 
      retained from diagnosis to relapse. We did observe reduction in VAF of simple or 
      single mutation clones, but VAFs were preserved or expanded in more complex clones 
      with multiple mutations. Our data provide the first insight into the genomic 
      complexity of pediatric CN FLT3-ITD+ AML and could help stratify future targeted 
      treatment strategies.
CI  -  2019 The Authors. Clinical and Translational Science published by Wiley 
      Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and 
      Therapeutics.
FAU - Buelow, Daelynn R
AU  - Buelow DR
AD  - Division of Pharmaceutics, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio, USA.
FAU - Pounds, Stanley B
AU  - Pounds SB
AD  - Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, 
      Tennessee, USA.
FAU - Wang, Yong-Dong
AU  - Wang YD
AD  - Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, 
      Tennessee, USA.
FAU - Shi, Lei
AU  - Shi L
AD  - Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, 
      Tennessee, USA.
FAU - Li, Yongjin
AU  - Li Y
AD  - Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, 
      Tennessee, USA.
FAU - Finkelstein, David
AU  - Finkelstein D
AD  - Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, 
      Tennessee, USA.
FAU - Shurtleff, Sheila
AU  - Shurtleff S
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, 
      USA.
FAU - Neale, Geoffrey
AU  - Neale G
AD  - Hartwell Center, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
FAU - Inaba, Hiroto
AU  - Inaba H
AD  - Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, 
      USA.
FAU - Ribeiro, Raul C
AU  - Ribeiro RC
AD  - Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, 
      USA.
FAU - Palumbo, Reid
AU  - Palumbo R
AD  - Division of Pharmaceutics, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio, USA.
FAU - Garrison, Dominique
AU  - Garrison D
AD  - Division of Pharmaceutics, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio, USA.
FAU - Orwick, Shelley J
AU  - Orwick SJ
AD  - Division of Hematology, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio, USA.
FAU - Kroll, Karl
AU  - Kroll K
AD  - Division of Hematology, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Pharmaceutics, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio, USA.
AD  - Division of Hematology, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio, USA.
FAU - Gruber, Tanja A
AU  - Gruber TA
AD  - Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, 
      USA.
FAU - Rubnitz, Jeffrey E
AU  - Rubnitz JE
AD  - Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, 
      USA.
FAU - Baker, Sharyn D
AU  - Baker SD
AD  - Division of Pharmaceutics, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio, USA.
AD  - Division of Hematology, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio, USA.
LA  - eng
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - P30 CA021765/CA/NCI NIH HHS/United States
GR  - R01 CA138744/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190820
TA  - Clin Transl Sci
JT  - Clinical and translational science
JID - 101474067
RN  - EC 2.7.10.1 (FLT3 protein, human)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cytogenetic Analysis
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Duplication
MH  - *Genetic Heterogeneity
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Myeloid, Acute/diagnosis/drug therapy/*genetics/mortality
MH  - Male
MH  - Neoplasm Recurrence, Local/*genetics
MH  - Precision Medicine
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
MH  - Remission Induction/methods
MH  - Sequence Analysis, RNA
MH  - Tandem Repeat Sequences/genetics
MH  - Young Adult
MH  - fms-Like Tyrosine Kinase 3/*genetics
PMC - PMC6853146
COIS- The authors declared no competing interests for this work.
EDAT- 2019/07/28 06:00
MHDA- 2020/09/01 06:00
CRDT- 2019/07/28 06:00
PHST- 2019/05/01 00:00 [received]
PHST- 2019/06/12 00:00 [accepted]
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
PHST- 2019/07/28 06:00 [entrez]
AID - CTS12669 [pii]
AID - 10.1111/cts.12669 [doi]
PST - ppublish
SO  - Clin Transl Sci. 2019 Nov;12(6):641-647. doi: 10.1111/cts.12669. Epub 2019 Aug 20.

PMID- 31375516
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20200908
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 25
IP  - 21
DP  - 2019 Nov 1
TI  - Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies 
      in Cytogenetically Normal Acute Myeloid Leukemia.
PG  - 6524-6531
LID - 10.1158/1078-0432.CCR-19-0725 [doi]
AB  - PURPOSE: Uniparental disomy (UPD) is a way cancer cells duplicate a mutated gene, 
      causing loss of heterozygosity (LOH). Patients with cytogenetically normal acute 
      myeloid leukemia (CN-AML) do not have microscopically detectable chromosome 
      abnormalities, but can harbor UPDs. We examined the prognostic significance of UPDs 
      and frequency of LOH in patients with CN-AML.Experimental Design: We examined the 
      frequency and prognostic significance of UPDs in a set of 425 adult patients with de 
      novo CN-AML who were previously sequenced for 81 genes typically mutated in cancer. 
      Associations of UPDs with outcome were analyzed in the 315 patients with CN-AML 
      younger than 60 years. RESULTS: We detected 127 UPDs in 109 patients. Most UPDs were 
      large and typically encompassed all or most of the affected chromosome arm. The most 
      common UPDs occurred on chromosome arms 13q (7.5% of patients), 6p (2.8%), and 11p 
      (2.8%). Many UPDs significantly cooccurred with mutations in genes they encompassed, 
      including 13q UPD with FLT3-internal tandem duplication (FLT3-ITD; P < 0.001), and 
      11p UPD with WT1 mutations (P = 0.02). Among patients younger than 60 years, UPD of 
      11p was associated with longer overall survival (OS) and 13q UPD with shorter 
      disease-free survival (DFS) and OS. In multivariable models that accounted for known 
      prognostic markers, including FLT3-ITD and WT1 mutations, UPD of 13q maintained 
      association with shorter DFS, and UPD of 11p maintained association with longer OS. 
      CONCLUSIONS: LOH mediated by UPD is a recurrent feature of CN-AML. Detection of UPDs 
      of 13q and 11p might be useful for genetic risk stratification of patients with 
      CN-AML.
CI  - 2019 American Association for Cancer Research.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 
      Christopher.walker@osumc.edu clara.bloomfield@osumc.edu.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, Ohio.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Liyanarachchi, Sandya
AU  - Liyanarachchi S
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Song, Chi
AU  - Song C
AD  - Division of Biostatistics, College of Public Health, The Ohio State University, 
      Columbus, Ohio.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, Ohio.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Bill, Marius
AU  - Bill M
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Papaioannou, Dimitrios
AU  - Papaioannou D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Oakes, Christopher C
AU  - Oakes CC
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Giacopelli, Brian
AU  - Giacopelli B
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Genutis, Luke K
AU  - Genutis LK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Maharry, Sophia E
AU  - Maharry SE
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Archer, Kellie J
AU  - Archer KJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
AD  - Division of Biostatistics, College of Public Health, The Ohio State University, 
      Columbus, Ohio.
FAU - Powell, Bayard L
AU  - Powell BL
AD  - Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina.
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - Monter Cancer Center, Zucker School of Medicine at Hofstra/Northwell, Lake Success, 
      New York.
FAU - Uy, Geoffrey L
AU  - Uy GL
AD  - Washington University School of Medicine in St. Louis, Siteman Cancer Center, St. 
      Louis, Missouri.
FAU - Wang, Eunice S
AU  - Wang ES
AD  - Roswell Park Comprehensive Cancer Center, Buffalo, New York.
FAU - Carroll, Andrew J
AU  - Carroll AJ
AUID- ORCID: 0000-0001-9844-730X
AD  - University of Alabama at Birmingham, Birmingham, Alabama.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts.
FAU - Byrd, John C
AU  - Byrd JC
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - de la Chapelle, Albert
AU  - de la Chapelle A
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AUID- ORCID: 0000-0001-5465-7591
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 
      Christopher.walker@osumc.edu clara.bloomfield@osumc.edu.
LA  - eng
SI  - ClinicalTrials.gov/NCT00085124
SI  - ClinicalTrials.gov/NCT00742625
SI  - ClinicalTrials.gov/NCT00651261
SI  - ClinicalTrials.gov/NCT00006363
SI  - ClinicalTrials.gov/NCT00900224
SI  - ClinicalTrials.gov/NCT00048958
SI  - ClinicalTrials.gov/NCT00899223
SI  - ClinicalTrials.gov/NCT00003190
GR  - U10 CA077658/CA/NCI NIH HHS/United States
GR  - P30 CA016056/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U10 CA180850/CA/NCI NIH HHS/United States
GR  - UG1 CA233180/CA/NCI NIH HHS/United States
GR  - UG1 CA233191/CA/NCI NIH HHS/United States
GR  - U10 CA180833/CA/NCI NIH HHS/United States
GR  - U10 CA180867/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - UG1 CA233331/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - UG1 CA233338/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - U10 CA180866/CA/NCI NIH HHS/United States
GR  - UG1 CA233339/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190802
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Nuclear Proteins)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cytogenetics/methods
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/epidemiology/*genetics/pathology
MH  - Loss of Heterozygosity/*genetics
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Nuclear Proteins/genetics
MH  - *Prognosis
MH  - Uniparental Disomy/*genetics/pathology
MH  - Young Adult
PMC - PMC6825549
MID - NIHMS1536703
COIS- Conflict of Interest Disclosure Statement: The authors declare no potential 
      conflicts of interest.
EDAT- 2019/08/04 06:00
MHDA- 2020/09/09 06:00
CRDT- 2019/08/04 06:00
PHST- 2019/03/01 00:00 [received]
PHST- 2019/06/06 00:00 [revised]
PHST- 2019/07/30 00:00 [accepted]
PHST- 2019/08/04 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
PHST- 2019/08/04 06:00 [entrez]
AID - 1078-0432.CCR-19-0725 [pii]
AID - 10.1158/1078-0432.CCR-19-0725 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2019 Nov 1;25(21):6524-6531. doi: 10.1158/1078-0432.CCR-19-0725. 
      Epub 2019 Aug 2.

PMID- 27756747
OWN - NLM
STAT- MEDLINE
DCOM- 20170731
LR  - 20210202
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 128
IP  - 26
DP  - 2016 Dec 29
TI  - Targeting BTK through microRNA in chronic lymphocytic leukemia.
PG  - 3101-3112
LID - 10.1182/blood-2016-07-727750 [doi]
AB  - Bruton's tyrosine kinase (BTK) is a critical mediator of survival in B-cell 
      neoplasms. Although BTK inhibitors have transformed therapy in chronic lymphocytic 
      leukemia (CLL), patients with high-risk genetics are at risk for relapse and have a 
      poor prognosis. Identification of novel therapeutic strategies for this group of 
      patients is an urgent unmet clinical need, and therapies that target BTK via 
      alternative mechanisms may fill this niche. Herein, we identify a set of microRNAs 
      (miRs) that target BTK in primary CLL cells and show that the histone deacetylase 
      (HDAC) repressor complex is recruited to these miR promoters to silence their 
      expression. Targeting the HDACs by using either RNA interference against HDAC1 in 
      CLL or a small molecule inhibitor (HDACi) in CLL and mantle cell lymphoma restored 
      the expression of the BTK-targeting miRs with loss of BTK protein and downstream 
      signaling and consequent cell death. We have also made the novel and clinically 
      relevant discovery that inhibition of HDAC induces the BTK-targeting miRs in 
      ibrutinib-sensitive and resistant CLL to effectively reduce both wild-type and 
      C481S-mutant BTK. This finding identifies a novel strategy that may be promising as 
      a therapeutic modality to eliminate the C481S-mutant BTK clone that drives 
      resistance to ibrutinib and provides the rationale for a combination strategy that 
      includes ibrutinib to dually target BTK to suppress its prosurvival signaling.
CI  -  2016 by The American Society of Hematology.
FAU - Bottoni, Arianna
AU  - Bottoni A
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Rizzotto, Lara
AU  - Rizzotto L
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Lai, Tzung-Huei
AU  - Lai TH
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Liu, Chaomei
AU  - Liu C
AD  - Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer 
      Center, Houston, TX; and.
FAU - Smith, Lisa L
AU  - Smith LL
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Mantel, Rose
AU  - Mantel R
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Reiff, Sean
AU  - Reiff S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - El-Gamal, Dalia
AU  - El-Gamal D
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Larkin, Karilyn
AU  - Larkin K
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Johnson, Amy J
AU  - Johnson AJ
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Lapalombella, Rosa
AU  - Lapalombella R
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Lehman, Amy
AU  - Lehman A
AD  - Center for Biostatistics, The Ohio State University, Columbus, OH.
FAU - Plunkett, William
AU  - Plunkett W
AD  - Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer 
      Center, Houston, TX; and.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Sampath, Deepa
AU  - Sampath D
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
LA  - eng
GR  - R01 CA197870/CA/NCI NIH HHS/United States
GR  - K23 CA178183/CA/NCI NIH HHS/United States
GR  - P01 CA081534/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20161017
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Benzofurans)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Hydroxamic Acids)
RN  - 0 (MicroRNAs)
RN  - 0 (Mutant Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 1X70OSD4VX (ibrutinib)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase)
RN  - EC 2.7.10.2 (BTK protein, human)
RN  - EC 2.7.10.2 (Btk protein, mouse)
RN  - IYO470654U (abexinostat)
SB  - AIM
SB  - IM
CIN - Blood. 2016 Dec 29;128(26):3023-3024. PMID: 28034867
MH  - Agammaglobulinaemia Tyrosine Kinase
MH  - Animals
MH  - Benzofurans/pharmacology
MH  - Cell Survival/drug effects
MH  - Clone Cells
MH  - Drug Resistance, Neoplasm/drug effects
MH  - Drug Synergism
MH  - Epigenesis, Genetic/drug effects
MH  - Gene Expression Profiling
MH  - Gene Silencing/drug effects
MH  - Histone Deacetylase Inhibitors/pharmacology
MH  - Humans
MH  - Hydroxamic Acids/pharmacology
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*enzymology/*genetics
MH  - Mice, Inbred C57BL
MH  - MicroRNAs/*metabolism
MH  - *Molecular Targeted Therapy
MH  - Mutant Proteins/metabolism
MH  - Neoplasm Proteins/metabolism
MH  - Promoter Regions, Genetic/genetics
MH  - Protein-Tyrosine Kinases/*metabolism
MH  - Pyrazoles/pharmacology
MH  - Pyrimidines/pharmacology
MH  - RNA Interference/drug effects
MH  - Signal Transduction/drug effects
MH  - Up-Regulation/drug effects
PMC - PMC5201097
EDAT- 2016/10/21 06:00
MHDA- 2017/08/02 06:00
CRDT- 2016/10/21 06:00
PHST- 2016/07/12 00:00 [received]
PHST- 2016/09/21 00:00 [accepted]
PHST- 2016/10/21 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
PHST- 2016/10/21 06:00 [entrez]
AID - S0006-4971(20)33854-4 [pii]
AID - 2016/727750 [pii]
AID - 10.1182/blood-2016-07-727750 [doi]
PST - ppublish
SO  - Blood. 2016 Dec 29;128(26):3101-3112. doi: 10.1182/blood-2016-07-727750. Epub 2016 
      Oct 17.

PMID- 33277314
OWN - NLM
STAT- In-Process
LR  - 20210927
IS  - 2159-8290 (Electronic)
IS  - 2159-8274 (Print)
IS  - 2159-8274 (Linking)
VI  - 11
IP  - 3
DP  - 2021 Mar
TI  - Poor Survival and Differential Impact of Genetic Features of Black Patients with 
      Acute Myeloid Leukemia.
PG  - 626-637
LID - 10.1158/2159-8290.CD-20-1579 [doi]
AB  - Clinical outcome of patients with acute myeloid leukemia (AML) is associated with 
      cytogenetic and molecular factors and patient demographics (e.g., age and race). We 
      compared survival of 25,523 non-Hispanic Black and White adults with AML using 
      Surveillance Epidemiology and End Results (SEER) Program data and performed 
      mutational profiling of 1,339 patients with AML treated on frontline Alliance for 
      Clinical Trials in Oncology (Alliance) protocols. Black patients had shorter 
      survival than White patients, both in SEER and in the setting of Alliance clinical 
      trials. The disparity was especially pronounced in Black patients <60 years, after 
      adjustment for socioeconomic (SEER) and molecular (Alliance) factors. Black race was 
      an independent prognosticator of poor survival. Gene mutation profiles showed fewer 
      NPM1 and more IDH2 mutations in younger Black patients. Overall survival of younger 
      Black patients was adversely affected by IDH2 mutations and FLT3-ITD, but, in 
      contrast to White patients, was not improved by NPM1 mutations. SIGNIFICANCE: We 
      show that young Black patients have not benefited as much as White patients from 
      recent progress in AML treatment in the United States. Our data suggest that both 
      socioeconomic factors and differences in disease biology contribute to the survival 
      disparity and need to be urgently addressed.See related commentary by Vyas, p. 
      540.This article is highlighted in the In This Issue feature, p. 521.
CI  - 2020 American Association for Cancer Research.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 
      Ann.Kathrin.Eisfeld@osumc.edu Bhavana.Bhatnagar@osumc.edu 
      Krzysztof.Mrozek@osumc.edu.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
AD  - The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center 
      for Leukemia Outcomes Research, Columbus, Ohio.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, Ohio.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 
      Ann.Kathrin.Eisfeld@osumc.edu Bhavana.Bhatnagar@osumc.edu 
      Krzysztof.Mrozek@osumc.edu.
AD  - The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center 
      for Leukemia Outcomes Research, Columbus, Ohio.
FAU - Zhao, Qiuhong
AU  - Zhao Q
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, Ohio.
FAU - Fisher, James L
AU  - Fisher JL
AUID- ORCID: 0000-0003-3211-2691
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
AD  - The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center 
      for Leukemia Outcomes Research, Columbus, Ohio.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, Ohio.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
AD  - The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center 
      for Leukemia Outcomes Research, Columbus, Ohio.
FAU - Mims, Alice S
AU  - Mims AS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, Ohio.
FAU - Oakes, Christopher
AU  - Oakes C
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Giacopelli, Brian
AU  - Giacopelli B
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Orwick, Shelley
AU  - Orwick S
AUID- ORCID: 0000-0002-4537-1409
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Boateng, Isaiah
AU  - Boateng I
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Maharry, Sophia E
AU  - Maharry SE
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Carroll, Andrew J
AU  - Carroll AJ
AUID- ORCID: 0000-0001-9844-730X
AD  - Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama.
FAU - Powell, Bayard L
AU  - Powell BL
AD  - Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina.
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - Monter Cancer Center, Hofstra Northwell School of Medicine, Lake Success, New York.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
FAU - Byrd, John C
AU  - Byrd JC
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
AD  - The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center 
      for Leukemia Outcomes Research, Columbus, Ohio.
FAU - Paskett, Electra D
AU  - Paskett ED
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
AD  - Division of Cancer Prevention and Control, Department of Internal Medicine, College 
      of Medicine, The Ohio State University, Columbus, Ohio.
FAU - de la Chapelle, Albert
AU  - de la Chapelle A
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Garzon, Ramiro
AU  - Garzon R
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 
      Ann.Kathrin.Eisfeld@osumc.edu Bhavana.Bhatnagar@osumc.edu 
      Krzysztof.Mrozek@osumc.edu.
AD  - The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center 
      for Leukemia Outcomes Research, Columbus, Ohio.
LA  - eng
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - UG1 CA189850/CA/NCI NIH HHS/United States
GR  - UG1 CA189824/CA/NCI NIH HHS/United States
GR  - U10 CA180867/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - UG1 CA233331/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - UG1 CA233338/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201204
TA  - Cancer Discov
JT  - Cancer discovery
JID - 101561693
SB  - IM
CIN - Cancer Discov. 2021 Mar;11(3):540-541. PMID: 33653919
PMC - PMC7933110
MID - NIHMS1660762
COIS- A potential conflict of interest disclosure: B. Bhatnagar has received advisory 
      board honoraria from Novartis, Kite Pharma, Celgene, Astellas and Cell Therapeutics 
      Inc. C.J. Walker is a consultant for Vigeo Therapeutics and employed at Karyopharm 
      Therapeutics; and has ownership interest in Karyopharm Therapeutics and 
      Bristol-Myers Squibb Co. J.S. Blachly is a consultant/advisory board member for 
      AbbVie, AstraZeneca, INNATE, KITE. B.L. Powell received honoraria from Jazz 
      Pharmaceuticals, Novartis, and Pfizer. J.E. Kolitz has received honoraria from 
      Gilead, Magellan, and Novartis; consulting fees from Gilead, Magellan, Novartis, 
      Pharmacyclics, and Seattle Genetics; institutional research funding from Boehringer 
      Ingelheim, Cantex, Erytech, and Millennium; and travel support from Gilead, 
      Novartis, and Seattle Genetics. R.M. Stone has served on independent data safety 
      monitoring committees for trials supported by Celgene, Takeda, and Argenix; has 
      consulted for AbbVie, Actinium, Agios, Amgen, Arog, Astellas, AstraZeneca, 
      Biolinerx, Celgene, Daiichi Sankyo, Fujifilm, Janssen, Juno, Macrogenics, Novartis, 
      Ono, Orsenix, Pfizer, Roche, Stemline, Sumitomo, Takeda, and Trovagene; and has 
      received research support (to the institution) for clinical trials sponsored by 
      AbbVie, Agios, Arog, and Novartis. E.D. Paskett has received grants from Merck 
      Foundation and Pfizer. J.C. Byrd has a consultancy/advisory role with Syndax, 
      Novartis, Vincera; research funding from Pharmacyclics LLC, an AbbVie Company, 
      Genentech, Janssen, Acerta; ownership for Vincera. A.-K. Eisfeld has received a 
      research grant from Novartis and has ownership interest in Karyopharm Therapeutics. 
      The other authors declare no conflicts of interest.
EDAT- 2020/12/06 06:00
MHDA- 2020/12/06 06:00
CRDT- 2020/12/05 05:26
PHST- 2020/10/30 00:00 [received]
PHST- 2020/11/19 00:00 [revised]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2020/12/06 06:00 [medline]
PHST- 2020/12/05 05:26 [entrez]
AID - 2159-8290.CD-20-1579 [pii]
AID - 10.1158/2159-8290.CD-20-1579 [doi]
PST - ppublish
SO  - Cancer Discov. 2021 Mar;11(3):626-637. doi: 10.1158/2159-8290.CD-20-1579. Epub 2020 
      Dec 4.

PMID- 30737482
OWN - NLM
STAT- MEDLINE
DCOM- 20191112
LR  - 20210109
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 33
IP  - 7
DP  - 2019 Jul
TI  - Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes 
      differ molecularly and clinically.
PG  - 1620-1634
LID - 10.1038/s41375-019-0390-3 [doi]
AB  - Complex karyotype (CK) with3 abnormalities is detected in 10-12% of patients with 
      acute myeloid leukemia (AML) and associated with poor prognosis. The most common 
      unbalanced abnormalities found in CK result in loss of material from the 5q, 7q, 
      and/or 17p chromosome arms. The presence of 5q, 7q, and/or 17p abnormalities denotes 
      typical CK and their absence denotes atypical CK. Since molecular features of CK-AML 
      are not well characterized, we investigated mutational status of 81 
      leukemia/cancer-associated genes in 160 clinically well-characterized patients. They 
      included 136 patients with3 exclusively unbalanced chromosome abnormalities, 96 
      of whom had a typical CK and 40 atypical CK, and 24 patients with1 balanced 
      abnormality in addition to2 unbalanced ones. Patients with atypical CK-AML 
      differed from those with typical CK-AML: they carried TP53 mutations less often 
      (P<0.001) and more often PHF6 (P=0.008), FLT3-TKD (P=0.02), MED12 (P=0.02), 
      and NPM1 (P=0.02) mutations. They were younger (P=0.007), had higher WBC 
      (P=0.001) and percentages of marrow (P<0.001) and blood (P=0.006) blasts, 
      higher complete remission rates (P=0.02), and longer overall survival (P<0.001), 
      thus indicating that atypical and typical CK-AMLs constitute distinct disease 
      subtypes. We also identified smaller patient subsets within both typical and 
      atypical CK-AML that differed molecularly and clinically.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      krzysztof.mrozek@osumc.edu.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      ann-kathrin.eisfeld@osumc.edu.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH, USA.
FAU - Carroll, Andrew J
AU  - Carroll AJ
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Bill, Marius
AU  - Bill M
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Papaioannou, Dimitrios
AU  - Papaioannou D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Wang, Eunice S
AU  - Wang ES
AD  - Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
FAU - Uy, Geoffrey L
AU  - Uy GL
AD  - Washington University School of Medicine in St. Louis, Siteman Cancer Center, St. 
      Louis, MO, USA.
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - Monter Cancer Center, Hofstra Northwell School of Medicine, Lake Success, NY, USA.
FAU - Powell, Bayard L
AU  - Powell BL
AD  - Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
FAU - Blum, William
AU  - Blum W
AD  - Emory University School of Medicine, Atlanta, GA, USA.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Dana-Farber/Partners CancerCare, Boston, MA, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      clara.bloomfield@osumc.edu.
LA  - eng
GR  - U10 CA077658/CA/NCI NIH HHS/United States
GR  - P30 CA016056/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - UG1 CA233180/CA/NCI NIH HHS/United States
GR  - UG1 CA233191/CA/NCI NIH HHS/United States
GR  - U10 CA180867/CA/NCI NIH HHS/United States
GR  - U10 CA180866/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - UG1 CA233331/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - UG1 CA233338/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190208
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics
MH  - *Chromosome Aberrations
MH  - Chromosomes, Human/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Karyotyping/*methods
MH  - Leukemia, Myeloid, Acute/*genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Prognosis
MH  - Survival Rate
MH  - Young Adult
PMC - PMC6609457
MID - NIHMS1518382
COIS- The authors declare no conflicts of interest.
EDAT- 2019/02/10 06:00
MHDA- 2019/11/13 06:00
CRDT- 2019/02/10 06:00
PHST- 2018/09/17 00:00 [received]
PHST- 2019/01/09 00:00 [accepted]
PHST- 2018/12/17 00:00 [revised]
PHST- 2019/02/10 06:00 [pubmed]
PHST- 2019/11/13 06:00 [medline]
PHST- 2019/02/10 06:00 [entrez]
AID - 10.1038/s41375-019-0390-3 [pii]
AID - 10.1038/s41375-019-0390-3 [doi]
PST - ppublish
SO  - Leukemia. 2019 Jul;33(7):1620-1634. doi: 10.1038/s41375-019-0390-3. Epub 2019 Feb 8.

PMID- 30592587
OWN - NLM
STAT- MEDLINE
DCOM- 20190103
LR  - 20190103
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 379
IP  - 24
DP  - 2018 Dec 13
TI  - Case 28-2018: A Man with Epistaxis, Pain and Erythema of the Forearm, and 
      Pancytopenia.
PG  - 2381-2382
LID - 10.1056/NEJMc1813964 [doi]
FAU - Rogers, Kerry A
AU  - Rogers KA
AD  - Ohio State University, Columbus, OH
FAU - Blachly, James S
AU  - Blachly JS
AD  - Ohio State University, Columbus, OH
FAU - Grever, Michael R
AU  - Grever MR
AD  - Ohio State University, Columbus, OH
AD  - michael.grever@osumc.edu
LA  - eng
PT  - Comment
PT  - Letter
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
SB  - AIM
SB  - IM
CON - N Engl J Med. 2018 Sep 13;379(11):1072-1081. PMID: 30207921
CIN - N Engl J Med. 2018 Dec 13;379(24):2382. PMID: 30575470
MH  - Adult
MH  - *Epistaxis
MH  - *Erythema
MH  - Forearm
MH  - Humans
MH  - Male
MH  - Pain
MH  - Pancytopenia
EDAT- 2018/12/29 06:00
MHDA- 2019/01/04 06:00
CRDT- 2018/12/29 06:00
PHST- 2018/12/29 06:00 [entrez]
PHST- 2018/12/29 06:00 [pubmed]
PHST- 2019/01/04 06:00 [medline]
AID - 10.1056/NEJMc1813964#SA1 [pii]
AID - 10.1056/NEJMc1813964 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Dec 13;379(24):2381-2382. doi: 10.1056/NEJMc1813964.

PMID- 27780867
OWN - NLM
STAT- MEDLINE
DCOM- 20170526
LR  - 20210209
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 291
IP  - 49
DP  - 2016 Dec 2
TI  - Interferon- Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.
PG  - 25656-25666
AB  - Acute myeloid leukemia (AML) is characterized by the proliferation of immature 
      myeloid lineage blasts. Due to its heterogeneity and to the high rate of acquired 
      drug resistance and relapse, new treatment strategies are needed. Here, we 
      demonstrate that IFN promotes AML blasts to act as effector cells within the 
      context of antibody therapy. Treatment with IFN drove AML blasts toward a more 
      differentiated state, wherein they showed increased expression of the M1-related 
      markers HLA-DR and CD86, as well as of FcRI, which mediates effector responses to 
      therapeutic antibodies. Importantly, IFN was able to up-regulate CD38, the target 
      of the therapeutic antibody daratumumab. Because the antigen (CD38) and effector 
      receptor (FcRI) were both simultaneously up-regulated on the AML blasts, we tested 
      whether IFN treatment of the AML cell lines THP-1 and MV4-11 could stimulate them 
      to target one another after the addition of daratumumab. Results showed that IFN 
      significantly increased daratumumab-mediated cytotoxicity, as measured both by 
      (51)Cr release and lactate dehydrogenase release assays. We also found that the 
      combination of IFN and activation of FcR led to the release of granzyme B by AML 
      cells. Finally, using a murine NSG model of subcutaneous AML, we found that 
      treatment with IFN plus daratumumab significantly attenuated tumor growth. Taken 
      together, these studies show a novel mechanism of daratumumab-mediated killing and a 
      possible new therapeutic strategy for AML.
CI  -  2016 by The American Society for Biochemistry and Molecular Biology, Inc.
FAU - Fatehchand, Kavin
AU  - Fatehchand K
AD  - From the Medical Scientist Training Program.
AD  - Biomedical Sciences Graduate Program.
AD  - Department of Internal Medicine.
FAU - McMichael, Elizabeth L
AU  - McMichael EL
AD  - Biomedical Sciences Graduate Program.
AD  - Department of Internal Medicine.
FAU - Reader, Brenda F
AU  - Reader BF
AD  - Department of Internal Medicine.
FAU - Fang, Huiqing
AU  - Fang H
AD  - Department of Internal Medicine.
FAU - Santhanam, Ramasamy
AU  - Santhanam R
AD  - Department of Internal Medicine.
FAU - Gautam, Shalini
AU  - Gautam S
AD  - Department of Internal Medicine.
FAU - Elavazhagan, Saranya
AU  - Elavazhagan S
AD  - Department of Internal Medicine.
FAU - Mehta, Payal
AU  - Mehta P
AD  - Department of Internal Medicine.
FAU - Buteyn, Nathaniel J
AU  - Buteyn NJ
AD  - Molecular, Cellular, and Developmental Biology Program, and.
FAU - Merchand-Reyes, Giovanna
AU  - Merchand-Reyes G
AD  - Molecular, Cellular, and Developmental Biology Program, and.
FAU - Vasu, Sumithira
AU  - Vasu S
AD  - Department of Internal Medicine.
FAU - Mo, Xiaokui
AU  - Mo X
AD  - Center for Biostatistics, Ohio State University, Columbus, Ohio 43210.
FAU - Benson, Don M Jr
AU  - Benson DM Jr
AD  - Department of Internal Medicine.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Department of Internal Medicine.
FAU - Carson, William E 3rd
AU  - Carson WE 3rd
AD  - From the Medical Scientist Training Program.
AD  - Biomedical Sciences Graduate Program.
AD  - Department of Internal Medicine.
FAU - Byrd, John C
AU  - Byrd JC
AD  - From the Medical Scientist Training Program.
AD  - Biomedical Sciences Graduate Program.
AD  - Department of Internal Medicine.
FAU - Butchar, Jonathan P
AU  - Butchar JP
AD  - Department of Internal Medicine, butchar.2@osu.edu.
FAU - Tridandapani, Susheela
AU  - Tridandapani S
AD  - From the Medical Scientist Training Program, tridandapani.2@osu.edu.
AD  - Biomedical Sciences Graduate Program.
AD  - Department of Internal Medicine.
AD  - Molecular, Cellular, and Developmental Biology Program, and.
LA  - eng
GR  - R01 CA162411/CA/NCI NIH HHS/United States
GR  - R01 CA203584/CA/NCI NIH HHS/United States
GR  - P01 CA095426/CA/NCI NIH HHS/United States
GR  - T32 HL007946/HL/NHLBI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20161025
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Cytotoxins)
RN  - 0 (IFNG protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Receptors, IgG)
RN  - 4Z63YK6E0E (daratumumab)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 3.4.21.- (GZMB protein, human)
RN  - EC 3.4.21.- (Granzymes)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Cell Line, Tumor
MH  - Cytotoxins/*pharmacology
MH  - Female
MH  - Granzymes/metabolism
MH  - Humans
MH  - Interferon-gamma/*pharmacology
MH  - Leukemia, Myeloid, Acute/*drug therapy/metabolism/pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Neoplasm Proteins/metabolism
MH  - Receptors, IgG/metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC5207262
OTO - NOTNLM
OT  - *Fc receptor
OT  - *antibody
OT  - *interferon
OT  - *signal transduction
OT  - *tumor immunology
EDAT- 2016/10/27 06:00
MHDA- 2017/05/27 06:00
CRDT- 2016/10/27 06:00
PHST- 2016/08/10 00:00 [received]
PHST- 2016/10/12 00:00 [revised]
PHST- 2016/10/27 06:00 [pubmed]
PHST- 2017/05/27 06:00 [medline]
PHST- 2016/10/27 06:00 [entrez]
AID - S0021-9258(20)34553-1 [pii]
AID - M116.753145 [pii]
AID - 10.1074/jbc.M116.753145 [doi]
PST - ppublish
SO  - J Biol Chem. 2016 Dec 2;291(49):25656-25666. doi: 10.1074/jbc.M116.753145. Epub 2016 
      Oct 25.

PMID- 29296742
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 2473-9529 (Print)
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Linking)
VI  - 1
IP  - 15
DP  - 2017 Jun 27
TI  - Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients.
PG  - 995-1000
LID - 10.1182/bloodadvances.2017007062 [doi]
AB  - We identify and characterize novel SF3B1 in-frame deletions in chronic lymphocytic 
      leukemia.These deletions are functionally similar to well-known SF3B1 hotspot 
      mutations and are sensitive to splicing modulation.
FAU - Agrawal, Anant A
AU  - Agrawal AA
AD  - H3 Biomedicine, Inc., Cambridge, MA; and.
FAU - Seiler, Michael
AU  - Seiler M
AD  - H3 Biomedicine, Inc., Cambridge, MA; and.
FAU - Brinton, Lindsey T
AU  - Brinton LT
AD  - Ohio State University Comprehensive Cancer Center, Columbus, OH.
FAU - Mantel, Rose
AU  - Mantel R
AD  - Ohio State University Comprehensive Cancer Center, Columbus, OH.
FAU - Lapalombella, Rosa
AU  - Lapalombella R
AD  - Ohio State University Comprehensive Cancer Center, Columbus, OH.
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - Ohio State University Comprehensive Cancer Center, Columbus, OH.
FAU - Johnson, Amy J
AU  - Johnson AJ
AD  - Ohio State University Comprehensive Cancer Center, Columbus, OH.
FAU - Zhu, Ping
AU  - Zhu P
AD  - H3 Biomedicine, Inc., Cambridge, MA; and.
FAU - Warmuth, Markus
AU  - Warmuth M
AD  - H3 Biomedicine, Inc., Cambridge, MA; and.
FAU - Yu, Lihua
AU  - Yu L
AD  - H3 Biomedicine, Inc., Cambridge, MA; and.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Ohio State University Comprehensive Cancer Center, Columbus, OH.
FAU - Smith, Peter G
AU  - Smith PG
AD  - H3 Biomedicine, Inc., Cambridge, MA; and.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Ohio State University Comprehensive Cancer Center, Columbus, OH.
FAU - Buonamici, Silvia
AU  - Buonamici S
AD  - H3 Biomedicine, Inc., Cambridge, MA; and.
LA  - eng
GR  - K23 CA178183/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170614
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
PMC - PMC5728324
COIS- Conflict-of-interest disclosure: A.A.A., M.S., M.W., P.Z., L.Y., P.G.S., and S.B. 
      are full time employees of H3 Biomedicine, Inc. The remaining authors declare no 
      competing financial interests.
EDAT- 2018/01/04 06:00
MHDA- 2018/01/04 06:01
CRDT- 2018/01/04 06:00
PHST- 2017/03/22 00:00 [received]
PHST- 2017/05/08 00:00 [accepted]
PHST- 2018/01/04 06:00 [entrez]
PHST- 2018/01/04 06:00 [pubmed]
PHST- 2018/01/04 06:01 [medline]
AID - 2017/007062 [pii]
AID - 10.1182/bloodadvances.2017007062 [doi]
PST - epublish
SO  - Blood Adv. 2017 Jun 14;1(15):995-1000. doi: 10.1182/bloodadvances.2017007062. 
      eCollection 2017 Jun 27.

PMID- 25678431
OWN - NLM
STAT- MEDLINE
DCOM- 20150421
LR  - 20210202
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 125
IP  - 7
DP  - 2015 Feb 12
TI  - Separating the wheat from the chaff in cHL.
PG  - 1051-2
LID - 10.1182/blood-2014-12-617555 [doi]
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - AIM
SB  - IM
CON - Blood. 2015 Feb 12;125(7):1061-72. PMID: 25488972
MH  - Exome/*genetics
MH  - Female
MH  - *Genes, Neoplasm
MH  - Hodgkin Disease/*genetics/*pathology
MH  - Humans
MH  - Male
MH  - Reed-Sternberg Cells/*metabolism/*pathology
EDAT- 2015/02/14 06:00
MHDA- 2015/04/22 06:00
CRDT- 2015/02/14 06:00
PHST- 2015/02/14 06:00 [entrez]
PHST- 2015/02/14 06:00 [pubmed]
PHST- 2015/04/22 06:00 [medline]
AID - S0006-4971(20)35260-5 [pii]
AID - 10.1182/blood-2014-12-617555 [doi]
PST - ppublish
SO  - Blood. 2015 Feb 12;125(7):1051-2. doi: 10.1182/blood-2014-12-617555.

PMID- 27890934
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20200206
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 31
IP  - 7
DP  - 2017 Jul
TI  - EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic 
      leukemia.
PG  - 1547-1554
LID - 10.1038/leu.2016.359 [doi]
AB  - Recurrent mutations within EGR2 were recently reported in advanced-stage chronic 
      lymphocytic leukemia (CLL) patients and associated with a worse outcome. To study 
      their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 
      hotspot region including a screening (n=1283) and two validation cohorts (UK CLL4 
      trial patients, n=366; CLL Research Consortium (CRC) patients, n=490). Targeted 
      deep-sequencing of 27 known/postulated CLL driver genes was also performed in 38 
      EGR2-mutated patients to assess concurrent mutations. EGR2 mutations were detected 
      in 91/2403 (3.8%) investigated cases, and associated with younger age at diagnosis, 
      advanced clinical stage, high CD38 expression and unmutated IGHV genes. EGR2-mutated 
      patients frequently carried ATM lesions (42%), TP53 aberrations (18%) and 
      NOTCH1/FBXW7 mutations (16%). EGR2 mutations independently predicted shorter 
      time-to-first-treatment (TTFT) and overall survival (OS) in the screening cohort; 
      they were confirmed associated with reduced TTFT and OS in the CRC cohort and 
      independently predicted short OS from randomization in the UK CLL4 cohort. A 
      particularly dismal outcome was observed among EGR2-mutated patients who also 
      carried TP53 aberrations. In summary, EGR2 mutations were independently associated 
      with an unfavorable prognosis, comparable to CLL patients carrying TP53 aberrations, 
      suggesting that EGR2-mutated patients represent a new patient subgroup with very 
      poor outcome.
FAU - Young, E
AU  - Young E
AD  - Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, 
      Uppsala University, Sweden.
FAU - Noerenberg, D
AU  - Noerenberg D
AD  - Department of Hematology, Oncology, and Tumor Immunology, Charit, University 
      Medical Center, Berlin, Germany.
FAU - Mansouri, L
AU  - Mansouri L
AD  - Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, 
      Uppsala University, Sweden.
FAU - Ljungstrm, V
AU  - Ljungstrm V
AD  - Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, 
      Uppsala University, Sweden.
FAU - Frick, M
AU  - Frick M
AD  - Department of Hematology, Oncology, and Tumor Immunology, Charit, University 
      Medical Center, Berlin, Germany.
FAU - Sutton, L-A
AU  - Sutton LA
AD  - Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, 
      Uppsala University, Sweden.
FAU - Blakemore, S J
AU  - Blakemore SJ
AD  - Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
FAU - Galan-Sousa, J
AU  - Galan-Sousa J
AD  - Department of Hematology, Oncology, and Tumor Immunology, Charit, University 
      Medical Center, Berlin, Germany.
FAU - Plevova, K
AU  - Plevova K
AD  - Central European Institute of Technology, Masaryk University and University Hospital 
      Brno, Brno, Czech Republic.
FAU - Baliakas, P
AU  - Baliakas P
AD  - Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, 
      Uppsala University, Sweden.
FAU - Rossi, D
AU  - Rossi D
AD  - Division of Hematology, Department of Translational Medicine, Amedeo Avogadro 
      University of Eastern Piedmont, Novara, Italy.
AD  - Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology 
      Research, Bellinzona, Switzerland.
FAU - Clifford, R
AU  - Clifford R
AD  - Oxford National Institute for Health Research Biomedical Research Centre and 
      Department of Oncology, University of Oxford, Oxford, UK.
FAU - Roos-Weil, D
AU  - Roos-Weil D
AD  - INSERM, U1170, Institut Gustave Roussy, Villejuif, France.
FAU - Navrkalova, V
AU  - Navrkalova V
AD  - Central European Institute of Technology, Masaryk University and University Hospital 
      Brno, Brno, Czech Republic.
FAU - Drken, B
AU  - Drken B
AD  - Department of Hematology, Oncology, and Tumor Immunology, Charit, University 
      Medical Center, Berlin, Germany.
FAU - Schmitt, C A
AU  - Schmitt CA
AD  - Department of Hematology, Oncology, and Tumor Immunology, Charit, University 
      Medical Center, Berlin, Germany.
FAU - Smedby, K E
AU  - Smedby KE
AD  - Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, and 
      Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
FAU - Juliusson, G
AU  - Juliusson G
AD  - Department of Laboratory Medicine, Stem Cell Center, Lund University, Lund, Sweden.
FAU - Giacopelli, B
AU  - Giacopelli B
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Blachly, J S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Belessi, C
AU  - Belessi C
AD  - Hematology Department, General Hospital of Nikea, Piraeus, Greece.
FAU - Panagiotidis, P
AU  - Panagiotidis P
AD  - First Department of Propaedeutic Medicine, School of Medicine, University of Athens, 
      Athens, Greece.
FAU - Chiorazzi, N
AU  - Chiorazzi N
AUID- ORCID: 0000-0003-1023-6650
AD  - Karches Center for Chronic Lymphocytic Leukemia Research, The Feinstein Institute 
      for Medical Research, Manhasset, New York, USA.
FAU - Davi, F
AU  - Davi F
AD  - Laboratory of Hematology and Universite Pierre et Marie Curie, Hopital 
      Pitie-Salpetriere, Paris, France.
FAU - Langerak, A W
AU  - Langerak AW
AD  - Department of Immunology, Laboratory for Medical Immunology, Erasmus MC, University 
      Medical Center, Rotterdam, The Netherlands.
FAU - Oscier, D
AU  - Oscier D
AD  - Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK.
FAU - Schuh, A
AU  - Schuh A
AD  - Oxford National Institute for Health Research Biomedical Research Centre and 
      Department of Oncology, University of Oxford, Oxford, UK.
FAU - Gaidano, G
AU  - Gaidano G
AD  - Division of Hematology, Department of Translational Medicine, Amedeo Avogadro 
      University of Eastern Piedmont, Novara, Italy.
FAU - Ghia, P
AU  - Ghia P
AUID- ORCID: 0000-0003-3750-7342
AD  - Universit Vita-Salute San Raffaele, Milan, Italy.
AD  - Division of Experimental Oncology and Department of Onco-Hematology, Istituto di 
      Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, 
      Italy.
FAU - Xu, W
AU  - Xu W
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer 
      Personalized Medicine, Nanjing, China.
FAU - Fan, L
AU  - Fan L
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer 
      Personalized Medicine, Nanjing, China.
FAU - Bernard, O A
AU  - Bernard OA
AD  - INSERM, U1170, Institut Gustave Roussy, Villejuif, France.
FAU - Nguyen-Khac, F
AU  - Nguyen-Khac F
AD  - Laboratory of Hematology and Universite Pierre et Marie Curie, Hopital 
      Pitie-Salpetriere, Paris, France.
FAU - Rassenti, L
AU  - Rassenti L
AD  - Division of Hematology/Oncology, Department of Medicine, University of California at 
      San Diego/Moores Cancer Center, La Jolla, CA, USA.
FAU - Li, J
AU  - Li J
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer 
      Personalized Medicine, Nanjing, China.
FAU - Kipps, T J
AU  - Kipps TJ
AD  - Division of Hematology/Oncology, Department of Medicine, University of California at 
      San Diego/Moores Cancer Center, La Jolla, CA, USA.
FAU - Stamatopoulos, K
AU  - Stamatopoulos K
AD  - Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, 
      Uppsala University, Sweden.
AD  - Institute of Applied Biosciences, Center for Research and Technology Hellas, 
      Thessaloniki, Greece.
FAU - Pospisilova, S
AU  - Pospisilova S
AD  - Central European Institute of Technology, Masaryk University and University Hospital 
      Brno, Brno, Czech Republic.
FAU - Zenz, T
AU  - Zenz T
AD  - Department of Molecular Therapy in Haematology and Oncology (G250) and Department of 
      Translational Oncology, National Center for Tumor Diseases (NCT), German Cancer 
      Research Center (DKFZ), Heidelberg, Germany.
AD  - Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
AD  - German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
FAU - Oakes, C C
AU  - Oakes CC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH, USA.
FAU - Strefford, J C
AU  - Strefford JC
AD  - Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
FAU - Rosenquist, R
AU  - Rosenquist R
AD  - Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, 
      Uppsala University, Sweden.
FAU - Damm, F
AU  - Damm F
AD  - Department of Hematology, Oncology, and Tumor Immunology, Charit, University 
      Medical Center, Berlin, Germany.
AD  - German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
LA  - eng
GR  - P01 CA081534/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161128
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (EGR2 protein, human)
RN  - 0 (Early Growth Response Protein 2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Early Growth Response Protein 2/*genetics
MH  - Female
MH  - Genes, p53
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/classification/drug 
      therapy/*genetics/mortality
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Proportional Hazards Models
PMC - PMC7001738
MID - NIHMS1068606
COIS- CONFLICT OF INTEREST The authors declare no conflict of interest.
EDAT- 2016/11/29 06:00
MHDA- 2017/09/28 06:00
CRDT- 2016/11/29 06:00
PHST- 2016/08/01 00:00 [received]
PHST- 2016/11/04 00:00 [revised]
PHST- 2016/11/09 00:00 [accepted]
PHST- 2016/11/29 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
PHST- 2016/11/29 06:00 [entrez]
AID - leu2016359 [pii]
AID - 10.1038/leu.2016.359 [doi]
PST - ppublish
SO  - Leukemia. 2017 Jul;31(7):1547-1554. doi: 10.1038/leu.2016.359. Epub 2016 Nov 28.

PMID- 29872168
OWN - NLM
STAT- MEDLINE
DCOM- 20190613
LR  - 20200306
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 32
IP  - 12
DP  - 2018 Dec
TI  - NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.
PG  - 2536-2545
LID - 10.1038/s41375-018-0147-4 [doi]
AB  - Targeted mutation assessment of 81 genes in 1021 adults with de novo acute myeloid 
      leukemia (AML) identified recurrent mutations in the neurofibromin 1 (NF1) gene in 
      52 (5.1%) patients, including 36 (5.2%) younger and 16 (4.8%) older patients, which 
      suggests NF1 belongs to the 20 most frequently mutated genes in adult AML. NF1 
      mutations were found throughout the gene, and comprised missense, frameshift, and 
      nonsense mutations. One mutation hotspot, at amino acid threonine 676 (Thr676), was 
      found in 27% of AML patients with NF1 mutations. NF1-mutated patients belonged more 
      often to the adverse European LeukemiaNet (ELN) risk category than NF1 wild-type 
      patients. Among patients aged <60 years, the presence of NF1 Thr676 mutations was 
      associated with lower complete remission (CR) rates (P=0.04) and shorter overall 
      survival (OS; P=0.01), as was the presence of any NF1 mutation in patients in the 
      adverse ELN risk category (CR, P=0.05; OS, P<0.001). CR rates were also lower in 
      NF1-mutated patients aged 60 years compared with NF1 wild-type patients 
      (P=0.001). In summary, our findings provide novel insights into the frequency of 
      NF1 mutations in AML, and are suggestive of an adverse prognostic impact in patients 
      treated with standard chemotherapy.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      ann-kathrin.eisfeld@osumc.edu.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance for Clinical Trials in Oncology Statistics and Data Center, The Ohio State 
      University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      krzysztof.mrozek@osumc.edu.
FAU - Mims, Alice
AU  - Mims A
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance for Clinical Trials in Oncology Statistics and Data Center, The Ohio State 
      University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Maharry, Sophia E
AU  - Maharry SE
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Carroll, Andrew J
AU  - Carroll AJ
AD  - Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Powell, Bayard L
AU  - Powell BL
AD  - Department of Internal Medicine, The Comprehensive Cancer Center of Wake Forest 
      University, Wake Forest University, Winston-Salem, NC, USA.
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - Monter Cancer Center, Hofstra Northwell School of Medicine, Lake Success, NY, USA.
FAU - Wang, Eunice S
AU  - Wang ES
AD  - Roswell Park Cancer Institute, Buffalo, NY, USA.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - de la Chapelle, Albert
AU  - de la Chapelle A
AUID- ORCID: 0000-0001-9345-9248
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      clara.bloomfield@osumc.edu.
LA  - eng
GR  - U10 CA032291/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - U10 CA035279/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U10 CA059518/CA/NCI NIH HHS/United States
GR  - U10 CA180850/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - U10 CA180867/CA/NCI NIH HHS/United States
GR  - U10 CA003927/CA/NCI NIH HHS/United States
GR  - U10 CA180866/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180605
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (NF1 protein, human)
RN  - 0 (Neurofibromin 1)
SB  - IM
CIN - Leukemia. 2018 Dec;32(12):2715. PMID: 30275525
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Mutation/*genetics
MH  - Neurofibromin 1/*genetics
MH  - Prognosis
MH  - Remission Induction/methods
MH  - Risk Factors
MH  - Young Adult
PMC - PMC6281863
MID - NIHMS959885
COIS- The authors declare no conflicts of interest.
EDAT- 2018/06/07 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/06/07 06:00
PHST- 2017/12/27 00:00 [received]
PHST- 2018/04/13 00:00 [accepted]
PHST- 2018/03/29 00:00 [revised]
PHST- 2018/06/07 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2018/06/07 06:00 [entrez]
AID - 10.1038/s41375-018-0147-4 [pii]
AID - 10.1038/s41375-018-0147-4 [doi]
PST - ppublish
SO  - Leukemia. 2018 Dec;32(12):2536-2545. doi: 10.1038/s41375-018-0147-4. Epub 2018 Jun 
      5.

PMID- 30630817
OWN - NLM
STAT- MEDLINE
DCOM- 20200109
LR  - 20200309
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Print)
IS  - 2473-9529 (Linking)
VI  - 3
IP  - 2
DP  - 2019 Jan 22
TI  - Classic hairy cell leukemia complicated by pancytopenia and severe infection: a 
      report of 3 cases treated with vemurafenib.
PG  - 116-118
LID - 10.1182/bloodadvances.2018027466 [doi]
AB  - Infections are a major cause of morbidity and mortality in HCL patients, and 
      myelosuppressive therapies increase the risk of poor outcomes. Vemurafenib achieves 
      rapid hematologic improvement in HCL and may facilitate management during 
      life-threatening infection.
FAU - Shenoi, Daniel P
AU  - Shenoi DP
AD  - Division of Hospital Medicine, Department of Internal Medicine, The Ohio State 
      University, Columbus, OH.
FAU - Andritsos, Leslie A
AU  - Andritsos LA
AD  - The University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; and.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Rogers, Kerry A
AU  - Rogers KA
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Moran, Mollie E
AU  - Moran ME
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Anghelina, Mirela
AU  - Anghelina M
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Jones, Jeffrey A
AU  - Jones JA
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
FAU - Grever, Michael R
AU  - Grever MR
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 207SMY3FQT (Vemurafenib)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Humans
MH  - Infections/diagnosis/*etiology
MH  - Leukemia, Hairy Cell/*complications/diagnosis/drug therapy/genetics
MH  - Male
MH  - Middle Aged
MH  - Pancytopenia/diagnosis/*etiology
MH  - Protein Kinase Inhibitors/*adverse effects/therapeutic use
MH  - Severity of Illness Index
MH  - Vemurafenib/*adverse effects/therapeutic use
PMC - PMC6341189
COIS- Conflict-of-interest disclosure: K.A.R. receives research funding from Genentech and 
      consults for Acerta. L.A.A. participated in an advisory board and consults for 
      AstraZeneca. M.E.M. participated in an advisory board for AbbVie. J.S.B. has 
      consulted for AstraZeneca, AbbVie, and Kite Pharma. J.A.J. is employed with and has 
      equity in Celgene Corporation. M.R.G. consults for AstraZeneca, Acerta, and 
      Pharmacyclics. K.A.R., L.A.A., J.S.B., M.R.G., and M.A. receive research support 
      from and consult for the Hairy Cell Leukemia Foundation. D.P.S. declares no 
      competing financial interests.
EDAT- 2019/01/12 06:00
MHDA- 2020/01/10 06:00
CRDT- 2019/01/12 06:00
PHST- 2018/10/17 00:00 [received]
PHST- 2018/12/04 00:00 [accepted]
PHST- 2019/01/12 06:00 [entrez]
PHST- 2019/01/12 06:00 [pubmed]
PHST- 2020/01/10 06:00 [medline]
AID - bloodadvances.2018027466 [pii]
AID - 2018/027466 [pii]
AID - 10.1182/bloodadvances.2018027466 [doi]
PST - ppublish
SO  - Blood Adv. 2019 Jan 22;3(2):116-118. doi: 10.1182/bloodadvances.2018027466.

PMID- 29296799
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 2473-9529 (Print)
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Linking)
VI  - 1
IP  - 19
DP  - 2017 Aug 22
TI  - Near-tetraploidy is associated with Richter transformation in chronic lymphocytic 
      leukemia patients receiving ibrutinib.
PG  - 1584-1588
LID - 10.1182/bloodadvances.2017007302 [doi]
AB  - Ibrutinib is a highly effective targeted therapy for chronic lymphocytic leukemia 
      (CLL). However, ibrutinib must be discontinued in a subset of patients due to 
      progressive CLL or transformation to aggressive lymphoma (Richter transformation). 
      Transformation occurs early in the course of therapy and has an extremely poor 
      prognosis. Thus, identification of prognostic markers associated with transformation 
      is of utmost importance. Near-tetraploidy (4 copies of most chromosomes within a 
      cell) has been reported in various lymphomas, but its incidence and significance in 
      CLL has not been described. Using fluorescence in situ hybridization, we detected 
      near-tetraploidy in 9 of 297 patients with CLL prior to beginning ibrutinib 
      treatment on 1 of 4 clinical trials (3.0%; 95% confidence interval [CI], 1.4%-5.7%). 
      Near-tetraploidy was associated with aggressive disease characteristics: Rai stage 
      3/4 (P = .03), deletion 17p (P = .03), and complex karyotype (P = .01). 
      Near-tetraploidy was also associated with ibrutinib discontinuation due to Richter 
      transformation (P < .0001), but not due to progressive CLL (P = .41). Of the 9 
      patients with near-tetraploidy, 6 had Richter transformation with diffuse large 
      B-cell lymphoma. In a multivariable model, near-tetraploidy (hazard ratio [HR], 
      8.66; 95% CI, 3.83-19.59; P < .0001) and complex karyotype (HR, 4.77; 95% CI, 
      1.42-15.94; P = .01) were independent risk factors for discontinuing ibrutinib due 
      to transformation. Our results suggest that near-tetraploidy is a potential 
      prognostic marker for Richter transformation to assess in patients going on 
      ibrutinib.
FAU - Miller, Cecelia R
AU  - Miller CR
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Ruppert, Amy S
AU  - Ruppert AS
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Heerema, Nyla A
AU  - Heerema NA
AD  - Department of Pathology, and.
FAU - Maddocks, Kami J
AU  - Maddocks KJ
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Labanowska, Jadwiga
AU  - Labanowska J
AD  - Department of Pathology, and.
FAU - Breidenbach, Heather
AU  - Breidenbach H
AD  - Department of Pathology, and.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - Department of Pathology, and.
FAU - Zhao, Weiqiang
AU  - Zhao W
AD  - Department of Pathology, and.
FAU - Gordon, Amber L
AU  - Gordon AL
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Jones, Jeffrey A
AU  - Jones JA
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Flynn, Joseph M
AU  - Flynn JM
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Jaglowski, Samantha M
AU  - Jaglowski SM
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Andritsos, Leslie A
AU  - Andritsos LA
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Blum, Kristie A
AU  - Blum KA
AD  - Division of Hematology, Department of Internal Medicine.
FAU - T Awan, Farrukh
AU  - T Awan F
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Rogers, Kerry A
AU  - Rogers KA
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Grever, Michael R
AU  - Grever MR
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Johnson, Amy J
AU  - Johnson AJ
AD  - Division of Hematology, Department of Internal Medicine.
AD  - Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, 
      OH.
FAU - Abruzzo, Lynne V
AU  - Abruzzo LV
AD  - Department of Pathology, and.
FAU - Hertlein, Erin K
AU  - Hertlein EK
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine.
AD  - Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, 
      OH.
LA  - eng
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - T32 GM068412/GM/NIGMS NIH HHS/United States
GR  - R01 CA197870/CA/NCI NIH HHS/United States
GR  - K23 CA178183/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - P01 CA095426/CA/NCI NIH HHS/United States
GR  - R01 CA182905/CA/NCI NIH HHS/United States
GR  - R01 CA177292/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R01 CA183444/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170821
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
PMC - PMC5728464
COIS- Conflict-of-interest disclosure: M.R.G. is a paid consultant for Pharmacyclics. The 
      remaining authors declare no other competing financial interests.
EDAT- 2018/01/04 06:00
MHDA- 2018/01/04 06:01
CRDT- 2018/01/04 06:00
PHST- 2017/03/30 00:00 [received]
PHST- 2017/06/22 00:00 [accepted]
PHST- 2018/01/04 06:00 [entrez]
PHST- 2018/01/04 06:00 [pubmed]
PHST- 2018/01/04 06:01 [medline]
AID - 2017/007302 [pii]
AID - 10.1182/bloodadvances.2017007302 [doi]
PST - epublish
SO  - Blood Adv. 2017 Aug 21;1(19):1584-1588. doi: 10.1182/bloodadvances.2017007302. 
      eCollection 2017 Aug 22.

PMID- 33754642
OWN - NLM
STAT- In-Data-Review
LR  - 20210716
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 137
IP  - 25
DP  - 2021 Jun 24
TI  - Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
PG  - 3473-3483
LID - 10.1182/blood.2020009688 [doi]
AB  - Hairy cell leukemia (HCL) is a rare B-cell malignancy, and there is a need for novel 
      treatments for patients who do not benefit from purine analogs. Ibrutinib, an oral 
      agent targeting Bruton tyrosine kinase in the B-cell receptor signaling pathway, is 
      highly effective in several malignancies. Its activity in HCL was unknown, so we 
      conducted a multisite phase 2 study of oral ibrutinib in patients with either 
      relapsed classic or variant hairy cell leukemia. The primary outcome measure was the 
      overall response rate (ORR) at 32 weeks, and we also assessed response at 48 weeks 
      and best response during treatment. Key secondary objectives were characterization 
      of toxicity and determination of progression-free survival (PFS) and overall 
      survival (OS). Thirty-seven patients were enrolled at 2 different doses (24 at 420 
      mg, 13 at 840 mg). The median duration of follow-up was 3.5 years (range, 0-5.9 
      years). The ORR at 32 weeks was 24%, which increased to 36% at 48 weeks. The best 
      ORR was 54%. The estimated 36-month PFS was 73% and OS was 85%. The most frequent 
      adverse events were diarrhea (59%), fatigue (54%), myalgia (54%), and nausea (51%). 
      Hematologic adverse events were common: anemia (43%), thrombocytopenia (41%), and 
      neutropenia (35%). Ibrutinib can be safely administered to patients with HCL with 
      objective responses and results in prolonged disease control. Although the initial 
      primary outcome objective of the study was not met, the observation of objective 
      responses in heavily pretreated patients coupled with a favorable PFS suggests that 
      ibrutinib may be beneficial in these patients. This trial was registered at 
      www.clinicaltrials.gov as #NCT01841723.
FAU - Rogers, Kerry A
AU  - Rogers KA
AUID- ORCID: 0000-0001-5748-7874
AD  - Division of Hematology and.
FAU - Andritsos, Leslie A
AU  - Andritsos LA
AUID- ORCID: 0000-0003-0222-1766
AD  - Division of Hematology and.
FAU - Wei, Lai
AU  - Wei L
AUID- ORCID: 0000-0002-7248-3828
AD  - Center for Biostatistics, The Ohio State University, Columbus, OH.
FAU - McLaughlin, Eric M
AU  - McLaughlin EM
AD  - Center for Biostatistics, The Ohio State University, Columbus, OH.
FAU - Ruppert, Amy S
AU  - Ruppert AS
AD  - Division of Hematology and.
FAU - Anghelina, Mirela
AU  - Anghelina M
AD  - Division of Hematology and.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology and.
FAU - Call, Timothy
AU  - Call T
AD  - Mayo Clinic, Rochester, MN.
FAU - Chihara, Dai
AU  - Chihara D
AUID- ORCID: 0000-0002-1153-2294
AD  - Medical Oncology Service, Center for Cancer Research, National Cancer Institute, 
      National Institutes of Health, Bethesda, MD.
FAU - Dauki, Anees
AU  - Dauki A
AUID- ORCID: 0000-0003-2963-7884
AD  - College of Pharmacy and.
FAU - Guo, Ling
AU  - Guo L
AD  - Department of Pathology, The Ohio State University, Columbus, OH.
FAU - Ivy, S Percy
AU  - Ivy SP
AD  - Cancer Therapy Evaluation Program and.
FAU - James, Lacey R
AU  - James LR
AD  - Medical Oncology Service, Center for Cancer Research, National Cancer Institute, 
      National Institutes of Health, Bethesda, MD.
FAU - Jones, Daniel
AU  - Jones D
AD  - Department of Pathology, The Ohio State University, Columbus, OH.
FAU - Kreitman, Robert J
AU  - Kreitman RJ
AD  - Laboratory of Molecular Biology, National Cancer Institute, National Institutes of 
      Health, Bethesda, MD.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - Department of Pathology, The Ohio State University, Columbus, OH.
FAU - Lucas, David M
AU  - Lucas DM
AD  - Division of Hematology and.
FAU - Ngankeu, Apollinaire
AU  - Ngankeu A
AD  - Division of Hematology and.
FAU - Phelps, Mitch
AU  - Phelps M
AD  - College of Pharmacy and.
FAU - Ravandi, Farhad
AU  - Ravandi F
AD  - University of Texas MD Anderson Cancer Center, Houston, TX.
FAU - Schiffer, Charles A
AU  - Schiffer CA
AD  - Department of Oncology, Karmanos Cancer Institute, Wayne State University School of 
      Medicine, Detroit, MI; and.
FAU - Carson, William E
AU  - Carson WE
AUID- ORCID: 0000-0001-7024-7533
AD  - Department of Surgery, The Ohio State University, Columbus, OH.
FAU - Jones, Jeffrey A
AU  - Jones JA
AD  - Division of Hematology and.
FAU - Grever, Michael R
AU  - Grever MR
AD  - Division of Hematology and.
LA  - eng
SI  - ClinicalTrials.gov/NCT01841723
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - UM1 CA186712/CA/NCI NIH HHS/United States
PT  - Journal Article
TA  - Blood
JT  - Blood
JID - 7603509
SB  - AIM
SB  - IM
CIN - Blood. 2021 Jun 24;137(25):3461-3462. PMID: 34165548
PMC - PMC8225920
COIS- Conflict-of-interest disclosure: K.A.R. receives research funding from AbbVie, 
      Genentech, and Janssen, and participated in advisory boards for Acerta Pharma, 
      Pharmacyclics, AbbVie, Genentech, Innate Pharma, and AstraZeneca. L.A.A. consults 
      for AstraZeneca. A.S.R. serves on an independent data safety monitoring board for 
      Telios Pharma. M.A. has consulted for AstraZeneca. J.S.B. has received consulting 
      fees from AbbVie, AstraZeneca, and KITE Pharma. A.D. is employed by Gilead. R.J.K. 
      receives research support from agreements between the National Institutes of Health 
      and AstraZeneca, Genentech, Teva, and Novartis and is a coinventor on the National 
      Institutes of Health patent for moxetumomab pasudotox. G.L. receives research 
      funding from Genentech, Stemline, Novartis, and Beckman Coulter. D.J. receives 
      research or testing support from Pharmacyclics, AbbVie, Novartis, MingSight, Acerta 
      Pharma, ArQule, and Sunesis. C.A.S. served on a data safety monitoring board for 
      Pharmacyclics and receives research funding for clinical trials. J.A.J. is employed 
      by and has equity in Bristol Myers Squibb. M.R.G. has severed on a data safety 
      monitoring committee for Acerta Pharma and Axio and has consulted for AstraZeneca 
      and Pharmacyclics. The remaining authors declare no competing financial interests.
EDAT- 2021/03/24 06:00
MHDA- 2021/03/24 06:00
PMCR- 2022/06/24
CRDT- 2021/03/23 07:32
PHST- 2020/11/01 00:00 [received]
PHST- 2021/03/03 00:00 [accepted]
PHST- 2022/06/24 00:00 [pmc-release]
PHST- 2021/03/24 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
PHST- 2021/03/23 07:32 [entrez]
AID - S0006-4971(21)00697-2 [pii]
AID - 2021/BLD2020009688 [pii]
AID - 10.1182/blood.2020009688 [doi]
PST - ppublish
SO  - Blood. 2021 Jun 24;137(25):3473-3483. doi: 10.1182/blood.2020009688.

PMID- 34021247
OWN - NLM
STAT- Publisher
LR  - 20211005
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
DP  - 2021 May 21
TI  - Genomic analysis of cellular hierarchy in acute myeloid leukemia using 
      ultrasensitive LC-FACSeq.
LID - 10.1038/s41375-021-01295-1 [doi]
AB  - Hematopoiesis is hierarchical, and it has been postulated that acute myeloid 
      leukemia (AML) is organized similarly with leukemia stem cells (LSCs) residing at 
      the apex. Limited cells acquired by fluorescence activated cell sorting in tandem 
      with targeted amplicon-based sequencing (LC-FACSeq) enables identification of 
      mutations in small subpopulations of cells, such as LSCs. Leveraging this, we 
      studied clonal compositions of immunophenotypically-defined compartments in AML 
      through genomic and functional analyses at diagnosis, remission and relapse in 88 
      AML patients. Mutations involving DNA methylation pathways, transcription factors 
      and spliceosomal machinery did not differ across compartments, while signaling 
      pathway mutations were less frequent in putative LSCs. We also provide insights into 
      TP53-mutated AML by demonstrating stepwise acquisition of mutations beginning from 
      the preleukemic hematopoietic stem cell stage. In 10 analyzed cases, acquisition of 
      additional mutations and del(17p) led to genetic and functional heterogeneity within 
      the LSC pool with subclones harboring varying degrees of clonogenic potential. 
      Finally, we use LC-FACSeq to track clonal evolution in serial samples, which can 
      also be a powerful tool to direct targeted therapy against measurable residual 
      disease. Therefore, studying clinically significant small subpopulations of cells 
      can improve our understanding of AML biology and offers advantages over bulk 
      sequencing to monitor the evolution of disease.
CI  -  2021. The Author(s).
FAU - Saygin, Caner
AU  - Saygin C
AUID- ORCID: 0000-0001-7617-8356
AD  - Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
FAU - Hu, Eileen
AU  - Hu E
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Zhang, Pu
AU  - Zhang P
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Sher, Steven
AU  - Sher S
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Lozanski, Arletta
AU  - Lozanski A
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Doong, Tzyy-Jye
AU  - Doong TJ
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - Alliance Statistics and Data Center, The Ohio State University, Columbus, OH, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Labanowska, Jadwiga
AU  - Labanowska J
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA.
FAU - Skinner, Jordan N
AU  - Skinner JN
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Cempre, Casey
AU  - Cempre C
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Kauffman, Tierney
AU  - Kauffman T
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Goettl, Virginia M
AU  - Goettl VM
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Heerema, Nyla A
AU  - Heerema NA
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA.
FAU - Abruzzo, Lynne
AU  - Abruzzo L
AUID- ORCID: 0000-0001-6113-7447
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA.
FAU - Miller, Cecelia
AU  - Miller C
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA.
FAU - Lapalombella, Rosa
AU  - Lapalombella R
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Behbehani, Gregory
AU  - Behbehani G
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Mims, Alice S
AU  - Mims AS
AUID- ORCID: 0000-0002-8971-2199
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Larkin, Karilyn
AU  - Larkin K
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Grieselhuber, Nicole
AU  - Grieselhuber N
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Walker, Alison
AU  - Walker A
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AUID- ORCID: 0000-0001-5465-7591
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA. James.Blachly@osumc.edu.
LA  - eng
GR  - F30 CA225070/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20210521
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
SB  - IM
EIN - Leukemia. 2021 Sep 3;:. PMID: 34480107
EDAT- 2021/05/23 06:00
MHDA- 2021/05/23 06:00
CRDT- 2021/05/22 06:03
PHST- 2020/08/20 00:00 [received]
PHST- 2021/05/05 00:00 [accepted]
PHST- 2021/05/03 00:00 [revised]
PHST- 2021/05/23 06:00 [pubmed]
PHST- 2021/05/23 06:00 [medline]
PHST- 2021/05/22 06:03 [entrez]
AID - 10.1038/s41375-021-01295-1 [pii]
AID - 10.1038/s41375-021-01295-1 [doi]
PST - aheadofprint
SO  - Leukemia. 2021 May 21. doi: 10.1038/s41375-021-01295-1.

PMID- 25178460
OWN - NLM
STAT- MEDLINE
DCOM- 20150305
LR  - 20181202
IS  - 1367-4811 (Electronic)
IS  - 1367-4803 (Print)
IS  - 1367-4803 (Linking)
VI  - 30
IP  - 24
DP  - 2014 Dec 15
TI  - PrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq 
      data.
PG  - 3567-74
LID - 10.1093/bioinformatics/btu583 [doi]
AB  - MOTIVATION: DNA methylation is an epigenetic change occurring in genomic CpG 
      sequences that contribute to the regulation of gene transcription both in normal and 
      malignant cells. Next-generation sequencing has been used to characterize DNA 
      methylation status at the genome scale, but suffers from high sequencing cost in the 
      case of whole-genome bisulfite sequencing, or from reduced resolution (inability to 
      precisely define which of the CpGs are methylated) with capture-based techniques. 
      RESULTS: Here we present a computational method that computes nucleotide-resolution 
      methylation values from capture-based data by incorporating fragment length profiles 
      into a model of methylation analysis. We demonstrate that it compares favorably with 
      nucleotide-resolution bisulfite sequencing and has better predictive power with 
      respect to a reference than window-based methods, often used for enrichment data. 
      The described method was used to produce the methylation data used in tandem with 
      gene expression to produce a novel and clinically significant gene signature in 
      acute myeloid leukemia. In addition, we introduce a complementary statistical method 
      that uses this nucleotide-resolution methylation data for detection of 
      differentially methylated features.
CI  -  The Author 2014. Published by Oxford University Press. All rights reserved. For 
      Permissions, please e-mail: journals.permissions@oup.com.
FAU - Frankhouser, David E
AU  - Frankhouser DE
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Murphy, Mark
AU  - Murphy M
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Park, Jincheol
AU  - Park J
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA College of 
      Medicine, Biomedical Sciences Graduate Program, Department of Internal Medicine, 
      Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Zoller, Mike W
AU  - Zoller MW
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Ganbat, Javkhlan-Ochir
AU  - Ganbat JO
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Curfman, John
AU  - Curfman J
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Lin, Shili
AU  - Lin S
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Marcucci, Guido
AU  - Marcucci G
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Yan, Pearlly
AU  - Yan P
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
FAU - Bundschuh, Ralf
AU  - Bundschuh R
AD  - College of Medicine, Biomedical Sciences Graduate Program, Department of Internal 
      Medicine, Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA College of 
      Medicine, Biomedical Sciences Graduate Program, Department of Internal Medicine, 
      Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA College of 
      Medicine, Biomedical Sciences Graduate Program, Department of Internal Medicine, 
      Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA College of 
      Medicine, Biomedical Sciences Graduate Program, Department of Internal Medicine, 
      Division of Hematology, Department of Statistics, Mathematical Biosciences 
      Institute, Department of Physics, Department of Chemistry & Biochemistry and Center 
      for RNA Biology, The Ohio State University, Columbus, OH 43210, USA.
LA  - eng
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - R01 CA102031/CA/NCI NIH HHS/United States
GR  - CA140158/CA/NCI NIH HHS/United States
GR  - CA102031/CA/NCI NIH HHS/United States
GR  - CA101140/CA/NCI NIH HHS/United States
GR  - CA016058/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - T32 GM068412/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20140831
TA  - Bioinformatics
JT  - Bioinformatics (Oxford, England)
JID - 9808944
RN  - 0 (Nucleotides)
RN  - 0 (Sulfites)
RN  - OJ9787WBLU (hydrogen sulfite)
SB  - IM
MH  - Algorithms
MH  - CpG Islands
MH  - *DNA Methylation
MH  - Genomics/methods
MH  - High-Throughput Nucleotide Sequencing/*methods
MH  - Humans
MH  - Leukemia, Myeloid, Acute/genetics
MH  - Nucleotides/metabolism
MH  - Sequence Analysis, DNA/*methods
MH  - Sulfites
PMC - PMC4253832
EDAT- 2014/09/03 06:00
MHDA- 2015/03/07 06:00
CRDT- 2014/09/03 06:00
PHST- 2014/09/03 06:00 [entrez]
PHST- 2014/09/03 06:00 [pubmed]
PHST- 2015/03/07 06:00 [medline]
AID - btu583 [pii]
AID - 10.1093/bioinformatics/btu583 [doi]
PST - ppublish
SO  - Bioinformatics. 2014 Dec 15;30(24):3567-74. doi: 10.1093/bioinformatics/btu583. Epub 
      2014 Aug 31.

PMID- 25368506
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141104
LR  - 20201001
IS  - 1176-9351 (Print)
IS  - 1176-9351 (Electronic)
IS  - 1176-9351 (Linking)
VI  - 13
IP  - Suppl 3
DP  - 2014
TI  - Quality Control for RNA-Seq (QuaCRS): An Integrated Quality Control Pipeline.
PG  - 7-14
LID - 10.4137/CIN.S14022 [doi]
AB  - QuaCRS (Quality Control for RNA-Seq) is an integrated, simplified quality control 
      (QC) system for RNA-seq data that allows easy execution of several open-source QC 
      tools, aggregation of their output, and the ability to quickly identify quality 
      issues by performing meta-analyses on QC metrics across large numbers of samples in 
      different studies. It comprises two main sections. First is the QC Pack wrapper, 
      which executes three QC tools: FastQC, RNA-SeQC, and selected functions from RSeQC. 
      Combining these three tools into one wrapper provides increased ease of use and 
      provides a much more complete view of sample data quality than any individual tool. 
      Second is the QC database, which displays the resulting metrics in a user-friendly 
      web interface. It was designed to allow users with less computational experience to 
      easily generate and view QC information for their data, to investigate individual 
      samples and aggregate reports of sample groups, and to sort and search samples based 
      on quality. The structure of the QuaCRS database is designed to enable expansion 
      with additional tools and metrics in the future. The source code for not-for-profit 
      use and a fully functional sample user interface with mock data are available at 
      http://bioserv.mps.ohio-state.edu/QuaCRS/.
FAU - Kroll, Karl W
AU  - Kroll KW
AD  - Department of Internal Medicine, Division of Hematology, Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Mokaram, Nima E
AU  - Mokaram NE
AD  - Shared Genomics Resource, Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Pelletier, Alexander R
AU  - Pelletier AR
AD  - Department of Internal Medicine, Division of Hematology, Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Frankhouser, David E
AU  - Frankhouser DE
AD  - Shared Genomics Resource, Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Westphal, Maximillian S
AU  - Westphal MS
AD  - Shared Genomics Resource, Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Stump, Paige A
AU  - Stump PA
AD  - Shared Genomics Resource, Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Stump, Cameron L
AU  - Stump CL
AD  - Shared Genomics Resource, Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Bundschuh, Ralf
AU  - Bundschuh R
AD  - Department of Internal Medicine, Division of Hematology, Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA. ; Department of Physics, The Ohio 
      State University, Columbus, OH, USA. ; Department of Chemistry and Biochemistry, The 
      Ohio State University, Columbus, OH, USA. ; Center for RNA Biology, The Ohio State 
      University, Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Department of Internal Medicine, Division of Hematology, Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Yan, Pearlly
AU  - Yan P
AD  - Department of Internal Medicine, Division of Hematology, Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA. ; Shared Genomics Resource, Ohio 
      State University Comprehensive Cancer Center, Columbus, OH, USA.
LA  - eng
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - R01 CA102031/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - T32 GM068412/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20141015
TA  - Cancer Inform
JT  - Cancer informatics
JID - 101258149
PMC - PMC4214596
OTO - NOTNLM
OT  - FastQC
OT  - RNA-SeQC
OT  - RNA-seq
OT  - RSeQC
OT  - database
OT  - quality control
EDAT- 2014/11/05 06:00
MHDA- 2014/11/05 06:01
CRDT- 2014/11/05 06:00
PHST- 2014/06/02 00:00 [received]
PHST- 2014/07/31 00:00 [revised]
PHST- 2014/08/01 00:00 [accepted]
PHST- 2014/11/05 06:00 [entrez]
PHST- 2014/11/05 06:00 [pubmed]
PHST- 2014/11/05 06:01 [medline]
AID - cin-suppl.3-2014-007 [pii]
AID - 10.4137/CIN.S14022 [doi]
PST - epublish
SO  - Cancer Inform. 2014 Oct 15;13(Suppl 3):7-14. doi: 10.4137/CIN.S14022. eCollection 
      2014.

PMID- 28918710
OWN - NLM
STAT- MEDLINE
DCOM- 20190125
LR  - 20201114
IS  - 1029-2403 (Electronic)
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 59
IP  - 4
DP  - 2018 Apr
TI  - Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
PG  - 1008-1011
LID - 10.1080/10428194.2017.1365853 [doi]
FAU - Andritsos, Leslie A
AU  - Andritsos LA
AD  - a Division of Hematology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Grieselhuber, Nicole R
AU  - Grieselhuber NR
AD  - a Division of Hematology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Anghelina, Mirela
AU  - Anghelina M
AD  - a Division of Hematology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Rogers, Kerry A
AU  - Rogers KA
AD  - a Division of Hematology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Roychowdhury, Sameek
AU  - Roychowdhury S
AD  - b Division of Medical Oncology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Reeser, Julie W
AU  - Reeser JW
AD  - b Division of Medical Oncology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Timmers, Cynthia D
AU  - Timmers CD
AD  - b Division of Medical Oncology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Freud, Aharon G
AU  - Freud AG
AD  - c Department of Pathology , The Ohio State University , Columbus , OH , USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - a Division of Hematology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Lucas, David M
AU  - Lucas DM
AD  - a Division of Hematology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - c Department of Pathology , The Ohio State University , Columbus , OH , USA.
FAU - Jones, Jeffrey A
AU  - Jones JA
AD  - a Division of Hematology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Williams, Katie
AU  - Williams K
AD  - a Division of Hematology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Oakes, Christopher
AU  - Oakes C
AD  - a Division of Hematology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
FAU - Jones, Dan
AU  - Jones D
AD  - c Department of Pathology , The Ohio State University , Columbus , OH , USA.
FAU - Grever, Michael R
AU  - Grever MR
AD  - a Division of Hematology, Department of Internal Medicine , The Ohio State 
      University , Columbus , OH , USA.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Case Reports
PT  - Letter
DEP - 20170918
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Immunoglobulin Heavy Chains)
RN  - 0 (Immunoglobulin Variable Region)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridones)
RN  - 0 (Pyrimidinones)
RN  - 33E86K87QN (trametinib)
RN  - EC 2.7.12.2 (MAP Kinase Kinase 1)
RN  - EC 2.7.12.2 (MAP2K1 protein, human)
SB  - IM
MH  - Genes, Immunoglobulin Heavy Chain/*genetics
MH  - Humans
MH  - Immunoglobulin Heavy Chains/genetics
MH  - Immunoglobulin Variable Region/genetics
MH  - Leukemia, Hairy Cell/*drug therapy/genetics
MH  - MAP Kinase Kinase 1/*genetics
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Pyridones/*therapeutic use
MH  - Pyrimidinones/*therapeutic use
MH  - Treatment Outcome
PMC - PMC7664305
MID - NIHMS1585211
COIS- Potential conflict of interest Disclosure forms provided by the authors are 
      available with the full text of this article online at 
      https://doi.org/10.1080/10428194.2017.1365853.
EDAT- 2017/09/19 06:00
MHDA- 2019/01/27 06:00
CRDT- 2017/09/19 06:00
PHST- 2017/09/19 06:00 [pubmed]
PHST- 2019/01/27 06:00 [medline]
PHST- 2017/09/19 06:00 [entrez]
AID - 10.1080/10428194.2017.1365853 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2018 Apr;59(4):1008-1011. doi: 10.1080/10428194.2017.1365853. Epub 
      2017 Sep 18.

PMID- 26669971
OWN - NLM
STAT- MEDLINE
DCOM- 20180212
LR  - 20181113
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 30
IP  - 7
DP  - 2016 Jul
TI  - Clinical features and gene- and microRNA-expression patterns in adult acute leukemia 
      patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).
PG  - 1586-9
LID - 10.1038/leu.2015.345 [doi]
FAU - Bhatnagar, B
AU  - Bhatnagar B
AD  - Division of Hematology, Department of Internal Medicine, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Blachly, J S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Kohlschmidt, J
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, 
      Rochester, MN, USA.
FAU - Eisfeld, A-K
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Volinia, S
AU  - Volinia S
AD  - Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, 
      Ferrara, Italy.
FAU - Nicolet, D
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, 
      Rochester, MN, USA.
FAU - Carroll, A J
AU  - Carroll AJ
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Block, A W
AU  - Block AW
AD  - Roswell Park Cancer Institute, Buffalo, NY, USA.
FAU - Kolitz, J E
AU  - Kolitz JE
AD  - Monter Cancer Center, Hofstra North Shore-Long Island Jewish School of Medicine, 
      Lake Success, NY, USA.
FAU - Stone, R M
AU  - Stone RM
AD  - Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Mrzek, K
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Byrd, J C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Bloomfield, C D
AU  - Bloomfield CD
AD  - Division of Hematology, Department of Internal Medicine, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
LA  - eng
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U24 CA114725/CA/NCI NIH HHS/United States
GR  - U10 CA180850/CA/NCI NIH HHS/United States
GR  - UG1 CA189850/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - U10 CA180855/CA/NCI NIH HHS/United States
GR  - U10 CA180867/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Letter
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151216
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (MLL-ELL fusion protein, human)
RN  - 0 (MLLT1 protein, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Transcription Factors)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosomes, Human, Pair 11/genetics
MH  - Chromosomes, Human, Pair 19/genetics
MH  - DNA Mutational Analysis
MH  - Female
MH  - Humans
MH  - Leukemia/*genetics
MH  - Male
MH  - MicroRNAs/analysis/genetics
MH  - Middle Aged
MH  - Myeloid-Lymphoid Leukemia Protein/genetics
MH  - Neoplasm Proteins/genetics
MH  - Nuclear Proteins/genetics
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Transcription Factors/genetics
MH  - Transcriptome/*genetics
MH  - Translocation, Genetic
MH  - Young Adult
PMC - PMC5004206
MID - NIHMS802629
COIS- The authors declare no conflict of interest.
EDAT- 2015/12/17 06:00
MHDA- 2018/02/13 06:00
CRDT- 2015/12/17 06:00
PHST- 2015/12/17 06:00 [entrez]
PHST- 2015/12/17 06:00 [pubmed]
PHST- 2018/02/13 06:00 [medline]
AID - leu2015345 [pii]
AID - 10.1038/leu.2015.345 [doi]
PST - ppublish
SO  - Leukemia. 2016 Jul;30(7):1586-9. doi: 10.1038/leu.2015.345. Epub 2015 Dec 16.

PMID- 34162404
OWN - NLM
STAT- In-Process
LR  - 20210929
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 14
IP  - 1
DP  - 2021 Jun 23
TI  - A precision medicine classification for treatment of acute myeloid leukemia in older 
      patients.
PG  - 96
LID - 10.1186/s13045-021-01110-5 [doi]
LID - 96
AB  - BACKGROUND: Older patients (60years) with acute myeloid leukemia (AML) often have 
      multiple, sequentially acquired, somatic mutations that drive leukemogenesis and are 
      associated with poor outcome. Beat AML is a Leukemia and Lymphoma Society-sponsored, 
      multicenter umbrella study that algorithmically segregates AML patients based upon 
      cytogenetic and dominant molecular abnormalities (variant allele frequencies 
      (VAF)0.2) into different cohorts to select for targeted therapies. During the 
      conception of the Beat AML design, a historical dataset was needed to help in the 
      design of the genomic algorithm for patient assignment and serve as the basis for 
      the statistical design of individual genomic treatment substudies for the Beat AML 
      study. METHODS: We classified 563 newly diagnosed older AML patients treated with 
      standard intensive chemotherapy on trials conducted by Cancer and Leukemia Group B 
      based on the same genomic algorithm and assessed clinical outcomes. RESULTS: Our 
      classification identified core-binding factor and NPM1-mutated/FLT3-ITD-negative 
      groups as having the best outcomes, with 30-day early death (ED) rates of 0 and 20%, 
      respectively, and median overall survival (OS) of>1year and 3-year OS rates 
      of20%. All other genomic groups had ED rates of 17-42%, median OS1year and 
      3-year OS rates of15%. CONCLUSIONS: By classifying patients through this genomic 
      algorithm, outcomes were poor and not unexpected from a non-algorithmic, 
      non-dominant VAF approach. The exception is 30-day ED rate typicallyis not 
      available for intensive induction for individual genomic groups and therefore 
      difficult to compare outcomes with targeted therapeutics. This Alliance data 
      supported the use of this algorithm for patient assignment at the initiation of the 
      Beat AML study. This outcome data was also used for statistical design for Beat AML 
      substudies for individual genomic groups to determine goals for improvement from 
      intensive induction and hopefully lead to more rapid approval of new therapies. 
      Trial registration ClinicalTrials.gov Identifiers: NCT00048958 (CALGB 8461), 
      NCT00900224 (CALGB 20202), NCT00003190 (CALGB 9720), NCT00085124 (CALGB 10201), 
      NCT00742625 (CALGB 10502), NCT01420926 (CALGB 11002), NCT00039377 (CALGB 10801), and 
      NCT01253070 (CALGB 11001).
FAU - Mims, Alice S
AU  - Mims AS
AUID- ORCID: 0000-0002-8971-2199
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA. alice.mims@osumc.edu.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center 
      for Leukemia Outcomes Research, Columbus, OH, USA.
FAU - Borate, Uma
AU  - Borate U
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center 
      for Leukemia Outcomes Research, Columbus, OH, USA.
FAU - Papaioannou, Dimitrios
AU  - Papaioannou D
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center 
      for Leukemia Outcomes Research, Columbus, OH, USA.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center 
      for Leukemia Outcomes Research, Columbus, OH, USA.
FAU - Stein, Eytan
AU  - Stein E
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Dana-Farber/Partners CancerCare, Boston, MA, USA.
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - Monter Cancer Center, Hofstra Northwell School of Medicine, Lake Success, NY, USA.
FAU - Wang, Eunice S
AU  - Wang ES
AD  - Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
FAU - Powell, Bayard L
AU  - Powell BL
AD  - Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
FAU - Burd, Amy
AU  - Burd A
AD  - The Leukemia and Lymphoma Society, White Plains, NY, USA.
FAU - Levine, Ross L
AU  - Levine RL
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Druker, Brian J
AU  - Druker BJ
AD  - Oregon Health and Science University, Portland, OR, USA.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - The Ohio State University Comprehensive Cancer Center, 320 West 10th Avenue, 
      Starling Loving Hall B302, Columbus, OH, 43210, USA. John.Byrd@osumc.edu.
AD  - The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center 
      for Leukemia Outcomes Research, Columbus, OH, USA. John.Byrd@osumc.edu.
AD  - The Ohio State University Comprehensive Cancer Center, 455 CCC Wiseman Hall, 400 
      West 12th Avenue, Columbus, OH, 43210-1228, USA. John.Byrd@osumc.edu.
LA  - eng
SI  - ClinicalTrials.gov/NCT00039377
SI  - ClinicalTrials.gov/NCT00048958
SI  - ClinicalTrials.gov/NCT00900224
SI  - ClinicalTrials.gov/NCT01253070
SI  - ClinicalTrials.gov/NCT00003190
GR  - UG1 CA233331/CA/NCI NIH HHS/United States
GR  - R35 CA198183/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - UG1 CA233338/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - U10 CA180888/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210623
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
SB  - IM
PMC - PMC8220739
OTO - NOTNLM
OT  - *Acute myeloid leukemia
OT  - *Cytogenetics
OT  - *Mutation
OT  - *Outcome
OT  - *Precision medicine
COIS- The authors declare no conflicts of or competing interest.
EDAT- 2021/06/25 06:00
MHDA- 2021/06/25 06:00
CRDT- 2021/06/24 05:34
PHST- 2021/04/05 00:00 [received]
PHST- 2021/06/04 00:00 [accepted]
PHST- 2021/06/24 05:34 [entrez]
PHST- 2021/06/25 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s13045-021-01110-5 [pii]
AID - 1110 [pii]
AID - 10.1186/s13045-021-01110-5 [doi]
PST - epublish
SO  - J Hematol Oncol. 2021 Jun 23;14(1):96. doi: 10.1186/s13045-021-01110-5.

PMID- 25512507
OWN - NLM
STAT- MEDLINE
DCOM- 20150422
LR  - 20181113
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 111
IP  - 52
DP  - 2014 Dec 30
TI  - Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
PG  - 18679-84
LID - 10.1073/pnas.1422050112 [doi]
AB  - Long noncoding RNAs (lncRNAs) are transcripts longer than 200 nucleotides, located 
      within the intergenic stretches or overlapping antisense transcripts of protein 
      coding genes. LncRNAs are involved in numerous biological roles including 
      imprinting, epigenetic regulation, apoptosis, and cell cycle. To determine whether 
      lncRNAs are associated with clinical features and recurrent mutations in older 
      patients (aged 60 y) with cytogenetically normal (CN) acute myeloid leukemia (AML), 
      we evaluated lncRNA expression in 148 untreated older CN-AML cases using a custom 
      microarray platform. An independent set of 71 untreated older patients with CN-AML 
      was used to validate the outcome scores using RNA sequencing. Distinctive lncRNA 
      profiles were found associated with selected mutations, such as internal tandem 
      duplications in the FLT3 gene (FLT3-ITD) and mutations in the NPM1, CEBPA, IDH2, 
      ASXL1, and RUNX1 genes. Using the lncRNAs most associated with event-free survival 
      in a training cohort of 148 older patients with CN-AML, we derived a lncRNA score 
      composed of 48 lncRNAs. Patients with an unfavorable compared with favorable lncRNA 
      score had a lower complete response (CR) rate [P < 0.001, odds ratio = 0.14, 54% vs. 
      89%], shorter disease-free survival (DFS) [P < 0.001, hazard ratio (HR) = 2.88] and 
      overall survival (OS) (P < 0.001, HR = 2.95). The validation set analyses confirmed 
      these results (CR, P = 0.03; DFS, P = 0.009; OS, P = 0.009). Multivariable analyses 
      for CR, DFS, and OS identified the lncRNA score as an independent marker for 
      outcome. In conclusion, lncRNA expression in AML is closely associated with 
      recurrent mutations. A small subset of lncRNAs is correlated strongly with treatment 
      response and survival.
FAU - Garzon, Ramiro
AU  - Garzon R
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; 
      carlo.croce@osumc.edu ramiro.garzon@osumc.edu clara.bloomfield@osumc.edu.
FAU - Volinia, Stefano
AU  - Volinia S
AD  - Department of Morphology, Surgery, and Experimental Medicine, University of Ferrara, 
      Ferrara, FE 44121, Italy;
FAU - Papaioannou, Dimitrios
AU  - Papaioannou D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; Alliance 
      for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, 
      MN 55905;
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; Alliance 
      for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, 
      MN 55905;
FAU - Yan, Pearlly S
AU  - Yan PS
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
FAU - Bucci, Donna
AU  - Bucci D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
FAU - Carroll, Andrew J
AU  - Carroll AJ
AD  - Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294;
FAU - Baer, Maria R
AU  - Baer MR
AD  - Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201;
FAU - Wetzler, Meir
AU  - Wetzler M
AD  - Roswell Park Cancer Institute, Buffalo, NY 14263;
FAU - Carter, Thomas H
AU  - Carter TH
AD  - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242;
FAU - Powell, Bayard L
AU  - Powell BL
AD  - The Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157;
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - North Shore Cancer Institute, Lake Success, NY 11042;
FAU - Moore, Joseph O
AU  - Moore JO
AD  - Department of Medicine, Division of Hematology-Oncology, Duke University and Durham 
      VA Medical Centers, Durham, NC 27701; and.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
FAU - Blachly, James S
AU  - Blachly JS
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
FAU - Blum, William
AU  - Blum W
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
FAU - Caligiuri, Michael A
AU  - Caligiuri MA
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
FAU - Stone, Richard M
AU  - Stone RM
AD  - Dana-Farber Cancer Institute, Harvard University, Boston, MA 02215.
FAU - Marcucci, Guido
AU  - Marcucci G
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
FAU - Croce, Carlo M
AU  - Croce CM
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; 
      carlo.croce@osumc.edu ramiro.garzon@osumc.edu clara.bloomfield@osumc.edu.
FAU - Byrd, John C
AU  - Byrd JC
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; 
      carlo.croce@osumc.edu ramiro.garzon@osumc.edu clara.bloomfield@osumc.edu.
LA  - eng
SI  - GEO/GSE63614
SI  - GEO/GSE63646
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - CA101140/CA/NCI NIH HHS/United States
GR  - P50-CA140158-05/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U10 CA180850/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - CA180861/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20141215
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Neoplasm)
SB  - IM
MH  - Case-Control Studies
MH  - Disease-Free Survival
MH  - Female
MH  - *Gene Expression Regulation, Leukemic
MH  - Humans
MH  - Leukemia, Myeloid, Acute/genetics/*metabolism/*mortality
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Neoplasm Proteins/genetics/metabolism
MH  - RNA, Long Noncoding/*biosynthesis/genetics
MH  - RNA, Neoplasm/*biosynthesis/genetics
MH  - Sequence Analysis, RNA
MH  - Survival Rate
PMC - PMC4284555
OTO - NOTNLM
OT  - acute myeloid leukemia
OT  - lncRNAs
OT  - outcome
COIS- The authors declare no conflict of interest.
EDAT- 2014/12/17 06:00
MHDA- 2015/04/23 06:00
CRDT- 2014/12/17 06:00
PHST- 2014/12/17 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/04/23 06:00 [medline]
AID - 1422050112 [pii]
AID - 201422050 [pii]
AID - 10.1073/pnas.1422050112 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18679-84. doi: 
      10.1073/pnas.1422050112. Epub 2014 Dec 15.

PMID- 28827320
OWN - NLM
STAT- MEDLINE
DCOM- 20180604
LR  - 20190610
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 114
IP  - 36
DP  - 2017 Sep 5
TI  - Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF 
      inhibitor resistance in malignant melanoma.
PG  - 9629-9634
LID - 10.1073/pnas.1704371114 [doi]
AB  - Activating mutations in BRAF are found in 50% of melanomas and although treatment 
      with BRAF inhibitors (BRAFi) is effective, resistance often develops. We now show 
      that recently discovered NRAS isoform 2 is up-regulated in the setting of BRAF 
      inhibitor resistance in melanoma, in both cell lines and patient tumor tissues. When 
      isoform 2 was overexpressed in BRAF mutant melanoma cell lines, melanoma cell 
      proliferation and in vivo tumor growth were significantly increased in the presence 
      of BRAFi treatment. shRNA-mediated knockdown of isoform 2 in BRAFi resistant cells 
      restored sensitivity to BRAFi compared with controls. Signaling analysis indicated 
      decreased mitogen-activated protein kinase (MAPK) pathway signaling and increased 
      phosphoinositol-3-kinase (PI3K) pathway signaling in isoform 2 overexpressing cells 
      compared with isoform 1 overexpressing cells. Immunoprecipitation of isoform 2 
      validated a binding affinity of this isoform to both PI3K and BRAF/RAF1. The 
      addition of an AKT inhibitor to BRAFi treatment resulted in a partial restoration of 
      BRAFi sensitivity in cells expressing high levels of isoform 2. NRAS isoform 2 may 
      contribute to resistance to BRAFi by facilitating PI3K pathway activation.
FAU - Duggan, Megan C
AU  - Duggan MC
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
AD  - Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH 43210.
FAU - Stiff, Andrew R
AU  - Stiff AR
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
AD  - Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH 43210.
FAU - Bainazar, Maryam
AU  - Bainazar M
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
FAU - Regan, Kelly
AU  - Regan K
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
FAU - Olaverria Salavaggione, Gonzalo N
AU  - Olaverria Salavaggione GN
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
FAU - Maharry, Sophia
AU  - Maharry S
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
FAU - Krischak, Madison
AU  - Krischak M
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
FAU - Latchana, Nicholas
AU  - Latchana N
AD  - Division of Surgical Oncology, The Ohio State University, Columbus, OH 43210.
FAU - Tridandapani, Susheela
AU  - Tridandapani S
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
FAU - de la Chapelle, Albert
AU  - de la Chapelle A
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210; 
      Albert.delaChapelle@osumc.edu ann-kathrin.eisfeld@osumc.edu 
      william.carson@osumc.edu.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210; 
      Albert.delaChapelle@osumc.edu ann-kathrin.eisfeld@osumc.edu 
      william.carson@osumc.edu.
FAU - Carson, William E 3rd
AU  - Carson WE 3rd
AD  - Division of Surgical Oncology, The Ohio State University, Columbus, OH 43210 
      Albert.delaChapelle@osumc.edu ann-kathrin.eisfeld@osumc.edu 
      william.carson@osumc.edu.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - P01 CA095426/CA/NCI NIH HHS/United States
GR  - T32 GM068412/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20170821
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Membrane Proteins)
RN  - 0 (Protein Isoforms)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (Sulfonamides)
RN  - 207SMY3FQT (Vemurafenib)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (AKT1 protein, human)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 3.6.1.- (GTP Phosphohydrolases)
RN  - EC 3.6.1.- (NRAS protein, human)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Drug Resistance, Neoplasm/genetics
MH  - GTP Phosphohydrolases/antagonists & inhibitors/*genetics/metabolism
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Indoles/therapeutic use
MH  - MAP Kinase Signaling System/drug effects/genetics
MH  - Melanoma/*drug therapy/*genetics/metabolism
MH  - Membrane Proteins/antagonists & inhibitors/*genetics/metabolism
MH  - Mutation
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Protein Isoforms/genetics
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors/genetics
MH  - Proto-Oncogene Proteins c-akt/antagonists & inhibitors/genetics
MH  - RNA, Messenger/genetics/metabolism
MH  - RNA, Neoplasm/genetics/metabolism
MH  - Skin Neoplasms/*drug therapy/*genetics/metabolism
MH  - Sulfonamides/therapeutic use
MH  - Up-Regulation
MH  - Vemurafenib
PMC - PMC5594655
OTO - NOTNLM
OT  - *BRAF
OT  - *NRAS
OT  - *melanoma
OT  - *resistance
OT  - *vemurafenib
COIS- The authors declare no conflict of interest.
EDAT- 2017/08/23 06:00
MHDA- 2018/06/05 06:00
CRDT- 2017/08/23 06:00
PHST- 2017/08/23 06:00 [pubmed]
PHST- 2018/06/05 06:00 [medline]
PHST- 2017/08/23 06:00 [entrez]
AID - 1704371114 [pii]
AID - 201704371 [pii]
AID - 10.1073/pnas.1704371114 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9629-9634. doi: 
      10.1073/pnas.1704371114. Epub 2017 Aug 21.

PMID- 28321123
OWN - NLM
STAT- MEDLINE
DCOM- 20171024
LR  - 20181113
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 31
IP  - 10
DP  - 2017 Oct
TI  - The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients 
      with de novo acute myeloid leukemia.
PG  - 2211-2218
LID - 10.1038/leu.2017.86 [doi]
AB  - Recurrent chromosomal abnormalities and gene mutations detected at the time of 
      diagnosis of acute myeloid leukemia (AML) are associated with particular disease 
      features, treatment response and survival of AML patients, and are used to denote 
      specific disease entities in the World Health Organization classification of myeloid 
      neoplasms and acute leukemia. However, large studies that integrate cytogenetic and 
      comprehensive mutational information are scarce. We created a comprehensive 
      oncoprint of mutations associated with recurrent cytogenetic findings by combining 
      the information on mutational patterns of 80 cancer- and leukemia-associated genes 
      with cytogenetic findings in 1603 adult patients with de novo AML. We show unique 
      differences in the mutational profiles among major cytogenetic subsets, identify 
      novel associations between recurrent cytogenetic abnormalities and both specific 
      gene mutations and gene functional groups, and reveal differences in cytogenetic and 
      mutational features between patients younger than 60 years and those aged 60 years 
      or older. The identified associations between cytogenetic and molecular genetic data 
      may help guide mutation testing in AML, and result in more focused application of 
      targeted therapy in patients with de novo AML.
FAU - Eisfeld, A-K
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Mrzek, K
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Kohlschmidt, J
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
FAU - Nicolet, D
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
FAU - Orwick, S
AU  - Orwick S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Walker, C J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Kroll, K W
AU  - Kroll KW
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Blachly, J S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Carroll, A J
AU  - Carroll AJ
AD  - Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Kolitz, J E
AU  - Kolitz JE
AD  - Monter Cancer Center, Hofstra North Shore-Long Island Jewish School of Medicine, 
      Lake Success, NY, USA.
FAU - Powell, B L
AU  - Powell BL
AD  - Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA.
FAU - Wang, E S
AU  - Wang ES
AD  - Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
FAU - Stone, R M
AU  - Stone RM
AD  - Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA.
FAU - de la Chapelle, A
AU  - de la Chapelle A
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Byrd, J C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Bloomfield, C D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
LA  - eng
GR  - U10 CA032291/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - U10 CA077658/CA/NCI NIH HHS/United States
GR  - U10 CA035279/CA/NCI NIH HHS/United States
GR  - U10 CA031946/CA/NCI NIH HHS/United States
GR  - U10 CA033601/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U10 CA059518/CA/NCI NIH HHS/United States
GR  - U10 CA180850/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - U10 CA180860/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - U10 CA180866/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20170324
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - *Chromosome Aberrations
MH  - DNA Mutational Analysis
MH  - DNA, Neoplasm/genetics
MH  - Female
MH  - *Gene Ontology
MH  - *Genes, Neoplasm
MH  - Humans
MH  - Karyotyping
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Male
MH  - Middle Aged
MH  - *Mutation
PMC - PMC5628133
MID - NIHMS891242
COIS- The authors declare no conflict of interest.
EDAT- 2017/03/23 06:00
MHDA- 2017/10/25 06:00
CRDT- 2017/03/22 06:00
PHST- 2016/11/02 00:00 [received]
PHST- 2017/01/17 00:00 [revised]
PHST- 2017/02/16 00:00 [accepted]
PHST- 2017/03/23 06:00 [pubmed]
PHST- 2017/10/25 06:00 [medline]
PHST- 2017/03/22 06:00 [entrez]
AID - leu201786 [pii]
AID - 10.1038/leu.2017.86 [doi]
PST - ppublish
SO  - Leukemia. 2017 Oct;31(10):2211-2218. doi: 10.1038/leu.2017.86. Epub 2017 Mar 24.

PMID- 33707228
OWN - NLM
STAT- In-Data-Review
LR  - 20210628
IS  - 1549-5469 (Electronic)
IS  - 1088-9051 (Print)
IS  - 1088-9051 (Linking)
VI  - 31
IP  - 5
DP  - 2021 May
TI  - DNA methylation epitypes highlight underlying developmental and disease pathways in 
      acute myeloid leukemia.
PG  - 747-761
LID - 10.1101/gr.269233.120 [doi]
AB  - Acute myeloid leukemia (AML) is a molecularly complex disease characterized by 
      heterogeneous tumor genetic profiles and involving numerous pathogenic mechanisms 
      and pathways. Integration of molecular data types across multiple patient cohorts 
      may advance current genetic approaches for improved subclassification and 
      understanding of the biology of the disease. Here, we analyzed genome-wide DNA 
      methylation in 649 AML patients using Illumina arrays and identified a configuration 
      of 13 subtypes (termed "epitypes") using unbiased clustering. Integration of genetic 
      data revealed that most epitypes were associated with a certain recurrent mutation 
      (or combination) in a majority of patients, yet other epitypes were largely 
      independent. Epitypes showed developmental blockage at discrete stages of myeloid 
      differentiation, revealing epitypes that retain arrested hematopoietic 
      stem-cell-like phenotypes. Detailed analyses of DNA methylation patterns identified 
      unique patterns of aberrant hyper- and hypomethylation among epitypes, with variable 
      involvement of transcription factors influencing promoter, enhancer, and repressed 
      regions. Patients in epitypes with stem-cell-like methylation features showed 
      inferior overall survival along with up-regulated stem cell gene expression 
      signatures. We further identified a DNA methylation signature involving STAT motifs 
      associated with FLT3-ITD mutations. Finally, DNA methylation signatures were stable 
      at relapse for the large majority of patients, and rare epitype switching 
      accompanied loss of the dominant epitype mutations and reversion to stem-cell-like 
      methylation patterns. These results show that DNA methylation-based classification 
      integrates important molecular features of AML to reveal the diverse pathogenic and 
      biological aspects of the disease.
CI  -  2021 Giacopelli et al.; Published by Cold Spring Harbor Laboratory Press.
FAU - Giacopelli, Brian
AU  - Giacopelli B
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
FAU - Wang, Min
AU  - Wang M
AD  - Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio 
      43210, USA.
FAU - Cleary, Ada
AU  - Cleary A
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
FAU - Wu, Yue-Zhong
AU  - Wu YZ
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
FAU - Schultz, Anna Reister
AU  - Schultz AR
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 
      97239, USA.
FAU - Schmutz, Maximilian
AU  - Schmutz M
AD  - Hematology and Oncology, Medical Faculty, University of Augsburg, 86159 Augsburg, 
      Germany.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
AD  - Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio 
      43210, USA.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
FAU - Mundy-Bosse, Bethany
AU  - Mundy-Bosse B
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
FAU - Vosberg, Sebastian
AU  - Vosberg S
AD  - Department of Medicine III, University Hospital, LMU Munich, 80539 Munich, Germany.
AD  - Institute of Computational Biology, Helmholtz Zentrum Mnchen-German Research Center 
      for Environmental Health, 85764 Munich, Germany.
FAU - Greif, Philipp A
AU  - Greif PA
AD  - Department of Medicine III, University Hospital, LMU Munich, 80539 Munich, Germany.
AD  - German Cancer Consortium (DKTK), Partner Site Munich, 69120 Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Claus, Rainer
AU  - Claus R
AD  - Department of Medicine II, Stem Cell Transplantation Unit, Klinikum Augsburg, 
      Ludwig-Maximilians University Munich, 86156 Munich, Germany.
FAU - Bullinger, Lars
AU  - Bullinger L
AD  - Department of Hematology, Oncology and Tumorimmunology, Charit-Universittsmedizin, 
      13353 Berlin, Germany.
FAU - Garzon, Ramiro
AU  - Garzon R
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
FAU - Coombes, Kevin R
AU  - Coombes KR
AD  - Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio 
      43210, USA.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
FAU - Druker, Brian J
AU  - Druker BJ
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 
      97239, USA.
FAU - Tyner, Jeffrey W
AU  - Tyner JW
AD  - Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 
      97239, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
FAU - Oakes, Christopher C
AU  - Oakes CC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio 43210, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
AD  - Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio 
      43210, USA.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - U01 CA217862/CA/NCI NIH HHS/United States
GR  - U54 CA224019/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20210311
TA  - Genome Res
JT  - Genome research
JID - 9518021
SB  - IM
PMC - PMC8092005
EDAT- 2021/03/13 06:00
MHDA- 2021/03/13 06:00
CRDT- 2021/03/12 06:26
PHST- 2020/07/23 00:00 [received]
PHST- 2021/03/09 00:00 [accepted]
PHST- 2021/03/13 06:00 [pubmed]
PHST- 2021/03/13 06:00 [medline]
PHST- 2021/03/12 06:26 [entrez]
AID - gr.269233.120 [pii]
AID - 10.1101/gr.269233.120 [doi]
PST - ppublish
SO  - Genome Res. 2021 May;31(5):747-761. doi: 10.1101/gr.269233.120. Epub 2021 Mar 11.

PMID- 27346418
OWN - NLM
STAT- MEDLINE
DCOM- 20171107
LR  - 20181113
IS  - 1098-1004 (Electronic)
IS  - 1059-7794 (Print)
IS  - 1059-7794 (Linking)
VI  - 37
IP  - 10
DP  - 2016 Oct
TI  - MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors 
      with Defective DNA Mismatch Repair.
PG  - 1004-12
LID - 10.1002/humu.23036 [doi]
AB  - Next-generation sequencing has revolutionized cancer genetics, but accurately 
      detecting mutations in repetitive DNA sequences, especially mononucleotide runs, 
      remains a challenge. This is a particular concern for tumors with defective mismatch 
      repair (MMR) that accumulate strand-slippage mutations. We developed MonoSeq to 
      improve indel mutation detection in mononucleotide runs, and used MonoSeq to 
      investigate strand-slippage mutations in endometrial cancers, a tumor type that has 
      frequent loss of MMR. We performed extensive Sanger sequencing to validate both 
      clonal and subclonal MonoSeq mutation calls. Eighty-one regions containing 
      mononucleotide runs were sequenced in 540 primary endometrial cancers (223 with 
      defective MMR). Our analyses revealed that the overall mutation rate in 
      MMR-deficient tumors was 20-30-fold higher than in MMR-normal tumors. MonoSeq 
      analysis identified several previously unreported mutations, including a novel 
      hotspot in an A7 run in the terminal exon of ARID5B.The ARID5B indel mutations were 
      seen in both MMR-deficient and MMR-normal tumors, suggesting biologic selection. The 
      analysis of tumor mRNAs revealed the presence of mutant transcripts that could 
      result in translation of neopeptides. Improved detection of mononucleotide run 
      strand-slippage mutations has clear implications for comprehensive mutation 
      detection in tumors with defective MMR. Indel frameshift mutations and the resultant 
      antigenic peptides could help guide immunotherapy strategies.
CI  -  2016 WILEY PERIODICALS, INC.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - James Comprehensive Cancer Center and the Department of Obstetrics and Gynecology, 
      Ohio State University, Columbus, OH.
FAU - Miranda, Mario A
AU  - Miranda MA
AD  - James Comprehensive Cancer Center and the Department of Obstetrics and Gynecology, 
      Ohio State University, Columbus, OH.
FAU - O'Hern, Matthew J
AU  - O'Hern MJ
AD  - James Comprehensive Cancer Center and the Department of Obstetrics and Gynecology, 
      Ohio State University, Columbus, OH.
FAU - Blachly, James S
AU  - Blachly JS
AD  - James Comprehensive Cancer Center and the Department of Internal Medicine, Ohio 
      State University, Columbus, Ohio.
FAU - Moyer, Cassandra L
AU  - Moyer CL
AD  - James Comprehensive Cancer Center and the Department of Obstetrics and Gynecology, 
      Ohio State University, Columbus, OH.
FAU - Ivanovich, Jennifer
AU  - Ivanovich J
AD  - Siteman Cancer Center and the Department of Surgery, Washington University School of 
      Medicine, St. Louis, MO.
FAU - Kroll, Karl W
AU  - Kroll KW
AD  - James Comprehensive Cancer Center, Ohio State University, Columbus, OH.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - James Comprehensive Cancer Center, Ohio State University, Columbus, OH.
FAU - Sapp, Caroline E
AU  - Sapp CE
AD  - James Comprehensive Cancer Center and the Department of Obstetrics and Gynecology, 
      Ohio State University, Columbus, OH.
FAU - Mutch, David G
AU  - Mutch DG
AD  - Siteman Cancer Center and the Department of Obstetrics and Gynecology, Washington 
      University School of Medicine, St. Louis, MO.
FAU - Cohn, David E
AU  - Cohn DE
AD  - James Comprehensive Cancer Center and the Department of Obstetrics and Gynecology, 
      Ohio State University, Columbus, OH.
FAU - Bundschuh, Ralf
AU  - Bundschuh R
AD  - Department of Physics, Department of Chemistry and Biochemistry, Department of 
      Internal Medicine, Ohio State University, Columbus, OH.
FAU - Goodfellow, Paul J
AU  - Goodfellow PJ
AD  - James Comprehensive Cancer Center and the Department of Obstetrics and Gynecology, 
      Ohio State University, Columbus, OH. paul.goodfellow@osumc.edu.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R01 CA151853/CA/NCI NIH HHS/United States
GR  - R21 CA155674/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160808
TA  - Hum Mutat
JT  - Human mutation
JID - 9215429
RN  - 0 (ARID5B protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Algorithms
MH  - DNA Mismatch Repair
MH  - DNA-Binding Proteins/*genetics
MH  - Endometrial Neoplasms/*genetics
MH  - Female
MH  - Frameshift Mutation
MH  - Gene Expression Profiling/methods
MH  - High-Throughput Nucleotide Sequencing/methods
MH  - Humans
MH  - *INDEL Mutation
MH  - Sequence Analysis, DNA/*methods
MH  - Transcription Factors/*genetics
PMC - PMC5021604
MID - NIHMS809417
OTO - NOTNLM
OT  - *endometrial cancer
OT  - *microsatellite instability
OT  - *mononucleotide run
OT  - *next-generation sequencing
COIS- All authors declare no conflict of interest.
EDAT- 2016/06/28 06:00
MHDA- 2017/11/08 06:00
CRDT- 2016/06/28 06:00
PHST- 2016/04/28 00:00 [received]
PHST- 2016/06/07 00:00 [accepted]
PHST- 2016/06/28 06:00 [entrez]
PHST- 2016/06/28 06:00 [pubmed]
PHST- 2017/11/08 06:00 [medline]
AID - 10.1002/humu.23036 [doi]
PST - ppublish
SO  - Hum Mutat. 2016 Oct;37(10):1004-12. doi: 10.1002/humu.23036. Epub 2016 Aug 8.

PMID- 27843138
OWN - NLM
STAT- MEDLINE
DCOM- 20171017
LR  - 20181113
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun
TI  - Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with 
      t(8;21)(q22;q22) acute myeloid leukemia.
PG  - 1278-1285
LID - 10.1038/leu.2016.332 [doi]
AB  - Core-binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of 
      either t(8;21)(q22;q22)/RUNX1-RUNX1T1 or 
      inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB-MYH11. The resulting fusion genes require 
      a 'second hit' to initiate leukemogenesis. Mutation assessment of 177 adults with 
      CBF-AML, including 68 with t(8;21) and 109 with inv(16)/t(16;16), identified not 
      only mutations well known in CBF-AML but also mutations in the CCND1 and CCND2 
      genes, which represent novel frequent molecular alterations in AML with t(8;21). 
      Altogether, CCND1 (n=2) and CCND2 (n=8) mutations were detected in 10 (15%) patients 
      with t(8;21) in our cohort. A single CCND2 mutation was also found in 1 (0.9%) 
      patient with inv(16). In contrast, CCND1 and CCND2 mutations were detected in only 
      11 (0.77%) of 1426 non-CBF-AML patients. All CCND2 mutations cluster around the 
      highly conserved amino-acid residue threonine 280 (Thr280). We show that 
      Thr280Ala-mutated CCND2 leads to increased phosphorylation of the retinoblastoma 
      protein, thereby causing significant cell cycle changes and increased proliferation 
      of AML cell lines. The identification of CCND1 and CCND2 mutations as frequent 
      mutational events in t(8;21) AML may provide further justification for cell 
      cycle-directed therapy in this disease.
FAU - Eisfeld, A-K
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Kohlschmidt, J
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
FAU - Schwind, S
AU  - Schwind S
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Nicolet, D
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
FAU - Blachly, J S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Orwick, S
AU  - Orwick S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Shah, C
AU  - Shah C
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Bainazar, M
AU  - Bainazar M
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Kroll, K W
AU  - Kroll KW
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Walker, C J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Carroll, A J
AU  - Carroll AJ
AD  - Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Powell, B L
AU  - Powell BL
AD  - Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA.
FAU - Stone, R M
AU  - Stone RM
AD  - Dana-Farber/Partners CancerCare, Boston, MA, USA.
FAU - Kolitz, J E
AU  - Kolitz JE
AD  - Monter Cancer Center, Hofstra North Shore-Long Island Jewish School of Medicine, 
      Lake Success, NY, USA.
FAU - Baer, M R
AU  - Baer MR
AD  - Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
FAU - de la Chapelle, A
AU  - de la Chapelle A
AUID- ORCID: 0000-0001-9345-9248
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Mrzek, K
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Byrd, J C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Bloomfield, C D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
LA  - eng
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - U10 CA077658/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20161115
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCND1 protein, human)
RN  - 0 (CCND2 protein, human)
RN  - 0 (Cyclin D2)
RN  - 136601-57-5 (Cyclin D1)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/genetics
MH  - *Chromosomes, Human, Pair 21
MH  - *Chromosomes, Human, Pair 8
MH  - Cyclin D1/*genetics
MH  - Cyclin D2/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Survival Rate
MH  - *Translocation, Genetic
MH  - Young Adult
PMC - PMC5462855
MID - NIHMS835710
COIS- The authors declare no conflicts of interest.
EDAT- 2016/11/16 06:00
MHDA- 2017/10/19 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/08/01 00:00 [received]
PHST- 2016/10/21 00:00 [revised]
PHST- 2016/11/04 00:00 [accepted]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/10/19 06:00 [medline]
PHST- 2016/11/16 06:00 [entrez]
AID - leu2016332 [pii]
AID - 10.1038/leu.2016.332 [doi]
PST - ppublish
SO  - Leukemia. 2017 Jun;31(6):1278-1285. doi: 10.1038/leu.2016.332. Epub 2016 Nov 15.

PMID- 25001469
OWN - NLM
STAT- MEDLINE
DCOM- 20150424
LR  - 20210202
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 124
IP  - 9
DP  - 2014 Aug 28
TI  - PKC- as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical 
      activity in CLL.
PG  - 1481-91
LID - 10.1182/blood-2014-05-574830 [doi]
AB  - Targeting B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) has 
      been successful with durable remissions observed with several targeted therapeutics. 
      Protein kinase C- (PKC-) is immediately downstream of BCR and has been shown to be 
      essential to CLL cell survival and proliferation in vivo. We therefore evaluated 
      sotrastaurin (AEB071), an orally administered potent PKC inhibitor, on CLL cell 
      survival both in vitro and in vivo. AEB071 shows selective cytotoxicity against 
      B-CLL cells in a dose-dependent manner. Additionally, AEB071 attenuates BCR-mediated 
      survival pathways, inhibits CpG-induced survival and proliferation of CLL cells in 
      vitro, and effectively blocks microenvironment-mediated survival signaling pathways 
      in primary CLL cells. Furthermore, AEB071 alters -catenin expression, resulting in 
      decreased downstream transcriptional genes as c-Myc, Cyclin D1, and CD44. Lastly, 
      our preliminary in vivo studies indicate beneficial antitumor properties of AEB071 
      in CLL. Taken together, our results indicate that targeting PKC- has the potential 
      to disrupt signaling from the microenvironment contributing to CLL cell survival and 
      potentially drug resistance. Future efforts targeting PKC with the PKC inhibitor 
      AEB071 as monotherapy in clinical trials of relapsed and refractory CLL patients are 
      warranted.
CI  -  2014 by The American Society of Hematology.
FAU - El-Gamal, Dalia
AU  - El-Gamal D
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Williams, Katie
AU  - Williams K
AD  - Division of Hematology, Department of Internal Medicine.
FAU - LaFollette, Taylor D
AU  - LaFollette TD
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Cannon, Matthew
AU  - Cannon M
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Zhong, Yiming
AU  - Zhong Y
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Williams, Erich
AU  - Williams E
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Awan, Farrukh T
AU  - Awan FT
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Jones, Jeffrey
AU  - Jones J
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Andritsos, Leslie
AU  - Andritsos L
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Maddocks, Kami
AU  - Maddocks K
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Wu, Chia-Hsien
AU  - Wu CH
AD  - Division of Medicinal Chemistry, College of Pharmacy, and.
FAU - Chen, Ching-Shih
AU  - Chen CS
AD  - Division of Medicinal Chemistry, College of Pharmacy, and.
FAU - Lehman, Amy
AU  - Lehman A
AD  - Center for Biostatistics, The Ohio State University, Columbus, OH.
FAU - Zhang, Xiaoli
AU  - Zhang X
AD  - Center for Biostatistics, The Ohio State University, Columbus, OH.
FAU - Lapalombella, Rosa
AU  - Lapalombella R
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine.
LA  - eng
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - R01 CA177292/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140707
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (CTNNB1 protein, human)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrroles)
RN  - 0 (Quinazolines)
RN  - 0 (Receptors, Antigen, B-Cell)
RN  - 0 (beta Catenin)
RN  - 7I279E1NZ8 (sotrastaurin)
RN  - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta)
RN  - EC 2.7.11.13 (Protein Kinase C beta)
RN  - EC 2.7.11.26 (Glycogen Synthase Kinase 3)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
SB  - AIM
SB  - IM
MH  - Apoptosis/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Drug Screening Assays, Antitumor
MH  - Glycogen Synthase Kinase 3/metabolism
MH  - Glycogen Synthase Kinase 3 beta
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy/*enzymology/pathology
MH  - Protein Kinase C beta/*antagonists & inhibitors
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Pyrroles/*therapeutic use
MH  - Quinazolines/*therapeutic use
MH  - Receptors, Antigen, B-Cell/metabolism
MH  - Tetradecanoylphorbol Acetate/pharmacology
MH  - Tumor Cells, Cultured
MH  - Tumor Microenvironment/drug effects
MH  - Wnt Signaling Pathway/drug effects
MH  - beta Catenin/metabolism
PMC - PMC4148770
EDAT- 2014/07/09 06:00
MHDA- 2015/04/25 06:00
CRDT- 2014/07/09 06:00
PHST- 2014/07/09 06:00 [entrez]
PHST- 2014/07/09 06:00 [pubmed]
PHST- 2015/04/25 06:00 [medline]
AID - S0006-4971(20)35576-2 [pii]
AID - 2014/574830 [pii]
AID - 10.1182/blood-2014-05-574830 [doi]
PST - ppublish
SO  - Blood. 2014 Aug 28;124(9):1481-91. doi: 10.1182/blood-2014-05-574830. Epub 2014 Jul 
      7.

PMID- 27784745
OWN - NLM
STAT- MEDLINE
DCOM- 20170724
LR  - 20190629
IS  - 1538-7445 (Electronic)
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 77
IP  - 1
DP  - 2017 Jan 1
TI  - Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias 
      with Monosomy 7 as a Sole Abnormality.
PG  - 207-218
LID - 10.1158/0008-5472.CAN-16-1386 [doi]
AB  - Monosomy of chromosome 7 is the most frequent autosomal monosomy in acute myeloid 
      leukemia (AML), where it associates with poor clinical outcomes. However, molecular 
      features associated with this sole monosomy subtype (-7 AML), which may give 
      insights into the basis for its poor prognosis, have not been characterized. In this 
      study, we analyzed 36 cases of -7 AML for mutations in 81 leukemia/cancer-associated 
      genes using a customized targeted next-generation sequencing panel (Miseq). Global 
      gene and miRNA expression profiles were also determined using paired RNA and small 
      RNA sequencing data. Notably, gene mutations were detected in all the major 
      AML-associated functional groups, which include activated signaling, chromatin 
      remodeling, cohesin complex, methylation, NPM1, spliceosome, transcription factors, 
      and tumor suppressors. Gene mutations in the chromatin remodeling groups were 
      relatively more frequent in patients <60 years of age, who also had less mutations 
      in the methylation and spliceosome groups compared with patients 60 years of age. 
      Novel recurrent mutational events in AML were identified in the SMARCA2 gene. In 
      patients 60 years of age, the presence of spliceosome mutations associated with a 
      lower complete remission rate (P = 0.03). RNA sequencing revealed distinct gene and 
      miRNA expression patterns between the sole -7 and non -7 AML cases, with reduced 
      expression, as expected, of many genes and miRNAs mapped to chromosome 7, and 
      overexpression of ID1, MECOM, and PTPRM, among others. Overall, our findings 
      illuminate a number of molecular features of the underlying aggressive pathobiology 
      in -7 AML patients. Cancer Res; 77(1); 207-18. 2016 AACR.
CI  - 2016 American Association for Cancer Research.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 
      ann-kathrin.eisfeld@osumc.edu clara.bloomfield@osumc.edu.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
AD  - Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Volinia, Stefano
AU  - Volinia S
AD  - Department of Morphology, Surgery, and Experimental Medicine, University of Ferrara, 
      Ferrara, Italy.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, Ohio.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
AD  - Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
FAU - Oakes, Christopher
AU  - Oakes C
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, Ohio.
FAU - Kroll, Karl
AU  - Kroll K
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, Ohio.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, Ohio.
FAU - Carroll, Andrew J
AU  - Carroll AJ
AD  - University of Alabama at Birmingham, Birmingham, Alabama.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Dana-Farber/Partners CancerCare, Boston, Massachusetts.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, Ohio.
FAU - de la Chapelle, Albert
AU  - de la Chapelle A
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 
      ann-kathrin.eisfeld@osumc.edu clara.bloomfield@osumc.edu.
LA  - eng
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - U10 CA077658/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U10 CA180850/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20161026
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - Chromosome 7, monosomy
SB  - IM
MH  - Adult
MH  - Aged
MH  - Chromosome Deletion
MH  - Chromosomes, Human, Pair 7/genetics
MH  - DNA Mutational Analysis
MH  - Female
MH  - Gene Expression Profiling
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - *Transcriptome
PMC - PMC5215102
MID - NIHMS835711
COIS- of Potential Conflicts of Interest: The authors declare no conflict of interest.
EDAT- 2016/10/28 06:00
MHDA- 2017/07/25 06:00
CRDT- 2016/10/28 06:00
PHST- 2016/05/13 00:00 [received]
PHST- 2016/09/16 00:00 [revised]
PHST- 2016/09/21 00:00 [accepted]
PHST- 2016/10/28 06:00 [pubmed]
PHST- 2017/07/25 06:00 [medline]
PHST- 2016/10/28 06:00 [entrez]
AID - 0008-5472.CAN-16-1386 [pii]
AID - 10.1158/0008-5472.CAN-16-1386 [doi]
PST - ppublish
SO  - Cancer Res. 2017 Jan 1;77(1):207-218. doi: 10.1158/0008-5472.CAN-16-1386. Epub 2016 
      Oct 26.

PMID- 25787252
OWN - NLM
STAT- MEDLINE
DCOM- 20150629
LR  - 20181113
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 112
IP  - 14
DP  - 2015 Apr 7
TI  - Immunoglobulin transcript sequence and somatic hypermutation computation from 
      unselected RNA-seq reads in chronic lymphocytic leukemia.
PG  - 4322-7
LID - 10.1073/pnas.1503587112 [doi]
AB  - Immunoglobulins (Ig) are produced by B lymphocytes as secreted antibodies or as part 
      of the B-cell receptor. There is tremendous diversity of potential Ig transcripts 
      (>1  10(12)) as a result of hundreds of germ-line gene segments, random nucleotide 
      incorporation during joining of gene segments into a complete transcript, and the 
      process of somatic hypermutation at individual nucleotides. This recombination and 
      mutation process takes place in the maturing B cell and is responsible for the 
      diversity of potential epitope recognition. Cancers arising from mature B cells are 
      characterized by clonal production of Ig heavy (IGH@) and light chain transcripts, 
      although whether the sequence has undergone somatic hypermutation is dependent on 
      the maturation stage at which the neoplastic clone arose. Chronic lymphocytic 
      leukemia (CLL) is the most common leukemia in adults and arises from a mature B cell 
      with either mutated or unmutated IGH@ transcripts, the latter having worse prognosis 
      and the assessment of which is routinely performed in the clinic. Currently, IGHV 
      mutation status is assessed by Sanger sequencing and comparing the transcript to 
      known germ-line genes. In this paper, we demonstrate that complete IGH@ V-D-J 
      sequences can be computed from unselected RNA-seq reads with results equal or 
      superior to the clinical procedure: in the only discordant case, the clinical 
      transcript was out-of-frame. Therefore, a single RNA-seq assay can simultaneously 
      yield gene expression profile, SNP and mutation information, as well as IGHV 
      mutation status, and may one day be performed as a general test to capture 
      multidimensional clinically relevant data in CLL.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210;
FAU - Ruppert, Amy S
AU  - Ruppert AS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210;
FAU - Zhao, Weiqiang
AU  - Zhao W
AD  - Department of Pathology, The Ohio State University, Columbus, OH 43210;
FAU - Long, Susan
AU  - Long S
AD  - Department of Pathology, The Ohio State University, Columbus, OH 43210;
FAU - Flynn, Joseph
AU  - Flynn J
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210;
FAU - Flinn, Ian
AU  - Flinn I
AD  - Hematologic Malignancies Research Program, Sarah Cannon Research Institute, 
      Nashville, TN 37203;
FAU - Jones, Jeffrey
AU  - Jones J
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210;
FAU - Maddocks, Kami
AU  - Maddocks K
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210;
FAU - Andritsos, Leslie
AU  - Andritsos L
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210;
FAU - Ghia, Emanuela M
AU  - Ghia EM
AD  - Moores Cancer Center, University of California at San Diego, La Jolla, CA 
      92092-0820;
FAU - Rassenti, Laura Z
AU  - Rassenti LZ
AD  - Moores Cancer Center, University of California at San Diego, La Jolla, CA 
      92092-0820;
FAU - Kipps, Thomas J
AU  - Kipps TJ
AD  - Moores Cancer Center, University of California at San Diego, La Jolla, CA 
      92092-0820;
FAU - de la Chapelle, Albert
AU  - de la Chapelle A
AD  - Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State 
      University, Columbus, OH 43210; and Albert.delaChapelle@osumc.edu 
      john.byrd@osumc.edu.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, OH 43210; College of Pharmacy, The Ohio State University, Columbus, OH 
      43210 Albert.delaChapelle@osumc.edu john.byrd@osumc.edu.
LA  - eng
SI  - GEO/GSE66228
GR  - P01 CA95426/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - P01 CA101956/CA/NCI NIH HHS/United States
GR  - R01 CA177292/CA/NCI NIH HHS/United States
GR  - P01 CA081534/CA/NCI NIH HHS/United States
GR  - P01 CA81534/CA/NCI NIH HHS/United States
GR  - P01 CA095426/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150318
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Complementarity Determining Regions)
RN  - 0 (Immunoglobulin Variable Region)
RN  - 0 (Immunoglobulins)
RN  - EC 2.7.7.- (VDJ Recombinases)
SB  - IM
MH  - Alleles
MH  - Base Sequence
MH  - Complementarity Determining Regions/chemistry/genetics
MH  - Genome
MH  - Humans
MH  - Immunoglobulin Variable Region/genetics
MH  - Immunoglobulins/*chemistry
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*immunology
MH  - Molecular Sequence Data
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - Sequence Analysis, RNA/*methods
MH  - Sequence Homology, Nucleic Acid
MH  - *Somatic Hypermutation, Immunoglobulin
MH  - Transcriptome
MH  - VDJ Recombinases/genetics
PMC - PMC4394264
OTO - NOTNLM
OT  - B cells
OT  - CLL
OT  - RNA sequencing
OT  - immunoglobulin
OT  - somatic hypermutation
COIS- The authors declare no conflict of interest.
EDAT- 2015/03/20 06:00
MHDA- 2015/06/30 06:00
CRDT- 2015/03/20 06:00
PHST- 2015/03/20 06:00 [entrez]
PHST- 2015/03/20 06:00 [pubmed]
PHST- 2015/06/30 06:00 [medline]
AID - 1503587112 [pii]
AID - 201503587 [pii]
AID - 10.1073/pnas.1503587112 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4322-7. doi: 10.1073/pnas.1503587112. 
      Epub 2015 Mar 18.

PMID- 27435003
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20190816
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 30
IP  - 11
DP  - 2016 Nov
TI  - Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is 
      characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, 
      U2AF1, FLT3-ITD and IDH2.
PG  - 2254-2258
LID - 10.1038/leu.2016.196 [doi]
FAU - Eisfeld, A-K
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Kohlschmidt, J
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, 
      Rochester, MN, USA.
FAU - Mrzek, K
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Blachly, J S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Nicolet, D
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, 
      Rochester, MN, USA.
FAU - Kroll, K
AU  - Kroll K
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Orwick, S
AU  - Orwick S
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Carroll, A J
AU  - Carroll AJ
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Stone, R M
AU  - Stone RM
AD  - Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - de la Chapelle, A
AU  - de la Chapelle A
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Byrd, J C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Bloomfield, C D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
LA  - eng
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - U10 CA077658/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U10 CA180850/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - U10 CA180855/CA/NCI NIH HHS/United States
GR  - U10 CA180867/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Letter
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160720
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (KMT2A protein, human)
RN  - 0 (Splicing Factor U2AF)
RN  - 0 (U2AF1 protein, human)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 1.1.1.41 (isocitrate dehydrogenase 2, human)
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)
RN  - EC 2.1.1.37 (DNA methyltransferase 3A)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
RN  - EC 2.7.10.1 (FLT3 protein, human)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosomes, Human, Pair 11
MH  - DNA (Cytosine-5-)-Methyltransferases/*genetics
MH  - Female
MH  - Histone-Lysine N-Methyltransferase/*genetics
MH  - Humans
MH  - Isocitrate Dehydrogenase/*genetics
MH  - Leukemia, Myeloid, Acute/*genetics
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Myeloid-Lymphoid Leukemia Protein/*genetics
MH  - Splicing Factor U2AF/*genetics
MH  - *Trisomy
MH  - fms-Like Tyrosine Kinase 3/*genetics
PMC - PMC5244485
MID - NIHMS835712
COIS- The authors declare no conflicts of interest. CONFLICT OF INTEREST The authors 
      declare no conflicts of interest.
EDAT- 2016/11/03 06:00
MHDA- 2018/03/10 06:00
CRDT- 2016/07/21 06:00
PHST- 2016/11/03 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
PHST- 2016/07/21 06:00 [entrez]
AID - leu2016196 [pii]
AID - 10.1038/leu.2016.196 [doi]
PST - ppublish
SO  - Leukemia. 2016 Nov;30(11):2254-2258. doi: 10.1038/leu.2016.196. Epub 2016 Jul 20.

PMID- 34424958
OWN - NLM
STAT- Publisher
LR  - 20210921
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
DP  - 2021 Aug 23
TI  - Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs 
      with distinct origin and behavior.
LID - blood.2021012052 [pii]
LID - 10.1182/blood.2021012052 [doi]
AB  - Glycosylation of the surface immunoglobulin variable region is a remarkable 
      follicular lymphoma-associated feature rarely seen in normal B cells. Here, we 
      define a subset of diffuse large B-cell lymphomas (DLBCL) which acquire 
      N-glycosylation sites selectively in the immunoglobulin (Ig) 
      complementary-determining-regions (CDR) of the antigen-binding sites. 
      Mass-spectrometry and X-ray crystallography demonstrate how the inserted glycans are 
      stalled at oligomannose-type structures due to burial in the CDR loops. Acquisition 
      of sites occurs in ~50% of germinal center B-cell-like DLBCL, mainly of the genetic 
      EZB subtype, irrespective of IGHV-D-J use. This markedly contrasts with the 
      activated B-cell-like DLBCL Ig, which rarely has sites in the CDR, and appears not 
      to acquire oligomannose-type structures. Acquisition of CDR-located acceptor sites 
      associates with mutations of epigenetic regulators and BCL2 translocations, 
      indicating an origin shared with follicular lymphoma. Within the EZB subtype, these 
      sites associate with more rapid disease progression and with significant gene-set 
      enrichment of the B-cell receptor, PI3K/AKT/MTORC1, glucose metabolism, and MYC 
      signaling pathways, particularly in the fraction devoid of MYC translocations. The 
      oligomannose-type glycans on the lymphoma cells interact with the candidate lectin 
      DC-SIGN, mediating low-level signals, and lectin-expressing cells form clusters with 
      lymphoma cells. Both clustering and signaling are inhibited by antibodies 
      specifically targeting the DC-SIGN carbohydrate-recognition-domain. 
      Oligomannosylation of the tumor immunoglobulin is a post-translational modification 
      that readily identifies a distinct GCB-DLBCL category with more aggressive clinical 
      behavior, and could be a potential precise therapeutic target via antibody-mediated 
      inhibition of the tumor Ig interaction with DC-SIGN-expressing M2-polarized 
      macrophages.
CI  - Copyright  2021 American Society of Hematology.
FAU - Chiodin, Giorgia
AU  - Chiodin G
AUID- ORCID: 0000-0002-1456-8997
AD  - University of Southampton, Southampton, United Kingdom.
FAU - Allen, Joel D
AU  - Allen JD
AUID- ORCID: 0000-0003-2547-968X
AD  - University of Southampton, Southampton, United Kingdom.
FAU - Bryant, Dean
AU  - Bryant D
AD  - University of Southampton, Southampton, United Kingdom.
FAU - Rock, Philip
AU  - Rock P
AUID- ORCID: 0000-0003-0031-6032
AD  - University of Rochester Medical Center, Rochester, New York, United States.
FAU - Martino, Enrica Antonia
AU  - Martino EA
AD  - University of Southampton, Southampton, United Kingdom.
FAU - Valle-Argos, Beatriz
AU  - Valle-Argos B
AD  - University of Southampton, Southampton, United Kingdom.
FAU - Duriez, Patrick J
AU  - Duriez PJ
AD  - University of Southampton, Southampton, United Kingdom.
FAU - Watanabe, Yasunori
AU  - Watanabe Y
AUID- ORCID: 0000-0002-7952-1268
AD  - University of Oxford, Oxford, United Kingdom.
FAU - Henderson, Isla
AU  - Henderson I
AD  - University of Southampton, Southampton, United Kingdom.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - The Ohio State University, Columbus, Ohio, United States.
FAU - McCann, Katy J
AU  - McCann KJ
AD  - University of Southampton & SUHT, Southampton, United Kingdom.
FAU - Strefford, Jonathan C
AU  - Strefford JC
AUID- ORCID: 0000-0002-0972-2881
AD  - University of Southampton, Southampton, United Kingdom.
FAU - Packham, Graham
AU  - Packham G
AUID- ORCID: 0000-0002-9232-5691
AD  - University of Southampton, Southampton, United Kingdom.
FAU - Geijtenbeek, Teunis Bh
AU  - Geijtenbeek TB
AUID- ORCID: 0000-0002-5710-2839
AD  - Amsterdam UMC, Amsterdam, Netherlands.
FAU - Figdor, Carl
AU  - Figdor C
AD  - Radboud Institute for Molecular Life Sciences, Radboud university medical center.
FAU - Wright, George
AU  - Wright G
AD  - NIH/NCI, Rockville, Maryland, United States.
FAU - Staudt, Louis Michael
AU  - Staudt LM
AD  - National Cancer Institute, Bethesda, Maryland, United States.
FAU - Burack, Richard
AU  - Burack R
AUID- ORCID: 0000-0002-5584-584X
AD  - University of Rochester, Rochester NY, New York, United States.
FAU - Bowden, Thomas
AU  - Bowden T
AUID- ORCID: 0000-0002-8066-8785
AD  - University of Oxford, Oxford, United Kingdom.
FAU - Crispin, Max
AU  - Crispin M
AUID- ORCID: 0000-0002-1072-2694
AD  - University of Southampton, Southampton, Alabama, United Kingdom.
FAU - Stevenson, Freda Kathryn
AU  - Stevenson FK
AD  - University of Southampton, Southampton, United Kingdom.
FAU - Forconi, Francesco
AU  - Forconi F
AUID- ORCID: 0000-0002-2211-1831
AD  - University of Southampton, Southampton, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20210823
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - AIM
SB  - IM
EDAT- 2021/08/24 06:00
MHDA- 2021/08/24 06:00
CRDT- 2021/08/23 17:37
PHST- 2021/08/03 00:00 [accepted]
PHST- 2021/04/09 00:00 [received]
PHST- 2021/08/02 00:00 [revised]
PHST- 2021/08/23 17:37 [entrez]
PHST- 2021/08/24 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
AID - S0006-4971(21)01511-1 [pii]
AID - 10.1182/blood.2021012052 [doi]
PST - aheadofprint
SO  - Blood. 2021 Aug 23:blood.2021012052. doi: 10.1182/blood.2021012052.

PMID- 29386193
OWN - NLM
STAT- MEDLINE
DCOM- 20190830
LR  - 20200306
IS  - 2159-8290 (Electronic)
IS  - 2159-8274 (Print)
IS  - 2159-8274 (Linking)
VI  - 8
IP  - 4
DP  - 2018 Apr
TI  - BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits 
      and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
PG  - 458-477
LID - 10.1158/2159-8290.CD-17-0902 [doi]
AB  - Bromodomain and extra-terminal (BET) family proteins are key regulators of gene 
      expression in cancer. Herein, we utilize BRD4 profiling to identify critical 
      pathways involved in pathogenesis of chronic lymphocytic leukemia (CLL). BRD4 is 
      overexpressed in CLL and is enriched proximal to genes upregulated or de novo 
      expressed in CLL with known functions in disease pathogenesis and progression. These 
      genes, including key members of the B-cell receptor (BCR) signaling pathway, provide 
      a rationale for this therapeutic approach to identify new targets in alternative 
      types of cancer. Additionally, we describe PLX51107, a structurally distinct BET 
      inhibitor with novel in vitro and in vivo pharmacologic properties that emulates or 
      exceeds the efficacy of BCR signaling agents in preclinical models of CLL. Herein, 
      the discovery of the involvement of BRD4 in the core CLL transcriptional program 
      provides a compelling rationale for clinical investigation of PLX51107 as epigenetic 
      therapy in CLL and application of BRD4 profiling in other cancers.Significance: To 
      date, functional studies of BRD4 in CLL are lacking. Through integrated genomic, 
      functional, and pharmacologic analyses, we uncover the existence of BRD4-regulated 
      core CLL transcriptional programs and present preclinical proof-of-concept studies 
      validating BET inhibition as an epigenetic approach to target BCR signaling in CLL. 
      Cancer Discov; 8(4); 458-77. 2018 AACR.This article is highlighted in the In This 
      Issue feature, p. 371.
CI  - 2018 American Association for Cancer Research.
FAU - Ozer, Hatice Gulcin
AU  - Ozer HG
AD  - Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
FAU - El-Gamal, Dalia
AU  - El-Gamal D
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Powell, Ben
AU  - Powell B
AD  - Plexxikon Inc., Berkeley, California.
FAU - Hing, Zachary A
AU  - Hing ZA
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Harrington, Bonnie
AU  - Harrington B
AD  - College of Veterinary Medicine, The Ohio State University, Columbus, Ohio.
FAU - Mitchell, Shaneice
AU  - Mitchell S
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Grieselhuber, Nicole R
AU  - Grieselhuber NR
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Williams, Katie
AU  - Williams K
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Lai, Tzung-Huei
AU  - Lai TH
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Alinari, Lapo
AU  - Alinari L
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Baiocchi, Robert A
AU  - Baiocchi RA
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Brinton, Lindsey
AU  - Brinton L
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Baskin, Elizabeth
AU  - Baskin E
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Cannon, Matthew
AU  - Cannon M
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Beaver, Larry
AU  - Beaver L
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Goettl, Virginia M
AU  - Goettl VM
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Lucas, David M
AU  - Lucas DM
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Woyach, Jennifer A
AU  - Woyach JA
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Sampath, Deepa
AU  - Sampath D
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio.
FAU - Lehman, Amy M
AU  - Lehman AM
AD  - Center for Biostatistics, The Ohio State University, Columbus, Ohio.
FAU - Yu, Lianbo
AU  - Yu L
AD  - Center for Biostatistics, The Ohio State University, Columbus, Ohio.
FAU - Zhang, Jiazhong
AU  - Zhang J
AD  - Plexxikon Inc., Berkeley, California.
FAU - Ma, Yan
AU  - Ma Y
AD  - Plexxikon Inc., Berkeley, California.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Plexxikon Inc., Berkeley, California.
FAU - Spevak, Wayne
AU  - Spevak W
AD  - Plexxikon Inc., Berkeley, California.
FAU - Shi, Songyuan
AU  - Shi S
AD  - Plexxikon Inc., Berkeley, California.
FAU - Severson, Paul
AU  - Severson P
AD  - Plexxikon Inc., Berkeley, California.
FAU - Shellooe, Rafe
AU  - Shellooe R
AD  - Plexxikon Inc., Berkeley, California.
FAU - Carias, Heidi
AU  - Carias H
AD  - Plexxikon Inc., Berkeley, California.
FAU - Tsang, Garson
AU  - Tsang G
AD  - Plexxikon Inc., Berkeley, California.
FAU - Dong, Ken
AU  - Dong K
AD  - Plexxikon Inc., Berkeley, California.
FAU - Ewing, Todd
AU  - Ewing T
AD  - Plexxikon Inc., Berkeley, California.
FAU - Marimuthu, Adhirai
AU  - Marimuthu A
AD  - Plexxikon Inc., Berkeley, California.
FAU - Tantoy, Christina
AU  - Tantoy C
AD  - Plexxikon Inc., Berkeley, California.
FAU - Walters, Jason
AU  - Walters J
AD  - Plexxikon Inc., Berkeley, California.
FAU - Sanftner, Laura
AU  - Sanftner L
AD  - Plexxikon Inc., Berkeley, California.
FAU - Rezaei, Hamid
AU  - Rezaei H
AD  - Plexxikon Inc., Berkeley, California.
FAU - Nespi, Marika
AU  - Nespi M
AD  - Plexxikon Inc., Berkeley, California.
FAU - Matusow, Bernice
AU  - Matusow B
AD  - Plexxikon Inc., Berkeley, California.
FAU - Habets, Gaston
AU  - Habets G
AD  - Plexxikon Inc., Berkeley, California.
FAU - Ibrahim, Prabha
AU  - Ibrahim P
AD  - Plexxikon Inc., Berkeley, California.
FAU - Zhang, Chao
AU  - Zhang C
AD  - Plexxikon Inc., Berkeley, California.
FAU - Math, Ewy A
AU  - Math EA
AD  - Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
FAU - Bollag, Gideon
AU  - Bollag G
AD  - Plexxikon Inc., Berkeley, California.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio. rosa.lapalombella@osumc.edu john.byrd@osumc.edu.
FAU - Lapalombella, Rosa
AU  - Lapalombella R
AD  - Division of Hematology, Department of Medicine, The Ohio State University, Columbus, 
      Ohio. rosa.lapalombella@osumc.edu john.byrd@osumc.edu.
LA  - eng
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - T32 GM068412/GM/NIGMS NIH HHS/United States
GR  - K99 CA208017/CA/NCI NIH HHS/United States
GR  - R01 CA214046/CA/NCI NIH HHS/United States
GR  - R01 CA177292/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180131
TA  - Cancer Discov
JT  - Cancer discovery
JID - 101561693
RN  - 0 (Antineoplastic Agents)
RN  - 0 (BRD4 protein, human)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Isoxazoles)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Pyridines)
RN  - 0 (Pyrroles)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Cell Cycle Proteins
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Leukemic
MH  - Humans
MH  - Isoxazoles/pharmacology/*therapeutic use
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug 
      therapy/genetics/metabolism/physiopathology
MH  - Mice
MH  - Mice, SCID
MH  - Nuclear Proteins/*genetics/metabolism
MH  - Pyridines/pharmacology/*therapeutic use
MH  - Pyrroles/pharmacology/*therapeutic use
MH  - *Signal Transduction
MH  - Transcription Factors/*genetics/metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC5882533
MID - NIHMS939555
COIS- DISCLOSURE OF CONFLICTS OF INTEREST Ben Powell, Jiazhong Zhang, Yan Ma, Ying Zhang, 
      Wayne Spevak, Songyuan Shi, Paul Severson, Rafe Shellooe, Heidi Carias, Garson 
      Tsang, Ken Dong, Todd Ewing, Adhirai Marimuthu, Christina Tantoy, Jason Walters, 
      Laura Sanftner, Hamid Rezaei, Marika Nespi, Bernice Matusow, Gaston Habets, Prabha 
      Ibrahim, Chao Zhang, and Gideon Bollag are employees of Plexxikon Inc.
EDAT- 2018/02/02 06:00
MHDA- 2019/08/31 06:00
CRDT- 2018/02/02 06:00
PHST- 2017/08/28 00:00 [received]
PHST- 2017/12/12 00:00 [revised]
PHST- 2018/01/26 00:00 [accepted]
PHST- 2018/02/02 06:00 [pubmed]
PHST- 2019/08/31 06:00 [medline]
PHST- 2018/02/02 06:00 [entrez]
AID - 2159-8290.CD-17-0902 [pii]
AID - 10.1158/2159-8290.CD-17-0902 [doi]
PST - ppublish
SO  - Cancer Discov. 2018 Apr;8(4):458-477. doi: 10.1158/2159-8290.CD-17-0902. Epub 2018 
      Jan 31.

PMID- 24781527
OWN - NLM
STAT- MEDLINE
DCOM- 20140922
LR  - 20181113
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 96
IP  - 2
DP  - 2014 Aug
TI  - Erlotinib in African Americans with advanced non-small cell lung cancer: a 
      prospective randomized study with genetic and pharmacokinetic analyses.
PG  - 182-91
LID - 10.1038/clpt.2014.93 [doi]
AB  - Prospective studies on epidermal growth factor receptor (EGFR) inhibitors in African 
      Americans with non-small cell lung cancer (NSCLC) have not previously been 
      performed. In this phase II randomized study, 55 African Americans with NSCLC 
      received 150mg/day erlotinib or a body weight-adjusted dose with subsequent 
      escalations to the maximum-allowable dose, 200mg/day, to achieve rash. Erlotinib 
      and OSI-420 exposures were lower than those observed in previous studies, consistent 
      with CYP3A pharmacogenetics implying higher metabolic activity. Tumor genetics 
      showed only two EGFR mutations, EGFR amplification in 17/47 samples, eight KRAS 
      mutations, and five EML4-ALK translocations. Although absence of rash was associated 
      with shorter time to progression (TTP), disease-control rate, TTP, and 1-year 
      survival were not different between the two dose groups, indicating the dose-to-rash 
      strategy failed to increase clinical benefit. Low incidence of toxicity and low 
      erlotinib exposure suggest standardized and maximum-allowable dosing may be 
      suboptimal in African Americans.
FAU - Phelps, M A
AU  - Phelps MA
AD  - 1] College of Pharmacy, The Ohio State University, Columbus, Ohio, USA [2] College 
      of Medicine, The Ohio State University, Columbus, Ohio, USA.
FAU - Stinchcombe, T E
AU  - Stinchcombe TE
AD  - University of North Carolina College of Medicine, Chapel Hill, North Carolina, USA.
FAU - Blachly, J S
AU  - Blachly JS
AD  - College of Medicine, The Ohio State University, Columbus, Ohio, USA.
FAU - Zhao, W
AU  - Zhao W
AD  - College of Medicine, The Ohio State University, Columbus, Ohio, USA.
FAU - Schaaf, L J
AU  - Schaaf LJ
AD  - 1] College of Pharmacy, The Ohio State University, Columbus, Ohio, USA [2] College 
      of Medicine, The Ohio State University, Columbus, Ohio, USA.
FAU - Starrett, S L
AU  - Starrett SL
AD  - Wexner Medical Center, Department of Medicine and Comprehensive Cancer Center, The 
      Ohio State University, Columbus, Ohio, USA.
FAU - Wei, L
AU  - Wei L
AD  - Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA.
FAU - Poi, M
AU  - Poi M
AD  - College of Medicine, The Ohio State University, Columbus, Ohio, USA.
FAU - Wang, D
AU  - Wang D
AD  - College of Medicine, The Ohio State University, Columbus, Ohio, USA.
FAU - Papp, A
AU  - Papp A
AD  - College of Medicine, The Ohio State University, Columbus, Ohio, USA.
FAU - Aimiuwu, J
AU  - Aimiuwu J
AD  - College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
FAU - Gao, Y
AU  - Gao Y
AD  - College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
FAU - Li, J
AU  - Li J
AD  - College of Public Health, The Ohio State University, Columbus, Ohio, USA.
FAU - Otterson, G A
AU  - Otterson GA
AD  - College of Medicine, The Ohio State University, Columbus, Ohio, USA.
FAU - Hicks, W J
AU  - Hicks WJ
AD  - College of Medicine, The Ohio State University, Columbus, Ohio, USA.
FAU - Socinski, M A
AU  - Socinski MA
AD  - University of North Carolina College of Medicine, Chapel Hill, North Carolina, USA.
FAU - Villalona-Calero, M A
AU  - Villalona-Calero MA
AD  - College of Medicine, The Ohio State University, Columbus, Ohio, USA.
LA  - eng
GR  - KL2 RR025754/RR/NCRR NIH HHS/United States
GR  - U01 GM092655/GM/NIGMS NIH HHS/United States
GR  - 5KL2RR025754/RR/NCRR NIH HHS/United States
GR  - U01GM092655/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140429
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - DA87705X9K (Erlotinib Hydrochloride)
SB  - AIM
SB  - IM
MH  - Adult
MH  - African Americans/*genetics
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*genetics/metabolism
MH  - Erlotinib Hydrochloride
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/*genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - Pharmacogenetics
MH  - Prospective Studies
MH  - Protein Kinase Inhibitors/pharmacokinetics/therapeutic use
MH  - Quinazolines/pharmacokinetics/*therapeutic use
PMC - PMC4180036
MID - NIHMS612008
COIS- CONFLICTS OF INTEREST No authors have conflicts of interest to disclose. The 
      sponsors had no role in the design and conduct of the study, collection, management, 
      analysis, and interpretation of the data, or preparation, review, or approval of the 
      manuscript.
EDAT- 2014/05/02 06:00
MHDA- 2014/09/23 06:00
CRDT- 2014/05/01 06:00
PHST- 2013/10/10 00:00 [received]
PHST- 2014/04/15 00:00 [accepted]
PHST- 2014/05/01 06:00 [entrez]
PHST- 2014/05/02 06:00 [pubmed]
PHST- 2014/09/23 06:00 [medline]
AID - clpt201493 [pii]
AID - 10.1038/clpt.2014.93 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2014 Aug;96(2):182-91. doi: 10.1038/clpt.2014.93. Epub 2014 Apr 
      29.

PMID- 29563537
OWN - NLM
STAT- MEDLINE
DCOM- 20190401
LR  - 20190826
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 32
IP  - 6
DP  - 2018 Jun
TI  - Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 
      60 years or older who respond favorably to standard chemotherapy: an analysis of 
      Alliance studies.
PG  - 1338-1348
LID - 10.1038/s41375-018-0068-2 [doi]
AB  - Thus far, only 5-15% of AML patients aged 60 years are cured with chemotherapy. 
      Identification of patients who are less (more) likely to respond to standard 
      chemotherapy might enable early risk stratification toward alternative treatment 
      regimens. We used a next-generation sequencing panel of 80 cancer- and/or 
      leukemia-associated genes to profile molecularly 423 older patients with de novo 
      AML. Using variables identified in multivariable models and co-occurring mutations 
      in NPM1-mutated AML, we classified the patients into good-, intermediate-, and 
      poor-risk groups for complete remission (CR) attainment, disease-free (DFS), and 
      overall survival (OS). Whereas 81% of good-risk patients (comprising NPM1-mutated 
      patients harboring mutations in chromatin remodeling, cohesin complex, 
      methylation-related, spliceosome, and/or RAS pathway genes, FLT3-TKD, and/or 
      patients without FLT3-ITD) achieved a CR, only 32% of poor-risk patients (with 
      U2AF1, WT1 mutations and/or complex karyotype) did. Intermediate-risk patients had a 
      50% CR rate. Similarly, using NPM1 co-mutation patterns and SF1 mutation status, we 
      identified patients with favorable DFS and OS 3-year rates of 46% and 45%, 
      respectively. Patients with adverse genetic features had DFS and OS rates of only 2% 
      and 4%. We show that application of our proposed criteria may refine the 2017 
      European LeukemiaNet classification for older patients treated with chemotherapy.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      ann-kathrin.eisfeld@osumc.edu.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH, USA.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      krzysztof.mrozek@osumc.edu.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Department of Internal Medicine, The Ohio State University Comprehensive Cancer 
      Center, Division of Hematology, Columbus, OH, USA.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Department of Internal Medicine, The Ohio State University Comprehensive Cancer 
      Center, Division of Hematology, Columbus, OH, USA.
FAU - Maharry, Sophia E
AU  - Maharry SE
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Carroll, Andrew J
AU  - Carroll AJ
AD  - Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Dana-Farber/Partners CancerCare, Boston, MA, USA.
FAU - de la Chapelle, Albert
AU  - de la Chapelle A
AUID- ORCID: 0000-0001-9345-9248
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Wang, Eunice S
AU  - Wang ES
AD  - Roswell Park Cancer Institute, Buffalo, NY, USA.
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - Monter Cancer Center, Hofstra Northwell School of Medicine, Lake Success, NY, USA.
FAU - Powell, Bayard L
AU  - Powell BL
AD  - Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Department of Internal Medicine, The Ohio State University Comprehensive Cancer 
      Center, Division of Hematology, Columbus, OH, USA.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      clara.bloomfield@osumc.edu.
LA  - eng
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - K05 CA131504/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - U10 CA031946/CA/NCI NIH HHS/United States
GR  - U10 CA180850/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - UG1 CA189850/CA/NCI NIH HHS/United States
GR  - U10 CA180867/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - U10 CA180866/CA/NCI NIH HHS/United States
GR  - U10 CA003927/CA/NCI NIH HHS/United States
GR  - R01 CA152045/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - U10 CA041287/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180225
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Nuclear Proteins)
RN  - 117896-08-9 (nucleophosmin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Disease-Free Survival
MH  - Female
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Leukemia, Myeloid, Acute/drug therapy/*genetics/mortality
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Nuclear Proteins/genetics
MH  - Prognosis
PMC - PMC5992022
MID - NIHMS938564
COIS- The authors declare no conflicts of interest.
EDAT- 2018/03/23 06:00
MHDA- 2019/04/02 06:00
CRDT- 2018/03/23 06:00
PHST- 2017/09/25 00:00 [received]
PHST- 2018/01/29 00:00 [accepted]
PHST- 2018/01/23 00:00 [revised]
PHST- 2018/03/23 06:00 [pubmed]
PHST- 2019/04/02 06:00 [medline]
PHST- 2018/03/23 06:00 [entrez]
AID - 10.1038/s41375-018-0068-2 [pii]
AID - 10.1038/s41375-018-0068-2 [doi]
PST - ppublish
SO  - Leukemia. 2018 Jun;32(6):1338-1348. doi: 10.1038/s41375-018-0068-2. Epub 2018 Feb 
      25.

PMID- 28412730
OWN - NLM
STAT- MEDLINE
DCOM- 20180305
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 16
DP  - 2017 Apr 18
TI  - The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor 
      response to chemotherapy in chronic lymphocytic leukemia.
PG  - 25942-25954
LID - 10.18632/oncotarget.15401 [doi]
AB  - The study of long noncoding RNAs (lncRNAs) is an emerging area of cancer research, 
      in part due to their ability to serve as disease biomarkers. However, few studies 
      have investigated lncRNAs in chronic lymphocytic leukemia (CLL). We have identified 
      one particular lncRNA, treRNA, which is overexpressed in CLL B-cells. We measured 
      transcript expression in 144 CLL patient samples and separated samples into high or 
      low expression of treRNA relative to the overall median. We found that high 
      expression of treRNA is significantly associated with shorter time to treatment. 
      High treRNA also correlates with poor prognostic indicators such as unmutated IGHV 
      and high ZAP70 protein expression. We validated these initial findings in samples 
      collected in a clinical trial comparing the nucleoside analog fludarabine alone or 
      in combination with the alkylating agent cyclophosphamide in untreated CLL samples 
      collected prior to starting therapy (E2997). High expression of treRNA was 
      independently prognostic for shorter progression free survival in patients receiving 
      fludarabine plus cyclophosphamide. Given these results, in order to study the role 
      of treRNA in DNA damage response we generated a model cell line system where treRNA 
      was over-expressed in the human B-CLL cell line OSU-CLL. Relative to the vector 
      control line, there was less cell death in OSU-CLL over-expressing treRNA after 
      exposure to fludarabine and mafosfamide, due in part to a reduction in DNA damage. 
      Therefore, we suggest that treRNA is a novel biomarker in CLL associated with 
      aggressive disease and poor response to chemotherapy through enhanced protection 
      against cytotoxic mediated DNA damage.
FAU - Miller, Cecelia R
AU  - Miller CR
AD  - Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center 
      at The Ohio State University, Columbus, OH, USA.
FAU - Ruppert, Amy S
AU  - Ruppert AS
AD  - Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center 
      at The Ohio State University, Columbus, OH, USA.
FAU - Fobare, Sydney
AU  - Fobare S
AD  - Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center 
      at The Ohio State University, Columbus, OH, USA.
AD  - Hendrix College, Conway, AR, USA.
FAU - Chen, Timothy L
AU  - Chen TL
AD  - Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center 
      at The Ohio State University, Columbus, OH, USA.
FAU - Liu, Chaomei
AU  - Liu C
AD  - Department of Experimental Therapeutics, MD Anderson Cancer Center at University of 
      Texas, Houston, TX, USA.
FAU - Lehman, Amy
AU  - Lehman A
AD  - Center for Biostatistics, The Ohio State University, Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center 
      at The Ohio State University, Columbus, OH, USA.
FAU - Zhang, Xiaoli
AU  - Zhang X
AD  - Center for Biostatistics, The Ohio State University, Columbus, OH, USA.
FAU - Lucas, David M
AU  - Lucas DM
AD  - Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center 
      at The Ohio State University, Columbus, OH, USA.
FAU - Grever, Michael R
AU  - Grever MR
AD  - Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center 
      at The Ohio State University, Columbus, OH, USA.
FAU - Tallman, Martin S
AU  - Tallman MS
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Flinn, Ian W
AU  - Flinn IW
AD  - Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA.
FAU - Rassenti, Laura Z
AU  - Rassenti LZ
AD  - Department of Medicine, Moores Cancer Center at University of California at San 
      Diego, La Jolla CA, USA.
AD  - The Chronic Lymphocytic Leukemia (CLL) Research Consortium, La Jolla, CA, USA.
FAU - Kipps, Thomas J
AU  - Kipps TJ
AD  - Department of Medicine, Moores Cancer Center at University of California at San 
      Diego, La Jolla CA, USA.
AD  - The Chronic Lymphocytic Leukemia (CLL) Research Consortium, La Jolla, CA, USA.
FAU - Sampath, Deepa
AU  - Sampath D
AD  - Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center 
      at The Ohio State University, Columbus, OH, USA.
FAU - Coombes, Kevin R
AU  - Coombes KR
AD  - Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
FAU - Hertlein, Erin K
AU  - Hertlein EK
AD  - Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center 
      at The Ohio State University, Columbus, OH, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P01 CA081534/CA/NCI NIH HHS/United States
GR  - K12 CA133250/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - T32 GM068412/GM/NIGMS NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Journal Article
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Biomarkers)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (tre long noncoding RNA, human)
RN  - EC 2.7.10.2 (ZAP-70 Protein-Tyrosine Kinase)
RN  - EC 2.7.10.2 (ZAP70 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Biomarkers
MH  - *DNA Damage
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/*genetics/*mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - *RNA, Long Noncoding
MH  - Treatment Outcome
MH  - ZAP-70 Protein-Tyrosine Kinase/genetics
PMC - PMC5432228
OTO - NOTNLM
OT  - DNA damage
OT  - chronic lymphocytic leukemia
OT  - lncRNA
OT  - prognostic factor
OT  - treRNA
COIS- CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.
EDAT- 2017/04/17 06:00
MHDA- 2018/03/06 06:00
CRDT- 2017/04/17 06:00
PHST- 2017/01/26 00:00 [received]
PHST- 2017/01/30 00:00 [accepted]
PHST- 2017/04/17 06:00 [pubmed]
PHST- 2018/03/06 06:00 [medline]
PHST- 2017/04/17 06:00 [entrez]
AID - 15401 [pii]
AID - 10.18632/oncotarget.15401 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Apr 18;8(16):25942-25954. doi: 10.18632/oncotarget.15401.

PMID- 25583765
OWN - NLM
STAT- MEDLINE
DCOM- 20150910
LR  - 20200527
IS  - 1540-1413 (Electronic)
IS  - 1540-1405 (Print)
IS  - 1540-1405 (Linking)
VI  - 13
IP  - 1
DP  - 2015 Jan
TI  - Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
PG  - 9-13; quiz 13
AB  - The activating BRAF mutation p.V600E has been identified in many cancers, including 
      colon and lung adenocarcinomas, papillary thyroid cancer, malignant melanoma, and 
      hairy cell leukemia (HCL). Malignant melanoma and HCL are of particular interest 
      because of both the high proportion of cases harboring the mutation and the dramatic 
      responses to BRAF inhibitor therapy reported in the literature. This report presents 
      a patient with HCL and malignant melanoma with the BRAF p.V600E mutation, and 
      discusses the successful treatment of both cancers with the BRAF inhibitor 
      dabrafenib.
CI  - Copyright  2015 by the National Comprehensive Cancer Network.
FAU - Blachly, James S
AU  - Blachly JS
AD  - From the Division of Hematology, Department of Internal Medicine, Department of 
      Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State 
      University, Columbus, Ohio.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - From the Division of Hematology, Department of Internal Medicine, Department of 
      Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State 
      University, Columbus, Ohio.
FAU - Lucas, David M
AU  - Lucas DM
AD  - From the Division of Hematology, Department of Internal Medicine, Department of 
      Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State 
      University, Columbus, Ohio.
FAU - Grever, Michael R
AU  - Grever MR
AD  - From the Division of Hematology, Department of Internal Medicine, Department of 
      Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State 
      University, Columbus, Ohio.
FAU - Kendra, Kari
AU  - Kendra K
AD  - From the Division of Hematology, Department of Internal Medicine, Department of 
      Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State 
      University, Columbus, Ohio.
FAU - Andritsos, Leslie A
AU  - Andritsos LA
AD  - From the Division of Hematology, Department of Internal Medicine, Department of 
      Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State 
      University, Columbus, Ohio.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
TA  - J Natl Compr Canc Netw
JT  - Journal of the National Comprehensive Cancer Network : JNCCN
JID - 101162515
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Imidazoles)
RN  - 0 (Oximes)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - QGP4HA4G1B (dabrafenib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Humans
MH  - Imidazoles/pharmacology/*therapeutic use
MH  - Leukemia, Hairy Cell/diagnosis/*drug therapy
MH  - Male
MH  - Melanoma/diagnosis/*drug therapy
MH  - Mutation
MH  - *Neoplasms, Second Primary
MH  - Oximes/pharmacology/*therapeutic use
MH  - Positron-Emission Tomography
MH  - Protein Kinase Inhibitors/pharmacology/*therapeutic use
MH  - Proto-Oncogene Proteins B-raf/antagonists & inhibitors/genetics
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
PMC - PMC7250239
MID - NIHMS1583814
EDAT- 2015/01/15 06:00
MHDA- 2015/09/12 06:00
CRDT- 2015/01/14 06:00
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/09/12 06:00 [medline]
AID - 13/1/9 [pii]
AID - 10.6004/jnccn.2015.0004 [doi]
PST - ppublish
SO  - J Natl Compr Canc Netw. 2015 Jan;13(1):9-13; quiz 13. doi: 10.6004/jnccn.2015.0004.

PMID- 33542077
OWN - NLM
STAT- In-Data-Review
LR  - 20210518
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 27
IP  - 8
DP  - 2021 Apr 15
TI  - Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, 
      Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
PG  - 2352-2366
LID - 10.1158/1078-0432.CCR-20-3724 [doi]
AB  - PURPOSE: Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors (NAMPTi) are 
      currently in development, but may be limited as single-agent therapy due to 
      compound-specific toxicity and cancer metabolic plasticity allowing resistance 
      development. To potentially lower the doses of NAMPTis required for therapeutic 
      benefit against acute myeloid leukemia (AML), we performed a genome-wide CRISPRi 
      screen to identify rational disease-specific partners for a novel NAMPTi, KPT-9274. 
      EXPERIMENTAL DESIGN: Cell lines and primary cells were analyzed for cell viability, 
      self-renewal, and responses at RNA and protein levels with loss-of-function 
      approaches and pharmacologic treatments. In vivo efficacy of combination therapy was 
      evaluated with a xenograft model. RESULTS: We identified two histone deacetylases 
      (HDAC), HDAC8 and SIRT6, whose knockout conferred synthetic lethality with KPT-9274 
      in AML. Furthermore, HDAC8-specific inhibitor, PCI-34051, or clinical class I HDAC 
      inhibitor, AR-42, in combination with KPT-9274, synergistically decreased the 
      survival of AML cells in a dose-dependent manner. AR-42/KPT-9274 cotreatment 
      attenuated colony-forming potentials of patient cells while sparing healthy 
      hematopoietic cells. Importantly, combined therapy demonstrated promising in vivo 
      efficacy compared with KPT-9274 or AR-42 monotherapy. Mechanistically, genetic 
      inhibition of SIRT6 potentiated the effect of KPT-9274 on PARP-1 suppression by 
      abolishing mono-ADP ribosylation. AR-42/KPT-9274 cotreatment resulted in synergistic 
      attenuation of homologous recombination and nonhomologous end joining pathways in 
      cell lines and leukemia-initiating cells. CONCLUSIONS: Our findings provide evidence 
      that HDAC8 inhibition- or shSIRT6-induced DNA repair deficiencies are potently 
      synergistic with NAMPT targeting, with minimal toxicity toward normal cells, 
      providing a rationale for a novel-novel combination-based treatment for AML.
CI  - 2021 American Association for Cancer Research.
FAU - Zhang, Pu
AU  - Zhang P
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
AD  - College of Pharmacy, The Ohio State University, Columbus, Ohio.
FAU - Brinton, Lindsey T
AU  - Brinton LT
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Williams, Katie
AU  - Williams K
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Sher, Steven
AU  - Sher S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Orwick, Shelley
AU  - Orwick S
AUID- ORCID: 0000-0002-4537-1409
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Tzung-Huei, Lai
AU  - Tzung-Huei L
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Mims, Alice S
AU  - Mims AS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Coss, Christopher C
AU  - Coss CC
AUID- ORCID: 0000-0002-8184-9190
AD  - College of Pharmacy, The Ohio State University, Columbus, Ohio.
FAU - Kulp, Samuel K
AU  - Kulp SK
AD  - College of Pharmacy, The Ohio State University, Columbus, Ohio.
FAU - Youssef, Youssef
AU  - Youssef Y
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Chan, Wing Keung
AU  - Chan WK
AUID- ORCID: 0000-0002-5257-1521
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Mitchell, Shaneice
AU  - Mitchell S
AUID- ORCID: 0000-0001-9297-781X
AD  - Department of Pathology, Stanford University School of Medicine, Stanford, 
      California.
FAU - Mustonen, Allison
AU  - Mustonen A
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Cannon, Matthew
AU  - Cannon M
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Phillips, Hannah
AU  - Phillips H
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Lehman, Amy M
AU  - Lehman AM
AD  - Center for Biostatistics, Department of Biomedical Informatics, The Ohio State 
      University, Columbus, Ohio.
FAU - Kauffman, Tierney
AU  - Kauffman T
AUID- ORCID: 0000-0002-9802-1584
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Beaver, Larry
AU  - Beaver L
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Canfield, Daniel
AU  - Canfield D
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Grieselhuber, Nicole R
AU  - Grieselhuber NR
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Alinari, Lapo
AU  - Alinari L
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Sampath, Deepa
AU  - Sampath D
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Yan, Pearlly
AU  - Yan P
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
AD  - College of Pharmacy, The Ohio State University, Columbus, Ohio.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio.
FAU - Lapalombella, Rosa
AU  - Lapalombella R
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University, 
      Columbus, Ohio. rosa.lapalombella@osumc.edu.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R01 CA223165/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
GR  - T32 HL098049/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20210204
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
SB  - IM
PMC - PMC8054771
MID - NIHMS1672348
COIS- Conflicts of Interest: The authors declare no potential conflicts of interest.
EDAT- 2021/02/06 06:00
MHDA- 2021/02/06 06:00
PMCR- 2021/10/15
CRDT- 2021/02/05 05:46
PHST- 2020/09/29 00:00 [received]
PHST- 2020/12/24 00:00 [revised]
PHST- 2021/02/01 00:00 [accepted]
PHST- 2021/10/15 00:00 [pmc-release]
PHST- 2021/02/06 06:00 [pubmed]
PHST- 2021/02/06 06:00 [medline]
PHST- 2021/02/05 05:46 [entrez]
AID - 1078-0432.CCR-20-3724 [pii]
AID - 10.1158/1078-0432.CCR-20-3724 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2021 Apr 15;27(8):2352-2366. doi: 10.1158/1078-0432.CCR-20-3724. 
      Epub 2021 Feb 4.

PMID- 27476855
OWN - NLM
STAT- MEDLINE
DCOM- 20170515
LR  - 20181113
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 175
IP  - 2
DP  - 2016 Oct
TI  - Persistence of DNMT3A R882 mutations during remission does not adversely affect 
      outcomes of patients with acute myeloid leukaemia.
PG  - 226-236
LID - 10.1111/bjh.14254 [doi]
AB  - Somatic mutation of the DNMT3A gene at the arginine R882 site is common in acute 
      myeloid leukaemia (AML). The prognostic significance of DNMT3A R882 mutation 
      clearance, using traditional diagnostic next generation sequencing (NGS) methods, 
      during complete remission (CR) in AML patients is controversial. We examined the 
      impact of clearing DNMT3A R882 mutations at diagnosis to the detectable threshold of 
      3% during CR on outcome in 56 adult AML patients. Mutational remission, defined as 
      clearance of pre-treatment DNMT3A R882 and all other AML-associated mutations to a 
      variant allele frequency 3%, occurred in 14 patients whereas persistent DNMT3A R882 
      mutations were observed in 42 patients. There were no significant differences in 
      disease-free or overall survival between patients with and without DNMT3A R882 
      mutation clearance. Patients with persistent DNMT3A R882 who cleared all other AML 
      mutations and did not acquire new mutations (n=30), trended towards longer 
      disease-free survival (16 vs. 06years, P=006) than patients with persistence 
      of DNMT3A R882, in addition to other mutations or acquisition of new AML-associated 
      mutations, such as those in TET2, JAK2, ASXL1 and TP53 (n=12). These data 
      demonstrate that DNMT3A R882 mutations, as assessed by traditional NGS methods, 
      persist in the majority of AML patients in CR.
CI  -  2016 John Wiley & Sons Ltd.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA. Bhavana.Bhatnagar@osumc.edu.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      Bhavana.Bhatnagar@osumc.edu.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, 
      Rochester, MN, USA.
FAU - Mrzek, Krzysztof
AU  - Mrzek K
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Lucas, David M
AU  - Lucas DM
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Kohlschmidt, Jessica
AU  - Kohlschmidt J
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
AD  - Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, 
      Rochester, MN, USA.
FAU - Blum, William
AU  - Blum W
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Kolitz, Jonathan E
AU  - Kolitz JE
AD  - Monter Cancer Center, Hofstra North Shore-Long Island Jewish School of Medicine, 
      Lake Success, NY, USA.
FAU - Stone, Richard M
AU  - Stone RM
AD  - Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, Department of Internal Medicine, The Ohio State University 
      Comprehensive Cancer Center, Columbus, OH, USA. john.byrd@osumc.edu.
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 
      john.byrd@osumc.edu.
LA  - eng
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - U10 CA077658/CA/NCI NIH HHS/United States
GR  - U10 CA180821/CA/NCI NIH HHS/United States
GR  - U10 CA101140/CA/NCI NIH HHS/United States
GR  - U10 CA180882/CA/NCI NIH HHS/United States
GR  - U24 CA196171/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - U10 CA180867/CA/NCI NIH HHS/United States
GR  - R35 CA197734/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20160801
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Codon)
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)
RN  - EC 2.1.1.37 (DNA methyltransferase 3A)
SB  - IM
CIN - Br J Haematol. 2016 Oct;175(2):185-186. PMID: 27605414
MH  - Adult
MH  - Aged
MH  - *Amino Acid Substitution
MH  - Bone Marrow/pathology
MH  - *Codon
MH  - DNA (Cytosine-5-)-Methyltransferases/*genetics
MH  - DNA Mutational Analysis
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Myeloid, Acute/diagnosis/drug therapy/*genetics/*mortality
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Mutation Rate
MH  - Prognosis
MH  - Remission Induction
MH  - Treatment Outcome
PMC - PMC5063708
MID - NIHMS812262
OTO - NOTNLM
OT  - *DNA (cytosine-5)-methyltransferase 3 alpha
OT  - *acute myeloid leukaemia
OT  - *mutation clearance
OT  - *prognosis
OT  - *survival
COIS- of conflicts of interest The authors declare no conflicts of interest.
EDAT- 2016/08/02 06:00
MHDA- 2017/05/16 06:00
CRDT- 2016/08/02 06:00
PHST- 2016/05/04 00:00 [received]
PHST- 2016/06/07 00:00 [accepted]
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2017/05/16 06:00 [medline]
PHST- 2016/08/02 06:00 [entrez]
AID - 10.1111/bjh.14254 [doi]
PST - ppublish
SO  - Br J Haematol. 2016 Oct;175(2):226-236. doi: 10.1111/bjh.14254. Epub 2016 Aug 1.

PMID- 25361945
OWN - NLM
STAT- MEDLINE
DCOM- 20151015
LR  - 20191210
IS  - 1592-8721 (Electronic)
IS  - 0390-6078 (Print)
IS  - 0390-6078 (Linking)
VI  - 100
IP  - 1
DP  - 2015 Jan
TI  - Reduced dose pentostatin for initial management of hairy cell leukemia patients who 
      have active infection or risk of hemorrhage is safe and effective.
PG  - e18-20
LID - 10.3324/haematol.2014.113290 [doi]
FAU - Andritsos, Leslie A
AU  - Andritsos LA
AD  - The Ohio State University, Department of Internal Medicine, Division of Hematology, 
      Columbus, OH leslie.andritsos@osumc.edu.
FAU - Dunavin, Neil
AU  - Dunavin N
AD  - National Institutes of Health, National Heart, Lung, and Blood Institute, Hematology 
      Branch, Bethesda, MD.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - The Ohio State University, Department of Pathology, Columbus, OH, USA.
FAU - Jones, Jeffrey A
AU  - Jones JA
AD  - The Ohio State University, Department of Internal Medicine, Division of Hematology, 
      Columbus, OH.
FAU - Blachly, James S
AU  - Blachly JS
AD  - The Ohio State University, Department of Internal Medicine, Division of Hematology, 
      Columbus, OH.
FAU - Lucas, David M
AU  - Lucas DM
AD  - The Ohio State University, Department of Internal Medicine, Division of Hematology, 
      Columbus, OH.
FAU - Byrd, John C
AU  - Byrd JC
AD  - The Ohio State University, Department of Internal Medicine, Division of Hematology, 
      Columbus, OH.
FAU - Kraut, Eric
AU  - Kraut E
AD  - The Ohio State University, Department of Internal Medicine, Division of Hematology, 
      Columbus, OH.
FAU - Grever, Michael R
AU  - Grever MR
AD  - The Ohio State University, Department of Internal Medicine, Division of Hematology, 
      Columbus, OH.
LA  - eng
PT  - Letter
DEP - 20141031
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0 (Antineoplastic Agents)
RN  - 395575MZO7 (Pentostatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Disease Management
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/complications/*drug therapy
MH  - Humans
MH  - Infections/complications/*drug therapy
MH  - Leukemia, Hairy Cell/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Pentostatin/*therapeutic use
MH  - Prognosis
MH  - Remission Induction
PMC - PMC4281329
OTO - NOTNLM
OT  - hairy cell leukemia
OT  - pentostatin
EDAT- 2014/11/02 06:00
MHDA- 2015/10/16 06:00
CRDT- 2014/11/02 06:00
PHST- 2014/11/02 06:00 [entrez]
PHST- 2014/11/02 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - haematol.2014.113290 [pii]
AID - 1000e18 [pii]
AID - 10.3324/haematol.2014.113290 [doi]
PST - ppublish
SO  - Haematologica. 2015 Jan;100(1):e18-20. doi: 10.3324/haematol.2014.113290. Epub 2014 
      Oct 31.

PMID- 27354268
OWN - NLM
STAT- MEDLINE
DCOM- 20171103
LR  - 20181113
IS  - 2159-8290 (Electronic)
IS  - 2159-8274 (Print)
IS  - 2159-8274 (Linking)
VI  - 6
IP  - 9
DP  - 2016 Sep
TI  - Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 
      Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia.
PG  - 1036-51
LID - 10.1158/2159-8290.CD-16-0023 [doi]
AB  - Chromosomal aberrations and multiple genome-wide association studies (GWAS) have 
      established a major hematopoietic quantitative trait locus in chromosome 6q23.3. The 
      locus comprises an active enhancer region, in which some of the associated SNPs 
      alter transcription factor binding. We now identify miR-3662 as a new functional 
      driver contributing to the associated phenotypes. The GWAS SNPs are strongly 
      associated with higher miR-3662 expression. Genome editing of rs66650371, a 
      three-base-pair deletion, suggests a functional link between the SNP genotype and 
      the abundance of miR-3662. Increasing miR-3662's abundance increases colony 
      formation in hematopoietic progenitor cells, particularly the erythroid lineage. In 
      contrast, miR-3662 is not expressed in acute myeloid leukemia cells, and its 
      overexpression has potent antileukemic effects in vitro and in vivo Mechanistically, 
      miR-3662 directly targets NF-B-mediated transcription. Thus, miR-3662 is a new 
      player of the hematopoietic 6q23.3 locus. SIGNIFICANCE: The characterization of 
      miR-3662 has identified a new actor in the prominent hematopoietic quantitative 
      trait locus in chromosome 6q23.3. The mechanistic insights into miR-3662's function 
      may reveal novel or only partially known pathways for normal and malignant 
      hematopoietic cell proliferation. Cancer Discov; 6(9); 1036-51. 2016 AACR.This 
      article is highlighted in the In This Issue feature, p. 932.
CI  - 2016 American Association for Cancer Research.
FAU - Maharry, Sophia E
AU  - Maharry SE
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Walker, Christopher J
AU  - Walker CJ
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Liyanarachchi, Sandya
AU  - Liyanarachchi S
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Mehta, Sujay
AU  - Mehta S
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Patel, Mitra
AU  - Patel M
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Bainazar, Maryam A
AU  - Bainazar MA
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Huang, Xiaomeng
AU  - Huang X
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Lankenau, Malori A
AU  - Lankenau MA
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Hoag, Kevin W
AU  - Hoag KW
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Ranganathan, Parvathi
AU  - Ranganathan P
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Garzon, Ramiro
AU  - Garzon R
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Blachly, James S
AU  - Blachly JS
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Guttridge, Denis C
AU  - Guttridge DC
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - de la Chapelle, Albert
AU  - de la Chapelle A
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Eisfeld, Ann-Kathrin
AU  - Eisfeld AK
AD  - The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 
      ann-kathrin.eisfeld@osumc.edu.
LA  - eng
GR  - P50 CA140158/CA/NCI NIH HHS/United States
GR  - U10 CA180861/CA/NCI NIH HHS/United States
GR  - U10 CA033601/CA/NCI NIH HHS/United States
GR  - U24 CA114725/CA/NCI NIH HHS/United States
GR  - R01 CA095512/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160627
TA  - Cancer Discov
JT  - Cancer discovery
JID - 101561693
RN  - 0 (CCAAT-Enhancer-Binding Proteins)
RN  - 0 (GATA1 Transcription Factor)
RN  - 0 (MIRN-3662 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (NF-kappa B)
RN  - EC 2.7.11.10 (I-kappa B Kinase)
SB  - IM
MH  - Alleles
MH  - Animals
MH  - Binding Sites
MH  - CCAAT-Enhancer-Binding Proteins/metabolism
MH  - Cell Proliferation
MH  - Cell Survival/genetics
MH  - Cell Transformation, Neoplastic/genetics
MH  - *Chromosomes, Human, Pair 6
MH  - Colony-Forming Units Assay
MH  - Disease Models, Animal
MH  - Female
MH  - GATA1 Transcription Factor/metabolism
MH  - Gene Dosage
MH  - *Gene Expression Regulation, Leukemic
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - Genome-Wide Association Study
MH  - Hematopoiesis/*genetics
MH  - Hematopoietic Stem Cells/metabolism
MH  - Heterografts
MH  - Humans
MH  - I-kappa B Kinase/genetics/metabolism
MH  - Leukemia, Myeloid, Acute/*genetics/metabolism
MH  - Mice
MH  - MicroRNAs/chemistry/*genetics
MH  - Models, Biological
MH  - NF-kappa B/metabolism
MH  - Polymorphism, Single Nucleotide
MH  - Protein Binding
MH  - *Quantitative Trait Loci
MH  - RNA Interference
MH  - Response Elements
MH  - Signal Transduction
PMC - PMC5168803
MID - NIHMS835713
EDAT- 2016/06/30 06:00
MHDA- 2017/11/04 06:00
CRDT- 2016/06/30 06:00
PHST- 2016/01/05 00:00 [received]
PHST- 2016/06/23 00:00 [accepted]
PHST- 2016/06/30 06:00 [entrez]
PHST- 2016/06/30 06:00 [pubmed]
PHST- 2017/11/04 06:00 [medline]
AID - 2159-8290.CD-16-0023 [pii]
AID - 10.1158/2159-8290.CD-16-0023 [doi]
PST - ppublish
SO  - Cancer Discov. 2016 Sep;6(9):1036-51. doi: 10.1158/2159-8290.CD-16-0023. Epub 2016 
      Jun 27.

PMID- 26858310
OWN - NLM
STAT- MEDLINE
DCOM- 20180116
LR  - 20181113
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 22
IP  - 14
DP  - 2016 Jul 15
TI  - HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to 
      Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
PG  - 3537-49
LID - 10.1158/1078-0432.CCR-15-1063 [doi]
AB  - PURPOSE: The double-strand breaks elicited by sapacitabine, a clinically active 
      nucleoside analogue prodrug, are repaired by RAD51 and the homologous recombination 
      repair (HR) pathway, which could potentially limit its toxicity. We investigated the 
      mechanism by which histone deacetylase (HDAC) inhibitors targeted RAD51 and HR to 
      sensitize acute myelogenous leukemia (AML) cells to sapacitabine. EXPERIMENTAL 
      DESIGN: Chromatin immunoprecipitation identified the role of HDACs in silencing 
      miR-182 in AML. Immunoblotting, gene expression, overexpression, or inhibition of 
      miR-182 and luciferase assays established that miR-182 directly targeted RAD51. HR 
      reporter assays, apoptotic assays, and colony-forming assays established that the 
      miR-182, as well as the HDAC inhibition-mediated decreases in RAD51 inhibited HR 
      repair and sensitized cells to sapacitabine. RESULTS: The gene repressors, HDAC1 and 
      HDAC2, became recruited to the promoter of miR-182 to silence its expression in AML. 
      HDAC inhibition induced miR-182 in AML cell lines and primary AML blasts. miR-182 
      targeted RAD51 protein both in luciferase assays and in AML cells. Overexpression of 
      miR-182, as well as HDAC inhibition-mediated induction of miR-182 were linked to 
      time- and dose-dependent decreases in the levels of RAD51, an inhibition of HR, 
      increased levels of residual damage, and decreased survival after exposure to 
      double-strand damage-inducing agents. CONCLUSIONS: Our findings define the mechanism 
      by which HDAC inhibition induces miR-182 to target RAD51 and highlights a novel 
      pharmacologic strategy that compromises the ability of AML cells to conduct HR, 
      thereby sensitizing AML cells to DNA-damaging agents that activate HR as a repair 
      and potential resistance mechanism. Clin Cancer Res; 22(14); 3537-49. 2016 AACR.
CI  - 2016 American Association for Cancer Research.
FAU - Lai, Tsung-Huei
AU  - Lai TH
AD  - Division of Hematology, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio.
FAU - Ewald, Brett
AU  - Ewald B
AD  - Department of Experimental Therapeutics, The University of Texas M.D. Anderson 
      Cancer Center, Houston, Texas.
FAU - Zecevic, Alma
AU  - Zecevic A
AD  - Department of Experimental Therapeutics, The University of Texas M.D. Anderson 
      Cancer Center, Houston, Texas.
FAU - Liu, Chaomei
AU  - Liu C
AD  - Department of Experimental Therapeutics, The University of Texas M.D. Anderson 
      Cancer Center, Houston, Texas.
FAU - Sulda, Melanie
AU  - Sulda M
AD  - Department of Experimental Therapeutics, The University of Texas M.D. Anderson 
      Cancer Center, Houston, Texas.
FAU - Papaioannou, Dimitrios
AU  - Papaioannou D
AD  - Division of Hematology, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio.
FAU - Garzon, Ramiro
AU  - Garzon R
AD  - Division of Hematology, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio.
FAU - Blachly, James S
AU  - Blachly JS
AD  - Division of Hematology, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio.
FAU - Plunkett, William
AU  - Plunkett W
AD  - Department of Experimental Therapeutics, The University of Texas M.D. Anderson 
      Cancer Center, Houston, Texas. deepa.sampath@osumc.edu wplunket@mdanderson.org.
FAU - Sampath, Deepa
AU  - Sampath D
AD  - Division of Hematology, Comprehensive Cancer Center, The Ohio State University, 
      Columbus, Ohio. deepa.sampath@osumc.edu wplunket@mdanderson.org.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA028596/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160208
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Arabinonucleosides)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (MicroRNAs)
RN  - 0 (Mirn182 microRNA, human)
RN  - 8J337D1HZY (Cytosine)
RN  - EC 2.7.7.- (Rad51 Recombinase)
RN  - EC 3.5.1.98 (HDAC1 protein, human)
RN  - EC 3.5.1.98 (HDAC2 protein, human)
RN  - EC 3.5.1.98 (Histone Deacetylase 1)
RN  - EC 3.5.1.98 (Histone Deacetylase 2)
RN  - EC 3.5.1.98 (Histone Deacetylases)
RN  - W335P73C3L (sapacitabine)
SB  - IM
MH  - Apoptosis/drug effects/genetics
MH  - Arabinonucleosides/*pharmacology
MH  - Cell Line, Tumor
MH  - Cytosine/*analogs & derivatives/pharmacology
MH  - DNA Damage/drug effects/genetics
MH  - Gene Expression/drug effects/genetics
MH  - HeLa Cells
MH  - Histone Deacetylase 1/antagonists & inhibitors
MH  - Histone Deacetylase 2/antagonists & inhibitors
MH  - Histone Deacetylase Inhibitors/*pharmacology
MH  - Histone Deacetylases/*metabolism
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/genetics/metabolism
MH  - MicroRNAs/*genetics
MH  - Promoter Regions, Genetic/drug effects/genetics
MH  - Rad51 Recombinase/*genetics
MH  - Recombinational DNA Repair/*drug effects
PMC - PMC4947457
MID - NIHMS758708
COIS- The authors have no potential conflict of interest to disclose.
EDAT- 2016/02/10 06:00
MHDA- 2018/01/18 06:00
CRDT- 2016/02/10 06:00
PHST- 2015/05/03 00:00 [received]
PHST- 2016/01/27 00:00 [accepted]
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - 1078-0432.CCR-15-1063 [pii]
AID - 10.1158/1078-0432.CCR-15-1063 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2016 Jul 15;22(14):3537-49. doi: 10.1158/1078-0432.CCR-15-1063. 
      Epub 2016 Feb 8.

PMID- 34480107
OWN - NLM
STAT- Publisher
LR  - 20210904
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
DP  - 2021 Sep 3
TI  - Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using 
      ultrasensitive LC-FACSeq.
LID - 10.1038/s41375-021-01398-9 [doi]
FAU - Saygin, Caner
AU  - Saygin C
AUID- ORCID: 0000-0001-7617-8356
AD  - Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
FAU - Hu, Eileen
AU  - Hu E
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Zhang, Pu
AU  - Zhang P
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Sher, Steven
AU  - Sher S
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Lozanski, Arletta
AU  - Lozanski A
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Doong, Tzyy-Jye
AU  - Doong TJ
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Nicolet, Deedra
AU  - Nicolet D
AD  - Alliance Statistics and Data Center, The Ohio State University, Columbus, OH, USA.
FAU - Orwick, Shelley
AU  - Orwick S
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Labanowska, Jadwiga
AU  - Labanowska J
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA.
FAU - Skinner, Jordan N
AU  - Skinner JN
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Cempre, Casey
AU  - Cempre C
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Kauffman, Tierney
AU  - Kauffman T
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Goettl, Virginia M
AU  - Goettl VM
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Heerema, Nyla A
AU  - Heerema NA
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA.
FAU - Abruzzo, Lynne
AU  - Abruzzo L
AUID- ORCID: 0000-0001-6113-7447
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA.
FAU - Miller, Cecelia
AU  - Miller C
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA.
FAU - Lapalombella, Rosa
AU  - Lapalombella R
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Behbehani, Gregory
AU  - Behbehani G
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Mims, Alice S
AU  - Mims AS
AUID- ORCID: 0000-0002-8971-2199
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Larkin, Karilyn
AU  - Larkin K
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Grieselhuber, Nicole
AU  - Grieselhuber N
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Walker, Alison
AU  - Walker A
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Bhatnagar, Bhavana
AU  - Bhatnagar B
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Bloomfield, Clara D
AU  - Bloomfield CD
AUID- ORCID: 0000-0001-5465-7591
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Byrd, John C
AU  - Byrd JC
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA.
FAU - Lozanski, Gerard
AU  - Lozanski G
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA.
FAU - Blachly, James S
AU  - Blachly JS
AUID- ORCID: 0000-0002-4275-5562
AD  - Division of Hematology, The Ohio State University Comprehensive Cancer Center, 
      Columbus, OH, USA. James.Blachly@osumc.edu.
LA  - eng
PT  - Published Erratum
DEP - 20210903
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
SB  - IM
EFR - Leukemia. 2021 May 21;:. PMID: 34021247
EDAT- 2021/09/05 06:00
MHDA- 2021/09/05 06:00
CRDT- 2021/09/04 06:04
PHST- 2021/09/04 06:04 [entrez]
PHST- 2021/09/05 06:00 [pubmed]
PHST- 2021/09/05 06:00 [medline]
AID - 10.1038/s41375-021-01398-9 [pii]
AID - 10.1038/s41375-021-01398-9 [doi]
PST - aheadofprint
SO  - Leukemia. 2021 Sep 3. doi: 10.1038/s41375-021-01398-9.
